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Abstract 
Kidney disease is an important contributor to the burden of ill-health worldwide. Genetic 
factors have an important role in determining which people are affected by kidney disease, and 
this study aimed to identify the genes responsible for disease in families in which unusual 
kidney diseases were transmitted in a pattern suggesting autosomal dominant inheritance. I 
performed genome-wide single nucleotide polymorphism-based linkage studies and identified 
two new human disease genes. 
Hypoxia Inducible Factor-2α (HIF2α) is a widely expressed transcription factor which is 
rapidly broken down in the presence of oxygen. When oxygenation is reduced it activates the 
transcription of many genes, including erythropoietin which stimulates red blood cell 
production. I identified a heterozygous activating mutation of HIF2α which cosegregated with 
autosomal dominantly inherited erythrocytosis and pulmonary arterial hypertension in a British 
family, producing a phenotype similar to the effects of high altitude exposure. In vitro studies 
demonstrated that the mutant protein has increased transcriptional activity under normoxia. 
This suggests that HIF2α plays an important role in regulating the organism-wide responses to 
oxygen availability. 
Complement Factor H Related protein 5 (CFHR5) is a homologue of the complement 
regulating protein Complement Factor H and is of incompletely understood function. I 
uncovered an in-frame heterozygous duplication of exons 2 and 3 of the CFHR5 gene which 
cosegregated with autosomal dominantly inherited microscopic and synpharyngitic 
macroscopic haematuria, glomerulonephritis and renal failure in 2 families with ancestry in the 
Troodos Mountains of Cyprus. The mutation results in the production of a protein with 
impaired affinity for complement deposited in the kidney. This disease, which I named CFHR5 
nephropathy, is endemic in Cyprus, accounting for a significant proportion of renal disease on 
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the island, and may be amenable to systemic treatments. These findings implicate CFHR5 as a 
new and important regulator of complement in the human kidney. 
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1.1 The rationale for Genehunting 
Elucidation of the molecular basis of disease has a number of advantages. Firstly, it can 
allow the development of a non-invasive (i.e. genetic) test which can aid in diagnosis; secondly, 
this can provide prognostic information for an individual or cohort; thirdly, understanding the 
molecular basis may itself provide insight into the pathophysiology of the disease and the 
physiology of the underlying biological pathway. In turn, this can pave the way towards rational 
development of treatment for that disease. Examples of this include the administration of 
recombinant alpha-galactosidase to people with Fabry’s disease (Schiffmann, Kopp et al. 2001), 
and the use of the tyrosine kinase inhibitor Imatinib in chronic myeloid leukaemia (Druker, 
Talpaz et al. 2001). 
In addition, understanding how a rare mutation can cause a rare disease may also provide 
information leading to the development of new treatments for more common diseases. An 
example of this is the appreciation that mutations in the VHL gene cause von Hippel Lindau 
disease which includes a predisposition to renal cell carcinoma. Subsequently, it was found that 
sporadic renal cell carcinoma, which accounts for approximately 3% of cancer deaths (or 
~13,000 people in the USA) each year (Jemal, Siegel et al. 2009), in over 80% of cases is 
associated with somatic biallelic VHL inactivation (Barry and Krek 2004). The drugs Sorafenib 
and Sunitinib, which antagonise the receptor for vascular endothelial growth factor (which lies 
downstream of VHL, the product of the VHL gene), have shown efficacy in the treatment of 
sporadic renal cell carcinoma (Escudier, Eisen et al. 2007; Motzer, Hutson et al. 2007). 
The ability to make a genetic diagnosis is particularly relevant in renal disease where 
decisions surrounding organ transplantation (depending for instance on whether the disease is 
likely to recur in an allograft or whether a particular individual is a suitable kidney donor) may 
be informed by the results of genetic testing. 
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It is proposed that successfully understanding an “experiment of nature,” where a change 
in a gene causes a change in the phenotype of a human being, can provide both clinical and 
academic benefits. 
1.2 Historical perspective 
Over the past few decades, rapid advances in molecular genetics have allowed elucidation 
of the molecular causes of a wide range of Mendelian disorders, including those causing some 
renal diseases, such as autosomal dominant polycystic kidney disease (European Polycystic 
Kidney Disease Consortium 1994). A key tool used to identify the genetic basis of high-
penetrance Mendelian traits has been the linkage study, in which a set of genetic markers (or 
polymorphisms) are genotyped within a family or group of families. Within a family, those 
polymorphisms of which an allele is transmitted with the disease more often than would be 
expected by chance are likely to lie on a chromosomal segment near to the disease-causing 
variant and are considered to be linked with the disease. The likelihood that the observed 
pattern of cosegregation arose as a consequence of linkage divided by the likelihood that the 
observed pattern of cosegregation occurred by chance is known as the odds ratio, and its 
logarithm (conventionally in base 10) is termed the LOD score, which is the standard unit of 
linkage. Because of this logarithmic relationship, LOD scores of unrelated families sharing a 
phenotype (and hence assumed have mutations at the same locus) can be summated at a given 
chromosomal location, even if the markers and even the disease-causing mutation are 
different. Conventionally, since the prior probability of linkage for any chromosomal location is 
low (because the genome is so large), a LOD score of 3 (corresponding to an odds ratio of 
1000:1 in favour of linkage underlying the observed pattern of recombinations) is regarded as 
significant. Clearly, the power of such studies (i.e. the maximum possible LOD score) is 
dependent on the number of observed (or inferred) transmissions of the disease and markers 
within the family (i.e. the number of informative meioses) and their resolution (i.e. the 
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precision with which they are able to define the boundaries of the disease-linked locus) is 
dependent both on the density of markers used and also on the number of (or rather distance 
between) the recombinations within the families. 
Prior to the early years of the 21st century, genome-wide linkage studies were most 
commonly performed using up to several hundred polymorphic microsatellite markers 
distributed throughout the genome. Although each marker was likely to be informative, 
genotyping was slow and added significantly to the resources required for such studies. The 
cost of genotyping more markers across the genome did not justify the use of dense marker 
arrays and fine-mapping studies were performed on potentially linked regions to narrow down 
any linked interval as much as possible, with a fundamental limit being determined by the 
position of recombinations within the family (or families) under investigation. Analysis of the 
genotype data is not trivial and a range of computer programs were developed between the 
1970s to the 1990s which allowed computation of LOD scores, both for single markers and for 
multiple markers (Ott 1974; Lathrop, Lalouel et al. 1984; Cottingham, Idury et al. 1993; 
O'Connell and Weeks 1995; Kruglyak, Daly et al. 1996; Gudbjartsson, Jonasson et al. 2000). 
These programs employ algorithms such as the Elston-Stewart algorithm (Elston and Stewart 
1971) or the Lander-Green algorithm (Lander and Green 1987) in order to calculate linkage. 
The Elston-Stewart algorithm uses a process known as peeling, where a large pedigree is 
split into smaller nuclear families. The LOD score is calculated for each nuclear family 
separately and these values summated across the whole pedigree. While efficient for large 
families, this approach requires all possible genotypes at each marker to be considered for each 
step, so with increasing numbers of markers the computational requirement increases 
exponentially. The Lander-Green algorithm works by expressing the flow of alleles as 
inheritance vectors according to whether an allele is on the maternal or paternal haplotype for 
each individual. For those markers where there is only one possible vector (i.e. the phase is 
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known) this is straightforward, however in many instances there will be a number of possible 
routes of transmission, defining a set of possible inheritance vectors. The likelihood for each 
marker is a function of the probability of each of the 22i (where i is the number of non-founders 
in the pedigree) inheritance vectors. The algorithm treats the state of each marker as a function 
only of the state of the adjacent markers (i.e. a Markov modela), based on the genetic distance 
between them. Consequently, increasing the number of markers causes a linear increase in the 
computational requirement. Since each inheritance vector contains 22i elements there is an 
exponentially increasing computational requirement with increasing family size. Some of these 
limitations can be overcome by using sampling techniques to test only a set of possible 
inheritance vectors in proportion to their likelihood (Sobel and Lange 1996) but in practice this 
type of solution also poses a significant challenge to modern computers, and recent 
publications have tended to result from other (more modern) techniques for the identification 
of genes responsible for human disease. 
1.3 The whole genome era 
The near-complete, annotated record of the human genome is now publicly available, and 
while the functions of many genes are still poorly understood, elucidation of their genomic 
location and their organism-wide expression distribution, combined with estimation of the 
predicted structure of their products and likely homologues has resulted in an exponential 
increase in what is understood about the molecular pathways responsible for health and 
disease. In addition, the growing body of experimental results available in public databases 
provides an expanding pool of knowledge which can allow researchers to hypothesize which 
genes are likely to play a role in contributing to a disease.  
                                                          
a
 A model obeying the Markov property is one in which the future state of the model depends only 
on the present state. An example is a frog hopping from lily-pad to lily-pad. If it cannot remember which 
lily-pad it was last on its choice of where to hop to depends only on its current location and therefore 
obeys the Markov property. Mathematical tools have been developed to describe the behaviour of such 
a system. 
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The identification of several million single nucleotide polymorphisms (SNPs) which are 
common across human populations has provided the substrate for the systematic analysis of 
genetic variation and its relationship to disease. The burgeoning field of genome science has 
benefitted, in the last decade, from technologies which have allowed rapidly expanding insight 
into the molecular genetic contribution to what are usually regarded as non-Mendelian, or 
sporadic, diseases – a field known as complex trait genetics. Central to the ability to genotype 
(i.e. determine which alleles are present in an individual) large numbers of SNPs is the Charge 
Coupled Device (CCD), a computer chip which is able to respond, with great 2-dimensional 
spatial resolution, to small changes in electromagnetic radiation (i.e. light) emitted from a 
chemical reaction. The CCD was invented over 40 years ago (Boyle and Smith 1970), but its 
development was catalyzed by the commercial imaging market, most notably the Sony 
Corporation which developed its use in handheld video recorders. Today the CCD has almost 
completely replaced photographic film in the consumer camera market, and Boyle and Smith 
received the 2006 Nobel Prize for Physics for their invention. The CCD, among other advances, 
has provided a crucial tool for modern SNP genotyping technology, allowing up to several 
million SNPs to be genotyped in an individual rapidly, using less than a microgram of genomic 
DNA and for a few hundred dollars. 
These advances in high-throughput genotyping have allowed genetic variation among large 
cohorts of patients and controls to be studied, providing a new angle for the study of the 
molecular pathophysiology of common diseases (Wellcome Trust Case Control Consortium 
2007). This type of study is powerful enough to detect even tiny risk effects of common variants 
but needs significant resources to gather DNA and phenotypic information from sufficient 
patients and controls drawn from a single population. Consequently, the genome wide 
association study (GWAS) approach has been less successful in identifying the genetic 
contribution to less common diseases, including many kidney diseases, where small numbers of 
patients allow detection only of alleles which confer a large amount of risk. 
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With growing understanding of the molecular structure of physiological systems and the 
pathways which contribute to disease, it is clear that the ability of researchers to identify 
candidate genes which might be responsible for a phenotype is increasing.  
1.4 Genetic kidney disease 
It is common for people with kidney failure not to receive a diagnosis, and this is 
particularly true for individuals who present over the age of 16. In the UK, the cause of renal 
failure in 15.8% patients starting renal replacement is categorised as ‘aetiology uncertain’ in 
the 20-65 years age group (Byrne, Ford et al. 2009), and although this percentage has fallen 
from 19.7% in 2004 (Ansell, Feest et al. 2004), there are clearly many young adults reaching end 
stage renal disease (ESRD) in whom the diagnosis is not known.  It is notable that ESRD in 
childhood is less likely to be of unknown aetiology, with only 3% children requiring renal 
replacement therapy falling into this category in 2008 (Lewis 2008). The reasons for the failure 
to identify the cause of this significant contribution to renal disease are not clear. A 
contributing factor might be incomplete transfer of information to the registries, but 
nonetheless it is obvious that there are large numbers of patients receiving lifelong treatment 
for renal failure in the absence of an understanding of what their underlying disease is. 
Epidemiological evidence that genetic factors might be important in the aetiology of some 
of this undiagnosed kidney disease has come from 2 different observations: Firstly, that risk of 
renal failure varies between different ethnic groups, even within the same geographical 
location – for instance South Asians have a higher risk of reaching ESRD than Caucasians 
residing in Canada (Barbour, Er et al. 2010). Secondly, there is marked familial clustering of 
renal disease in many different ethnic groups, with up to five-fold increased risk of renal failure 
seen in individuals with a first degree relative who has reached ESRD. Up to one third of African 
American patients receiving renal replacement therapy report a first or second degree relative 
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with ESRD, compared with 12-15% Caucasians (Satko, Sedor et al. 2007). Even when known 
Mendelian disorders (such as polycystic kidney disease and Alport syndrome) were excluded, 
22.8% incident ESRD patients in one study reported a family history of ESRD (Freedman, 
Volkova et al. 2005). In this study, younger incident patients were more likely to have a family 
history than older ones, arguing against an environmental cause for the aggregation (since 
older people were hypothesised to have had greater exposure than the young to any putative 
environmental factors). 
It therefore seems likely that unrecognised genetic factors are important in the aetiology of 
renal disease. 
1.5 This study 
The aim of this investigation was to use advances in genotyping technology combined with 
an integrated approach to molecular physiology to identify the molecular basis of disease in 
families with Mendelian inheritance of unusual phenotypes encountered in clinical practice. 
This utilised knowledge of biological pathways implicated by the phenotype, combined with 
SNP-based linkage analysis in small families to exclude as many candidate genes as possible and 
concentrate resequencing (and other techniques) on the best non-excluded candidate genes in 
order to identify a candidate mutation. Identification of a candidate mutation would be 
followed, where appropriate, by population-based, in vitro and clinical investigations to 
understand more about the disease. 
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2.1 Introduction 
The aim of this study was to understand the underlying cause of erythrocytosis 
(overproduction of red blood cells) which segregated as an autosomal dominant trait in a single 
family from North London who were originally described in 1979 (Howarth, Chanarin et al. 
1979). Initial assessment had demonstrated that erythropoietin levels were inappropriately 
elevated in affected members of the family and, for reasons outlined below, this implied that 
the molecular defect was one involving altered oxygen sensing. This hypothesis was supported 
by the subsequent development of pulmonary arterial hypertension in older family members. 
2.1.1 Oxygen sensing in eukaryotes 
Oxygen is necessary for eukaryotic life and its predominant role is as the terminal electron 
acceptor for the respiratory chain, thus acting as the major substrate for energy metabolism. 
Complex multicellular animals, which are too large for all their cells to access oxygen by passive 
diffusion from the environment, have evolved respiratory and circulatory systems to provide 
oxygen to their organs and there is an oxygen gradient between the inspired air (20.9% oxygen 
with a pO2 of 159 mmHg at sea level) and the tissues. In healthy humans, pO2 is typically 25-60 
mmHg in well vascularised organs, but much lower values of 8-10 mmHg are common in certain 
tissues including articular cartilage, renal medulla and epidermis (Vaupel, Kallinowski et al. 
1989; Wang, Winlove et al. 2003; Cringle and Yu 2004; Gibson, Milner et al. 2008). Even within 
tissues, gradients of oxygenation exist, with subpopulations of the same cell-type experiencing 
different oxygen tensions within an organ. It has commonly been assumed that these variations 
in oxygenation are not important, and this assumption may have been based on the 
perspective that the level of oxygenation only becomes relevant at levels which are sufficiently 
low to compromise mitochondrial respiration, corresponding to a pO2 of approximately 1 
mmHg in the mitochondrion. Most studies have therefore concentrated on examining the 
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effects of compromised oxygen delivery where cessation of mitochondrial respiration leads to 
depletion of ATP and tissue necrosis.  
It is now clear that sensing and responding to changes in oxygenation, even above the 
range at which mitochondrial function is limited by oxygen availability, is a critical attribute of 
the cells of complex organisms. Advances in the last 20 years have identified a highly conserved 
system, present in all eukaryotes which have been studied, based on the Hypoxia Inducible 
Factor (HIF) system (Kaelin and Ratcliffe 2008). This molecular apparatus responds to 
alterations in oxygen availability by coordinating a complex and pleiotropic transcriptional 
response which has effects at the cellular, local and organism-wide levels. Importantly, HIF is 
active within the physiological range of oxygen tension and has significant effects on gene 
expression and cellular behaviour at levels of oxygenation much higher than that at which 
mitochondrial respiration is compromised. 
The molecular apparatus of the HIF pathway is now well understood, and the key insights 
which have unlocked its secrets have come both from experiments in model organisms and also 
clinical observations in humans. 
2.1.2 Oxygen, haematocrit and erythropoietin 
Evidence that oxygen plays a role in the regulation of haematocrit dates from the 19th 
century, when Bert and Jourdanet demonstrated that blood viscosity increased on exposure to 
altitude (Bert 1878) and Viault went on to show that high altitude exposure provokes a rise in 
blood haemoglobin concentration (Viault 1891). In 1906, Carnot and Deflandre injected serum 
from anaemic rabbits into normal rabbits and found that this led to an increase in haemoglobin 
concentration and proposed that this was mediated by a circulating factor (Carnot and 
Deflandre 1906). A key step was the development of reliable bioassays for erythropoietin 
(Cotes and Bangham 1961). Starting with the urine of patients with severe anaemia, 
Goldwasser succeeded in purifying erythropoietin (Miyake, Kung et al. 1977) leading to the 
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cloning of the EPO gene in 1985 (Jacobs, Shoemaker et al. 1985). Recombinant human 
erythropoietin was then developed to treat anaemia in patients with kidney failure and has 
been one of the most conspicuous success stories of molecular medicine (Winearls, Oliver et al. 
1986; Winearls 1995). Isolation of the EPO gene also provided key tools for studying its 
regulation by hypoxia, including mRNA probes and adjacent regulatory sequences. As shown in 
Table 2.1-1, conditions which lead to increased erythropoietin production and erythrocytosis 
are commonly associated with reduced tissue oxygen delivery. In contrast, uncoupling 
mitochondrial oxidative phosphorylation (for example with cyanide) does not increase 
erythropoietin expression (Necas and Thorling 1972; Tan and Ratcliffe 1991). This is because 
the underlying mechanism of oxygen sensing is not based on reduced ATP levels. Instead it is 
based on an enzyme reaction which uses molecular oxygen as a co-substrate. Cobalt increases 
erythropoietin production because at a molecular level it mimics the effect of low oxygen by 
disabling the “oxygen-sensing” enzyme reactions which regulate HIF (Goodman 1947; Semenza, 
Roth et al. 1994; Nytko, Spielmann et al. 2007). Some tumours which cause erythrocytosis are 
associated with genetic mutations in the VHL gene, which also lead to HIF activation (Wiesener, 
Seyfarth et al. 2002). 
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Conditions associated with hypoxaemia (reduced arterial pO2)  
Exposure to high altitude 
Pulmonary diseases 
Alveolar hypoventilation (e.g. owing to sleep apnoea or central 
nervous system disease) 
Cardiovascular disease causing a right-to-left shunt (e.g. 
cyanotic congenital heart disease) 
Conditions associated with normal arterial pO2 but reduced 
oxygen delivery to tissues  
Anaemia 
Exposure to carbon monoxide 
High affinity haemoglobin variants 
Methaemoglobinaemia 
2,3-Diphosphoglyceromutase deficiency 
Conditions associated with normal oxygen delivery to tissues  
Tumour-associated erythropoietin production  
Renal disorders (e.g. polycystic kidney disease and Bartter’s 
syndrome) 
Cobalt toxicity 
Chuvash polycythaemia  
PHD2 erythrocytosis  
 
Table 2.1-1 Conditions associated with increased erythropoietin production 
 
2.1.2.1 Renal erythropoietin production 
Organ ablation experiments in the 1950s first established that the kidney was essential for 
normal erythropoietic responses to low oxygen (Jacobson, Goldwasser et al. 1957). 
Subsequently it was shown that the gene for erythropoietin (the hormone responsible for 
mediating this response) is expressed at lower levels in a range of other cells and organs, 
including liver, brain, retina and testes (Eckardt, Pugh et al. 1994; Su, Wiltshire et al. 2004).  
Under basal conditions, erythropoietin is expressed in the kidney by peritubular fibroblasts 
located near the boundary between cortex and medulla (Maxwell, Osmond et al. 1993). When 
oxygen delivery to the kidney is reduced, fibroblasts located farther from the cortico-medullary 
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junction are progressively recruited to produce erythropoietin. There is some evidence that 
each fibroblast is recruited in an all-or-none manner (Eckardt, Koury et al. 1993).  
The signal for respiratory control detected by the carotid body is arterial pO2. This would 
not be suitable for regulating erythropoietin production since it is not dependent on 
haemoglobin concentration. Instead the system must measure the amount of oxygen delivered 
by the blood. Illustrating this, carbon monoxide exposure does not reduce arterial pO2, but 
decreases the blood oxygen content leading to increased erythropoietin production. This also 
explains why high affinity haemoglobin variants are associated with erythrocytosis. The 
physiology is incompletely understood but is based on sensing tissue pO2. 
At least two aspects of the kidney probably make it suitable for this task. First, the kidneys 
receive a high blood flow – although they account for less than 0.5% of the body mass in 
humans they receive approximately 20% of the cardiac output. This enormous blood flow is 
maintained by complex neuroendocrine autoregulatory mechanisms, so that renal blood flow is 
rather stable – even in the face of quite marked haemodynamic disturbance. Second, oxygen 
consumption in the kidneys mainly relates to resorption of sodium in the tubules, which is 
dependent on glomerular filtration rate (GFR). Any reduction in renal blood supply owing to the 
autoregulatory mechanisms being overwhelmed is accompanied by a fall in GFR, reduced 
sodium resorption, and hence decreased local oxygen consumption. Consequently, renal artery 
stenosis does not generally cause erythrocytosis. Supporting the model, experimental 
administration of acetazolamide, which reduces sodium reuptake and hence oxygen 
consumption inhibits the erythropoietin response to hypoxia (Eckardt, Kurtz et al. 1989). 
2.1.2.2 Hepatic Erythropoietin production  
Although the kidneys are the primary source of erythropoietin in adult mammals, an 
appreciable amount of erythropoietin is produced in the liver by hepatocytes and interstitial 
stellate cells – also known as Ito cells (Koury, Bondurant et al. 1991; Maxwell, Ferguson et al. 
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1994). Hepatic erythropoietin production is regulated by oxygen tension, with the least 
oxygenated part of the liver lobules responsible for most erythropoietin production. Curiously, 
cultured renal fibroblasts do not produce erythropoietin, although the reasons for this are not 
known. Fortunately, certain human hepatoma cell lines have provided an excellent model 
system for studies of the regulation of EPO expression by oxygen (Goldberg, Glass et al. 1987). 
2.1.3 Regulation of erythropoietin gene expression 
Three non-coding regions of the EPO gene are highly conserved among mammalian species 
– the promoter region, the first intron and an enhancer region lying approximately 100bp 3’ to 
exon 5. Mapping experiments using mice with transgenes containing mouse or human 
erythropoietin sequence have demonstrated the presence and location of elements concerned 
with tissue-specific gene expression; some of these elements are located many kilobases 5’ to 
the gene (Figure 2.1-1). A negative regulatory element located closer to the gene is important 
for suppressing expression in most tissues (Semenza, Dureza et al. 1990).  
 
Figure 2.1-1 The structure of the EPO gene  
The relative positions of the exons, promoter and enhancer elements responsible for the normal regulation of 
the human EPO gene (not to scale). Binding of HIF and other transcriptional co-activators to HRE is responsible for 
oxygen-dependent activation of EPO transcription. Transcription factors binding to the other enhancer/repressor 
elements determine organ-specific regulation of EPO gene expression. 
 
Experiments using human hepatoma cells identified an enhancer element downstream of 
the polyadenylation site which confers hypoxia responsiveness and is termed an Hypoxia 
Responsive Element (HRE) (Imagawa, Goldberg et al. 1991; Pugh, Tan et al. 1991; Madan and 
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Curtin 1993). The identification of the HRE allowed isolation of a protein complex that binds to 
it – the Hypoxia Inducible Factor (HIF) complex (Wang and Semenza 1993). Subsequently, it has 
been shown that numerous other genes contain an HRE in their flanking sequence, with the 
core consensus sequence (RCGTG). Further, all mammalian cells – not just those that produce 
erythropoietin - activate HIF in hypoxia (Beck, Weinmann et al. 1993; Maxwell, Pugh et al. 
1993; Wang and Semenza 1993) and that a large number of genes, in addition to EPO have an 
HRE and are upregulated by HIF activation (O'Rourke, Dachs et al. 1997).  Thus HIF is a widely 
operative oxygen-responsive transcription control system, and it regulates many other 
responses besides increased erythropoiesis. 
2.1.4 Oxygen sensing by HIF 
HIF is a heterodimeric transcription factor composed of alpha and beta subunits, termed 
HIF- and HIF- respectively. The HIF- subunit is oxygen-labile and unique to the HIF pathway, 
whereas the  subunit is constitutive and also heterodimerises with other transcription factors. 
It is also known as aryl hydrocarbon receptor nuclear translocator (ARNT). There are at least 
three genes for HIF-α, termed HIF1, -2 and -3 respectively, with additional complexity 
arising from the production of alternatively spliced transcripts. A comparison of HIF1α and 
HIF2α is shown in Figure 2.1-2. In hypoxic conditions, the alpha subunits are able to translocate 
to the nucleus and dimerize with the beta subunits. These bind to HREs, recruit co-activators 
and increase transcription of target genes. In addition, HIF can modulate gene expression by 
binding to other transcription factors. 
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Figure 2.1-2 The Structure of HIF-1α and HIF-2α 
Amino acid similarity (%) is shown between the two proteins at each domain: DNA-binding (blue); HIF1β-
binding (green); Terminal activation domain (red), including the oxygen dependent degradation domain (ODDD) and 
C-terminal activation/P300 binding domain. The residues involved in enzymatic hydroxylation are also shown above 
each molecule. Adapted from (Hu, Sataur et al. 2007).  
 
2.1.5 Regulation of HIF by oxygen 
In the presence of oxygen, the HIF- subunit is hydroxylated at one of two conserved 
proline residues (Pro-402 and -564 of human HIF1 and Pro-405 and -531 of HIF2) a reaction 
catalysed by Prolyl Hydroxylase Domain (PHD) enzymes. This prolyl-hydroxylation allows 
interaction with the von Hippel-Lindau E3 ubiquitin ligase (VHL) which leads to ubiquitin-
mediated targeting of HIF- for degradation by the proteasome (Maxwell, Wiesener et al. 
1999). In addition, hydroxylation of a conserved asparagine residue (Asn-803 of human HIF1 
and Asn-851 of HIF2 in the C-terminal transactivation domain occurs in the presence of 
oxygen (see Figure 2.1-3). This asparaginyl hydroxylation prevents recruitment to the HIF 
complex of co-activators (Hewitson, McNeill et al. 2002; Lando, Peet et al. 2002).  
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Figure 2.1-3 Regulation of Hypoxia Inducible Factor (HIF) 
In the presence of oxygen HIF-α undergoes prolyl hydroxylation at conserved residues, catalysed by a family of 
iron(II) (Fe
2+
) and 2-oxoglutarate (2-OG) dependent prolyl hydroxylase domain (PHD) enzymes leading to recognition 
by the von Hippel Lindau (VHL) protein which catalyses ubiquitination, targeting HIF-α for proteasomal degradation. 
In addition, a conserved asparagine residue undergoes hydroxylation, by Factor Inhibiting HIF (FIH), which blocks 
activation of HIF target genes, as well as having other functions. In hypoxic conditions, HIF-α translocates to the 
nucleus, binds to HIF-β and additional co-transactivators to activate transcription of target genes which, in turn, 
modulate a wide variety of cellular processes. 
 
2.1.5.1 Regulation of HIF destruction by PHD enzymes 
Prolyl-hydroxylation of HIF- subunits occurs through the action of prolyl-hydroxylase 
domain (PHD) enzymes of which there are at least three in humans, termed PHD1, 2 and 3 
(Epstein, Gleadle et al. 2001). These enzymes are non-haem iron(II)- and 2-oxoglutarate 
dependent dioxygenases which have homologues in all eukaryotes and even some prokaryotes 
(McDonough, Li et al. 2006).  In the presence of molecular oxygen they produce HIF-OH, CO2 
and succinate (Figure 2.1-4).  
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Figure 2.1-4 Prolyl Hydroxylase Domain (PHD) enzymes 
PHD enzymes require O2 and 2-oxoglutarate as co-substrates and non-haem ferrous iron (Fe
2+
) as a co-factor to 
hydroxylate conserved proline residues of HIF-α, allowing recognition of HIF-α-OH by VHL leading to its subsequent 
ubiquitination and degradation. The particularly low affinity of PHD enzymes for oxygen makes molecular oxygen 
concentration the determinant of enzymatic activity in most physiological conditions. However, significant depletion 
of 2-oxoglutarate or accumulation of succinate (for instance by deficiency of citric acid cycle enzymes or co-
substrates) may inhibit PHD enzymatic activity. Furthermore, deficiency of ferrous iron (Fe
2+
), for instance by 
excessive reactive oxygen species production, may also inhibit PHD activity and allow un-hydroxylated HIF-α to 
accumulate even when molecular oxygen is plentiful. 
 
The PHD enzymes are clearly suitable to act as a cellular “oxygen sensor”. Importantly, the 
availability of the other co-substrate (2-oxoglutarate) and of Fe2+ (which is present at the active 
site) could also affect PHD activity. Cobalt(II), by substituting for iron(II), disables PHD enzymes 
– explaining why it activates HIF in cell culture and causes erythrocytosis when administered to 
mammals (Goodman 1947; Nytko, Spielmann et al. 2007).  
2-oxoglutarate is an intermediate in the citric acid cycle. Other citric acid cycle 
intermediates, succinate and fumarate, competitively inhibit the interaction of 2-oxoglutarate 
with the PHD enzymes in vitro. In vivo, this may result in an important cross-talk between 
metabolism and HIF activation. Supporting this possibility, genetic defects in succinate 
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dehydrogenase and fumarate hydratase are associated with evidence of increased HIF activity 
(Pollard, Briere et al. 2005; Pollard, Spencer-Dene et al. 2007; Ratcliffe 2007).  
The PHD enzymes are highly conserved and were initially identified by their homology to 
the oxygen-dependent dioxygenase Egl9 in the nematode C. elegans (Epstein, Gleadle et al. 
2001). It is noteworthy that the molecular oxygen-sensing apparatus is conserved between 
mammals and organisms lacking EPO, blood vessels, or a haematopoietic system. 
The differential roles of the three PHD enzymes are not yet fully understood, but it is likely 
that their differing affinity for the two proline target residues in HIF- is important. Since the 
HIF hydroxylation reaction is not at equilibrium the amount of PHD enzyme present influences 
the level of HIF activity. Interestingly, expression of the PHD isoforms in rats is variable from 
one tissue to another, with PHD2 being ubiquitously expressed, and PHD1 and PHD3 being 
most abundant in the testis and heart respectively. While PHD1 appeared to be constitutively 
expressed, PHD2 and 3 were inducible by hypoxic exposure, possibly representing a feedback 
loop (Willam, Maxwell et al. 2006). At a subcellular level, PHD1 is predominantly expressed in 
the nucleus, PHD2 in the cytoplasm and PHD3 in both compartments (Metzen, Berchner-
Pfannschmidt et al. 2003).  
siRNA knockdown experiments in cell lines have shown that altered expression of all three 
PHD enzymes influences HIF activation in specific contexts, and that in most cell types PHD2 is 
the predominant isoform. Consistent with this, absence of PHD1 or PHD3 does not have 
obvious consequences in knockout mice, but PHD2 is required for embryonic development 
(Takeda, Cowan et al. 2007). PHD2 appears to have a key role in EPO regulation in humans, 
since heterozygosity for a PHD2 missense mutation is associated with autosomal dominant 
erythrocytosis (see below). 
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2.1.5.2 Factor Inhibiting HIF 
Like the PHD enzymes, Factor Inhibiting HIF (FIH) is a 2-oxoglutarate and iron(II)-dependent 
dioxygenase. In the presence of oxygen, FIH hydroxylates a conserved asparaginyl residue in 
the C-terminal transactivation domain of HIF-, causing repression of HIF mediated 
transcription by inhibiting the recruitment of co-activators. Under in vitro conditions the Km of 
the PHD enzymes for oxygen is in the range 230-250 μmol/l (water saturated with air has an 
oxygen concentration of approximately 200 μmol/l), whereas the Km of FIH for oxygen is 90 
μmol/l (Hirsila, Koivunen et al. 2003; Koivunen, Hirsila et al. 2004). Consistent with this, 
functional experiments suggest that FIH is more important in regulating HIF under severe 
hypoxic conditions in cell lines (Stolze, Tian et al. 2004). 
As well as being dependent on the availability of molecular oxygen, all four HIF hydroxylase 
enzymes require iron(II) and 2-oxoglutarate to function and are sensitive to highly oxidising 
environments (possibly owing to the conversion of iron(II) to iron(III)), so that the availability of 
reducing agents (such as ascorbate) can exert a significant influence on HIF activity (Pan, 
Mansfield et al. 2007; Vissers, Gunningham et al. 2007; Vissers and Wilkie 2007). 
2.1.6 Effects of HIF activation 
HIF activation alters the expression of many genes, and is activated in the physiological 
range of oxygen tension. Physiological processes dependent on HIF target genes include 
erythropoiesis, iron transport, angiogenesis and development, vascular tone, cellular energy 
metabolism, matrix metabolism, apoptosis and others (Schofield and Ratcliffe 2004). Given this 
pleiotropic range of actions, the central role of oxygen in cellular metabolism and the fact that 
oxygen delivery to tissue is reduced in many pathological settings it is not surprising that the 
HIF pathway plays a significant role in mammalian development, physiology and pathology. 
To date, the disease setting in which HIF is most strikingly involved is cancer. This illustrates 
the consequences of mutations in the pathway in humans and the potential of the pathway for 
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regulating angiogenesis and cellular energy metabolism (Maxwell, Dachs et al. 1997; Gordan 
and Simon 2007). Inheriting one defective VHL allele results in von Hippel Lindau disease, a 
multisystem disorder characterised by a very high risk of haemangioblastomas in the eye and 
central nervous  system, renal cell carcinoma, phaeochromocytoma and other tumours (Kaelin 
2008). The tumours are associated with somatic mutation or inactivation of the remaining VHL 
allele and constitutive HIF activation. Sporadic renal cell carcinomas are also associated with 
biallelic VHL loss-of-function in the great majority of cases (Gnarra, Tory et al. 1994) and re-
expressing VHL in cells derived from these tumours efficiently suppresses growth of 
experimental tumours (Zimmer, Doucette et al. 2004). Although VHL has other roles besides 
regulating HIF, activation of HIF appears to be the pivotal consequence of VHL loss-of-function, 
at least in the kidney.  
Apart from the role of genetic activation of HIF in renal cancer, activation of HIF through 
local hypoxia in other cancers is common (Serganova, Humm et al. 2006). In addition, other 
signals which are commonly activated in cancer cells interact with the pathway, and are able to 
provoke a HIF-mediated response even when oxygen levels are not reduced, or potentiate the 
HIF response at a particular level of oxygen (Laughner, Taghavi et al. 2001; Alam, Maizels et al. 
2004; Zhou, Schmid et al. 2004; Treins, Giorgetti-Peraldi et al. 2005; Peng, Karna et al. 2006). 
Key consequences of HIF activation in cancer are the effect on signalling from cancer cells to 
the vasculature, and on metabolism in the cancer cell. As tumours grow they require 
angiogenesis to provide oxygen (Folkman, Watson et al. 1989) and the role of HIF in this 
process is now well recognised. A number of angiogenic factors, including vascular endothelial 
growth factor (VEGF), platelet derived growth factor (PDGF), angiopoietin-1 and -2, Flt-1 (a 
VEGF receptor) are HIF targets, and their upregulation by HIF is consistent with a cellular 
adaptation to improve blood supply in hypoxia (Pugh and Ratcliffe 2003). Furthermore, HIF 
targets such as inducible nitric oxide synthase (iNOS), PDGF-β receptor and cyclooxygenase 
Chapter 2: HIF2α Erythrocytosis and Pulmonary Hypertension 
43 
 
(COX)-2 can also modify the behaviour of vascular smooth muscle cells to improve perfusion in 
hypoxic regions (Fong 2008).  
Another striking feature of activation of HIF is that it results in a comprehensive 
reprogramming of energy metabolism. First, it increases expression of glucose transporters and 
glycolytic enzymes, resulting in increased glucose uptake, glycolysis and lactate production 
(Semenza, Roth et al. 1994; Ebert, Firth et al. 1995; Firth, Ebert et al. 1995). Second, by 
increasing expression of pyruvate dehydrogenase kinase, it decreases entry of pyruvate into 
the citric acid cycle (Kim, Tchernyshyov et al. 2006; Zhang, Gao et al. 2007). Third, it alters 
expression of components of cytochrome c oxidase expression (Fukuda, Zhang et al. 2007). This 
major regulation of cellular energy metabolism is a key function of the HIF system and has 
important implications for cells, such as those of the immune system, which must adapt to a 
range of oxygen tensions. 
In addition to studies on metabolism in cancer cells, it is now becoming clear that HIF 
activation can have a powerful influence on energy utilization in other cell types.  For example, 
studies of haematopoietic cells have demonstrated that growth factor stimulation is necessary 
for HIF1α expression and that, when growing, HIF1α is necessary for these cells to survive in 
hypoxia. This is thought to result, at least in part, from the ability of growth factor-induced 
HIF1α to reprogram cellular glucose utilization from anabolic synthesis to lactate (i.e. energy) 
production, improving survival at the expense of growth when a key substrate (oxygen) 
becomes limiting (Lum, Bui et al. 2007).  
The molecular mechanisms underlying the cross-talk between growth factor signalling and 
cellular oxygen sensing are complex and only partly understood, but studies both in cancer cells 
and using other approaches, have established that HIF has complex bidirectional interactions 
with other signalling systems such as the PI3 kinase/AKT/mTOR and NFκB pathways (for review 
see (Gale and Maxwell 2010)). 
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2.1.7 Role of different HIF subunits in the EPO response 
HIF can activate the transcription of a large number of genes (Figure 2.1-5). A major 
challenge is to understand how the hypoxic response of different cell types is selected from this 
repertoire. Some selectivity probably arises from the different HIF- subunits each of which is 
encoded a different gene.  
Recently, it has been appreciated that HIF1 is very widely expressed and appears to have 
more selectivity for regulating changes in energy metabolism (Papandreou, Cairns et al. 2006; 
Pan, Mansfield et al. 2007; Webb, Coleman et al. 2009). Conversely, HIF2 expression is 
restricted both during development and in adult animals and appears to correlate with the 
proliferative phenotype of hypoxic and HIF-dysregulated cells and organisms (Sowter, Raval et 
al. 2003; Gordan, Lal et al. 2008; Webb, Coleman et al. 2009). While there are differences in the 
structure of the subunits, the significance of these differences is not yet well understood (see 
Figure 2.1-2). In a construct-reporter gene system it was found that the N-terminal activation 
domain (N-TAD) was responsible for conferring HIF1 or HIF2 target gene specificity whereas 
the C-TAD promoted the expression of target genes common to both subunits (Hu, Sataur et al. 
2007). Less is known concerning HIF3 which encodes several alternative splice forms, at least 
one of which can function as a dominant negative regulator of HIF (Makino, Cao et al. 2001; 
Maynard, Evans et al. 2007). Which of the HIF-α subunits is predominantly responsible for the 
regulation of erythropoietin is not known, with evidence existing for both HIF1 and HIF2 
playing a role (Yeo, Cho et al. 2008). 
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Figure 2.1-5 Selected HIF target genes 
 
Studies in genetically modified mice have also provided evidence that HIF1 and HIF2 
have distinct roles. HIF1 and HIF2 are clearly non-redundant in mice, since knocking out 
either gene has major consequences for embryonic development (Webb, Coleman et al. 2009). 
HIF2 is particularly important in regulating EPO production, and inactivation of hif2 in mice 
results in reduced EPO expression and anaemia which is reversed by administration of 
exogenous erythropoietin (Scortegagna, Ding et al. 2005; Gruber, Hu et al. 2007). HIF2 
knockdown in the mouse retina also reduces local EPO production strikingly (Morita, Ohneda et 
al. 2003; Ding, Scortegagna et al. 2005). Consistent with a dominant role for HIF2 in EPO 
regulation, in hypoxic rat liver and kidney, the hepatocytes and renal cortical fibroblasts 
express HIF2, but little or no HIF1 (Rosenberger, Mandriota et al. 2002). Nevertheless, HIF1 
likely also contributes to regulating EPO production, since the EPO response to hypoxia is 
reduced in hif1 +/- mice (Yu, Shimoda et al. 1999). 
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Figure 4. Selected HIF Target Genes 
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2.1.8 Genetic defects in the oxygen sensing pathway in humans 
Insights into how biological responses to hypoxia are controlled have come from disorders 
in which oxygen sensing is altered. To date, three distinct genetic defects of oxygen sensing 
have been recognised which have given insights into the role of the HIF system in mammalian 
oxygen homeostasis. 
2.1.8.1 Von Hippel-Lindau disease 
Von Hippel-Lindau disease is an autosomal dominant condition characterised by highly 
vascular tumours, most notably clear cell renal cell carcinoma, phaeochromocytoma and 
haemangioblastomas of the central nervous system and retina. The VHL gene was identified by 
positional cloning in 1993. VHL (the protein product of VHL) plays a crucial role in the 
degradation of prolyl-hydroxylated HIF- by the proteasome (Maxwell, Wiesener et al. 1999). 
One defective VHL allele is not sufficient to activate HIF, but somatic inactivation of the second 
allele in susceptible tissue leads to HIF activation, and following other events, to the 
development of a tumour. About 70% of sporadic clear cell renal cell carcinomas have defects 
in VHL, and re-expression of VHL suppresses tumour growth in xenograft assays.  
A hallmark of VHL defective tumours is HIF activation, and the biological role of HIF target 
genes such as vascular endothelial growth factor in angiogenesis is consistent with the highly 
vascular nature of the tumours of VHL disease. There is good evidence that control of HIF is a 
key aspect of VHL’s tumour suppressor actions, although other pathways almost certainly 
contribute (Wykoff, Pugh et al. 2000). 
Interestingly, neutrophils in VHL patients show a partial hypoxic phenotype showing that in 
these cells one functional copy of the VHL gene is insufficient to regulate HIF normally 
(Walmsley, Cowburn et al. 2006). But patients with VHL disease do not have erythrocytosis 
(unless there is ectopic production by a renal cell carcinoma) implying that a single normal VHL 
allele is enough to result in suppressed erythropoietin production in normoxia.  
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2.1.8.2 Chuvash Polycythaemia 
In 1974 endemic hereditary erythrocytosis was reported in the population of Chuvashia, in 
the mid-Volga region of Russia (Poliakova 1974). Affected individuals are homozygous for a 
C→T mutation at nucleotide 598 of the VHL coding sequence which results in an arginine to 
tryptophan substitution at amino acid 200 (R200W) of VHL (Ang, Chen et al. 2002; Ang, Chen et 
al. 2002). This change impairs the interaction of VHL with hydroxylated HIF-α causing relative 
overactivity of HIF. Haplotype analysis has indicated that this mutation is due to a founder 
effect originating 14,000-62,000 years ago (Liu, Ang et al. 2004). 
Chuvash Polycythaemia is characterised by elevated haemoglobin (mean haemoglobin in 
untreated affected cases is 22.6 +/- 1.4 g/dl) with inappropriately elevated levels of EPO. Other 
haematological parameters are normal. There is an increased incidence of vertebral 
haemangiomas, varicose veins and thrombosis. Premature mortality is increased, largely as a 
result of cerebrovascular disease and heart failure and, untreated, the life expectancy is 42 
years. Intriguingly, the response of erythrocyte precursors to erythropoietin ex vivo is 
exaggerated in affected individuals, which is consistent with the view that HIF regulates not 
only erythropoietin expression but also sensitivity, although how this is mediated is not clear 
(Ang, Chen et al. 2002). 
Unlike VHL disease, increased risk of malignancy is not a feature of Chuvash Polycythaemia. 
This may be because the mutated VHL is active enough to suppress HIF activity sufficient to 
prevent tumour genesis. Alternatively, it is possible that the mutated VHL has preserved affinity 
for prolyl-hydroxylated HIF2 sufficient to ensure that the proliferative phenotype of hypoxic 
exposure remains suppressed.  
Individuals with Chuvash Polycythaemia offer an incisive “experiment of nature” in which 
VHL function is reduced. Potentially they can give insight into what other aspects of physiology 
are regulated by VHL.  Affected individuals have mildly elevated pulmonary arterial blood 
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pressure and an exaggerated pulmonary arterial vasoconstriction response to mild hypoxic 
exposure (Smith, Brooks et al. 2006) suggesting that VHL has a role in these aspects of human 
physiology. Interestingly, systemic resting blood pressure is lower than in control subjects 
(Smith, Brooks et al. 2006). In addition, average resting pulmonary arterial pressures were 
elevated in a cohort of patients with Chuvash patients compared with controls (Bushuev, 
Miasnikova et al. 2006).  More recently, it was shown that transgenic mice homozygous for the 
same R200W mutation in vhl develop pulmonary hypertension in addition to erythrocytosis 
(Hickey, Richardson et al. 2010). 
2.1.8.3 PHD2 erythrocytosis 
Autosomal dominant inheritance due to a C→G change at nucleotide 950 in PHD2 has been 
described in a single UK family (Percy, Zhao et al. 2006). The clinical features include relatively 
mild erythrocytosis with inappropriately non-suppressed erythropoietin levels. The mutation 
predicts a substitution of arginine for proline at codon 317 of the protein – a residue which is 
close to two of the residues coordinating the ferrous atom at the active site of the enzyme. 
Mutant PHD2 with this substitution has a reduced ability to bind to HIF1 and HIF2 and 
reduced prolyl-hydroxylase activity, and the disease mechanism is thought to be 
haploinsufficiency. More recently, further mutations in PHD2 have been implicated in 
erythrocytosis with similar clinical features (Percy, Furlow et al. 2007; Al-Sheikh, Moradkhani et 
al. 2008).  
The observation that neither Chuvash polycythaemia nor PHD2 erythrocytosis are 
associated with an obvious increased risk of renal cell carcinoma illustrates the point that the 
ability of a cell to degrade HIF in oxygen must be almost completely ablated in order to cause 
tumorigenesis, or alternatively that some other function of VHL needs to be disabled. At a 
cellular level, VHL disease is recessive since it involves biallelic loss of VHL function through a 
somatic “second hit”. 
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2.1.8.4 A novel HIF pathway disease? 
A family has been identified in North London in whom erythrocytosis with raised circulating 
erythropoietin levels is transmitted in an autosomal dominant fashion and in whom exonic PCR 
amplification and sequencing has revealed no mutation in PHD2 or VHL. Two older affected 
members of this pedigree were recently diagnosed with pulmonary arterial hypertension and it 
seemed possible that a defect in HIF regulation is responsible for all the aspects of the 
phenotype. The aim of this investigation was to identify the manifestations of the disease and 
to understand its genetic basis. 
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2.2 Clinical histories 
The family was first described in 1979 (Howarth, Chanarin et al. 1979). The index case 
(individual II-1 in Figure 2.2-1) had been diagnosed with erythrocytosis at the age of 27 
following attendance at an antenatal clinic with her first pregnancy. She was entirely fit and 
well and her presenting haemoglobin (Hb) concentration was 18.1 g/dl. She was treated with 
500ml venesection (which reduced the Hb to 16.8 g/dl) and proceeded to uneventful labour 
and delivery of a healthy girl (designated III-2). 
 
Figure 2.2-1 Erythrocytosis pedigree 
Not standard nomenclature – additional unaffected relatives not shown 
4 months post-partum, the Hb had risen to 20.2g/dl (haematocrit 60.8%) and clinical 
examination was normal with no splenomegaly identified clinically or by technetium scanning. 
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The mean cell volume was 92 fl with a normal mean cell Hb concentration. Red cell mass was 
36ml/kg (196% predicted value corrected for body surface area) and plasma volume 28 ml/kg 
(normal range 40-50 ml/kg). The arterial pO2 was 13.2 kPa while breathing room air and other 
investigations, including arterial oxygen saturation, O2 dissociation curves and intravenous 
pyelogram were normal. Serum biochemistry (including lactate dehydrogenase and iron 
studies) was normal, as was peripheral differential blood cell count (Table 2.2-1). Bone marrow 
aspiration showed normoblastic erythropoiesis and iron was detectable (Figure 2.2-2). She had 
smoked 10 cigarettes a day since the age of 21. Treatment with recurrent venesection was 
administered and recovery of the Hb to >20g/dl in 6 months was observed if venesection was 
not performed. Between 1979 and 1989 she was also treated with hydroxyurea and a short 
course of chlorambucil. In 1989 the serum erythropoietin level was 1637 mIU/ml (NR 9.1-23 
mIU/ml) after venesection to an Hb of 15 g/dl and was 361 mIU/ml immediately prior to 
venesection on a subsequent occasion some years later. Erythropoietin levels subsequently 
rose to >2000 by the year 2000 at which time the haematocrit was normal with venesection 
sufficient to maintain marked iron deficiency with a mean cell volume <60 fl.  
 
Table 2.2-1 Laboratory parameters  
*
Not contemporaneous measurements  
†
Sampled at 5 years of age - mean value in this age group is 12.5 g/dl  
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In 2002, at the age of 54, she was admitted to hospital with breathlessness and ankle 
swelling. Oxygen saturation was 92-94% on room air. Ventilation-perfusion scanning and 
subsequent computer tomographic pulmonary angiography revealed no evidence of pulmonary 
embolic disease and echocardiography revealed significant pulmonary arterial hypertension 
(estimated at 90mmHg) which was confirmed on subsequent cardiac catheterisation (Table 
2.2-2). Left ventricular function was normal with no significant valvular pathology. Treatment 
with warfarin was started, however her symptoms of breathlessness worsened and she 
stopped work as a cleaner in 2004. She stopped smoking in 2005 following an episode of atrial 
flutter, treated with ablation and insertion of a permanent pacemaker. Treatment with 
bosentan (an endothelin receptor antagonist) provided some symptomatic relief however her 
oxygenation and mobility gradually decreased and she died in 2006 aged 58. 
 
Figure 2.2-2 Bone marrow aspirate from individual II-1  
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In 1973 (at the age of 62), the mother of the index case (designated I-2 in Figure 2.2-1) 
presented to her physician and was diagnosed with “mild congestive cardiac failure.” At this 
time her Hb had been 21.4 g/dl. In 1976 she complained of attacks of dizziness and the Hb was 
22.8 g/dl with a haematocrit of 61.3%. Other haematological indices are shown in Table 2.2-1. 
The attacks of dizziness persisted although were improved following regular venesection. She 
reportedly died from “heart failure” in the 1980s and there was no record of any 
echocardiographic investigations having been performed. 
 
Table 2.2-2 Right heart catheter study in II-1  
 
The brother of the index case (individual II-3) was also known to have erythrocytosis with 
an initial red cell mass of 56.6 ml/kg. He was 32 years old in 1976 and was being treated with 
regular venesection. White cell and platelet counts were normal as were tests of oxygenation 
and haemoglobin function (Table 2.2-1). He reported intermittent headaches associated with 
fortification spectra, light sensitivity and nausea which were alleviated following venesection 
which was performed intermittently lifelong to maintain a haematocrit <50%. He subsequently 
developed coeliac disease (anti-endomysial antibodies and scalloped duodenum detected 
following presentation with dermatitis herpetiformis); paroxysmal atrial fibrillation (treated 
with warfarin and amiodarone); hypothyroidism; and ischaemic heart disease, with an anterior 
myocardial infarction associated with left anterior descending artery stenosis which was 
stented in 1998. An echocardiogram at this time revealed an enlarged left ventricle with mild 
mitral and tricuspid regurgitation and an estimated right atrial/right ventricular pressure 
difference of 40 mmHg, indicating at least mild to moderate pulmonary arterial hypertension 
(the jugular venous pressure was not documented at this time). Subsequent echocardiography 
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performed in late 2006 to assess increasing shortness of breath demonstrated impairment of 
left ventricular function and increased pulmonary arterial resistance with pulmonary 
hypertension classed as moderate. His exercise tolerance declined with increasing shortness of 
breath and he died in 2007 at the age of 63 while awaiting further investigation for pulmonary 
hypertension. At this time he had received venesection to maintain haematocrit < 50% and his 
last EPO level had been 1980 mIU/ml. His karyotype was normal on cytogenetic examination. 
Erythrocytosis in the two children of II-3 (individuals III-7 and III-8) was identified in 
childhood when they were screened for the condition. They both exhibited elevated 
haematocrit with elevated erythropoietin levels identified subsequently (see Table 2.2-1). 
Individual III-7, born in 1974, has been generally well and has had three children (designated IV-
6, IV-7 and IV-8, born in 1994, 1999 and 2003 respectively) and 2 miscarriages. Child IV-6, a boy, 
complained of headaches at the age of 5 and was noted to have erythrocytosis with Hb of 16.1 
g/dl at that time (mean Hb in children between 2 and 6 years is 12.5 g/dl). He did not provide a 
DNA sample, although his siblings (individuals IV-7 and IV-8 who have normal Hb and 
erythropoietin levels) did. 
Individual III-1, the son of the index case, was born in 1981 and was noted to have 
erythrocytosis (Hb 20.2 g/dl) with an inappropriately non-suppressed erythropoietin level of 
13.2 mIU/mL. 
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2.3 Genetic Investigation 
The VHL and PHD2 genes were first sequenced in two family members prior to the start of 
this study and no mutations had been found in the coding or flanking intronic sequences of 
either gene, implying that the cause of the erythrocytosis was not due to a coding mutation in 
either of these genes. Blood for DNA extraction was collected from additional consenting family 
members and DNA was extracted. In view of the well-defined pathway regulating 
erythropoietin production and the limited number of known proteins participating in it (see 
Table 2.3-1), I performed a genome-wide linkage study in order to identify whether a common 
haplotype was inherited by all affected individuals at the locus of each of these candidate 
genes.  
 
Table 2.3-1 Candidate genes for erythrocytosis  
EPOR (Erythropoietin Receptor), JAK2 and STAT2 mutations would be predicted to cause erythrocytosis with 
suppressed EPO levels. *Sequenced with no coding sequence mutation detected prior to linkage study. 
 
With the available DNA, maximum possible LOD scores for markers with different 
recombination fractions with the condition in this pedigree was estimated using FastSLINK 
(Weeks, Ott et al. 1990). This yielded a maximum predicted LOD of 1.81 for a marker with a 
recombination fraction (Θ) of 0 (i.e. at a genetic distance 0 cM from the diseases-causing locus). 
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Although this would not be sufficient to prove linkage from an unbiased standpoint, it was 
hoped that a large proportion of the candidate genes would be excluded using this approach. 
Genotyping was performed by Dr C Mein (Queen Mary and Westfield College, University of 
London) using the Illumina Linkage IV panel which consists of bi-allelic markers distributed 
across the genome and separated by an average of 0.65cM (coverage is summarized in Figure 
2.3-1). Mean heterozygosity (in the Caucasian population) is 43%. 
 
Figure 2.3-1 Genome coverage of Illumina Linkage panel  
 
6008 SNPs were assayed in 9 individuals, yielding 54,072 genotypes which were called using 
Illumina software. In 16 SNPs, genotyping failed in all individuals. For the remaining 5992 SNPs, 
genotyping failed in one or more individuals on a further 569 occasions, distributed as shown in 
Table 2.3-2, yielding a total assay failure rate of 1.3%. 
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Table 2.3-2 Distribution of SNP genotyping failures.  
 
Genotypes were analysed using PEDCHECK (O'Connell and Weeks 1998)and this indicated 
that there were 33 Mendelian errors (in 33 different SNPs). This equated to approximately 
0.06% genotypes and indicated firstly that the SNP genotyping was very accurate, and secondly 
that ascertainment of the family tree and sample labelling/processing was likely to be without 
error. SNPs in which there were Mendelian errors were excluded from all further analyses as 
these errors were most likely explained by genotyping inaccuracy. 
The remaining 53,062 genotypes were analysed using GENEHUNTER (Markianos, Daly et al. 
2001) using the EasyLINKAGE interface (Hoffmann and Lindner 2005). The genotypes were 
divided into sets of 100 markers and parametric linkage analysis was performed in all 
individuals on each set sequentially, assuming a dominant model of inheritance. The analysis 
was repeated in sets of 71 and 59 markers and using MERLIN (Abecasis, Cherny et al. 2002). In 
all analyses, the results were essentially similar.  
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2.3.1 Genome-wide SNP linkage and haplotype analysis 
5522 SNPs (or 92.7% of those analysed) lay in regions of the genome at which the LOD 
score was less than -2.0 (robustly excluding linkage with erythrocytosis by conventional 
criteria), implying a >100:1 likelihood against linkage with these loci (at Θ = 0). As predicted, the 
maximum LOD score was 1.81: 121 SNPs (or 2% of all genotyped) lay in 4 regions of the 
genome at which the LOD score was >1.5, and a further 54 (0.9%) SNPs lay in regions at which 
the LOD was between 0 and 1.5. The LOD scores across the entire genome, generated using 
both GENEHUNTER and MERLIN, are summarized in Figure 2.3-2. The LOD scores at the specific 
genomic locations of each of the candidate genes are shown in Table 2.3-3. This indicated that, 
while most of the candidate genes were robustly excluded by conventional criteria (LOD < -2), 
three genes (HIF2α, VHL and Elongin B) lay in regions which were not formally excluded.  
 
Figure 2.3-2 Genome wide LOD plots with GENEHUNTER and MERLIN  
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I next performed haplotype analysis using the haplotypes generated by GENEHUNTER and 
visualised using HAPLOPAINTER (Thiele and Nurnberg 2005). This demonstrated that, of the 
three genes, only HIF2α lay in a region in which the same haplotype was inherited by all 
affected members of the pedigree, and hence the LOD score was maximal (Figure 2.3-3). 
 
Table 2.3-3 Parametric LOD score at each candidate gene 
*Not formally excluded by conventional criteria 
**Only candidate gene at locus which segregates perfectly with disease 
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Figure 2.3-3 Haplotype analysis 
A haplotype (pink) which spans the HIF2α locus is inherited by all (and only) the affected individuals in the 
family (filled symbols). The LOD plot was generated using GENEHUNTER scoring unaffected individuals as ‘unknown’  
 
I concluded that the mutation responsible for the disease was likely to lie within the HIF2α 
gene. 
2.3.2 HIF2α sequencing 
The HIF2α gene consists of 5160 base-pairs (bp) divided between 16 exons in a genomic 
region of approximately 42 kilobase-pairs (kbp). However, since the phenotype of the disease 
suggested increased HIF activity, I hypothesised that to produce such a gain-of-function, the 
mutation responsible, given that it lay within the HIF2α gene, would be more likely to disrupt 
the function of a regulatory domain than to enhance the function of an activation domain. This 
is because a random change in a complex system is more likely to impair its function than to 
enhance it. An analogy is shooting a bullet into a motor car. This will either result in no effect 
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on the function of the car or disruption of its function: either being stopped when it should be 
going or going when it should be stopped. If it is the latter, then the bullet would be intuitively 
more likely to have damaged the brakes rather than to have changed the engine in such a way 
as to increase its performance. In addition, experimental manipulation of the HIF pathway in 
cell-based models has been performed employing mutations of the critical proline and 
asparigine residues (to alanines) in order to generate HIF proteins which are resistant to 
oxygen-dependent degradation (Kondo, Klco et al. 2002). For these reasons, it seemed likely 
that the mutation responsible would lie at or near proline residues 405 or 531 or else the 
asparagine residue 847. 
 
Figure 2.3-4 Exons of HIF-2α mapped to functional domains of the protein 
ODDD, oxygen-dependent degradation domain; bHLH, basic helix-loop-helix; PAS Per-Arnt-Sim; TAD, Terminal 
activation domain 
 
I therefore mapped the exons of the HIF2α gene onto the various functional domains of the 
HIF2α corresponding to the oxygen dependent degradation domain (ODDD) and P300 binding 
domain (Figure 2.3-4) and amplified and sequenced exons 9, 12 and 16 of the gene in 2 
affected members of the family (II-1 and III-7) and one control person. This demonstrated 
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heterozygosity for a Guanine to Adenine (G to A) single nucleotide substitution at base 2097 
from the transcription start site in both affected (but not the unaffected) individuals (Figure 
2.3-5). This substitution was not represented in any online database of single nucleotide 
polymorphisms. 
 
Figure 2.3-5 Sequence trace  
Resequencing affected individuals II-1 and III-7 revealed heterozygosity for a G→A substitution at base 2097 in 
exon 12 of HIF-2α (arrow). This is not a previously reported SNP and predicts a Glycine (Gly) to Arginine (Arg) 
substitution at residue 537 of the HIF2α protein, 6 amino acids from the functionally important hydroxyl acceptor 
Proline (Pro – underlined). 
 
2.3.2.1 HIF2α G2097A may be pathogenic 
HIF2α G2097A is predicted to be a non-synonymous change: it predicts a change from the 
small and hydrophobic Glycine (G - wild type) to the large and hydrophilic Arginine (R). Notably, 
this residue is highly conserved across species (Figure 2.3-6) and lies just 6 residues from 
Proline 531, which is one of the two hydroxyl-acceptor prolines of the ODDD. It therefore 
seemed possible that this substitution could impair the hydroxylation of HIF2α or else reduce 
the ability of the VHL E3 ubiquitin ligase to recognise and/or ubiquitinate the hydroxylated 
protein, reducing the rate of its degradation. 
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Figure 2.3-6 Conservation of HIF2α537Gly 
537Gly (bold) is highly conserved across many species in HIF2α but is not present in HIF1α. Hydroxyl-acceptor 
Proline (P) is underlined  
 
2.3.2.2 HIF2α G2097A is a rare mutation which segregates with disease  
The substitution G2097A does not produce or abolish any known restriction sites, so in 
order to determine whether it was present in other members of the pedigree or in healthy 
controls I used an amplification refractory mutagenesis system PCR (ARMS-PCR) reaction. This 
technique was originally described in 2001 (Ye, Dhillon et al. 2001) and uses 2 primer pairs, 
each selective for one allele, to generate products of different sizes. The primers compete and 
the products can be separated by gel electrophoresis. This confirmed firstly that the mutation 
did cosegregate with the disease (Figure 2.3-7) and secondly that the allele was not present in 
88 members of the UK 1958 birth cohort (Figure 2.3-8). Together these findings supported the 
hypothesis that the G2097A mutation was responsible for erythrocytosis and pulmonary 
arterial hypertension in the family. 
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Figure 2.3-7 ARMS-PCR assay  
Demonstrating that the G2097A heterozygosity cosegregates with the disease within the family.  
 
 
Figure 2.3-8 ARMS-PCR in 88 UK controls  
Demonstrating lack of heterozygosity for G2097A in HIF2α among 88 members of the UK 1958 birth cohort 
(selected at random). Lane 1 (asterisk in first panel) is individual II-1, used as a positive control. 
Chapter 2: HIF2α Erythrocytosis and Pulmonary Hypertension 
65 
 
2.4 HIF2α Arg537 functional studies 
HIF2α 2097A codes for a protein identical to the wild type HIF2α with the exception of the 
substitution of an Arginine for the Glycine at position residue 537, 6 amino acids away from the 
critical hydroxyl acceptor proline. In order to test whether this substitution is sufficient to alter 
the function of the protein, I generated the mutant alleles in vitro using site-directed 
mutagenesis and used an HRE-luciferase reporter system in order to determine whether the 
mutant protein exhibited altered function compared with the wild type. 
2.4.1 HIF2α Arg537 has increased transcriptional activity 
At this time, a report of a different small family was published in which erythrocytosis and 
raised EPO levels cosegregated with a mutation which resulted in a Glycine to Tryptophan 
change at position 537 of HIF2α (i.e. a different mutation at the same codon as the mutation 
which I had identified) (Percy, Furlow et al. 2008). Pulmonary arterial hypertension was not 
reported in this family.  
I therefore generated constructs containing HIF2α with either the wild type sequence, or 
Arginine (Arg537) or Tryptophan (Trp537) instead of Glycine at position 537. I co-transfected 
these constructs, alongside an HRE-Firefly luciferase reporter construct (in which expression of 
a firefly luciferase gene is dependent on HIF) and a constitutively expressed Renilla luciferase 
construct, into cultured human hepatoma cells (HepG2) which produce EPO in response to 
hypoxia (i.e. cells in which oxygen dependent expression of EPO and HIF can be studied 
(Goldberg, Glass et al. 1987)). The ratio of firefly to Renilla luciferase activity (which can be 
separately measured) in lysates made from these cells is therefore dependent on HIF activity 
within the cells. This experiment is represented in Figure 2.4-1 and was performed with 
increasing doses (25, 50 and 100ng) of plasmid DNA, each time in triplicate. As a positive 
control, I co-transfected cells with the luciferase constructs and incubated cells co-transfected 
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with the different HIF2α alleles with desferrioxamine (DFO), which chelates iron, inhibiting 
prolyl- and asparaginyl-hydroxylation and therefore stabilising HIF. As a negative control I co-
transfected cells with the luciferase constructs and equimolar amounts of the empty pcDNA3.1 
vector.  
 
Figure 2.4-1 HIF activity reporter assay 
Wild type or mutant HIF2α in pcDNA3.1 was transfected into hepatoma (HepG2) cells alongside constructs 
containing an HRE-linked (i.e. HIF responsive) firefly luciferase gene and a constitutively expressed Renilla luciferase 
gene. The ratio of firefly:Renilla luciferase activity is dependent on the amount of HIF activity within the cell. 
 
In all experiments, the Firefly:Renilla luciferase ratio was greater in cells co-transfected 
with the same quantity of the Arg537 mutant HIF2α construct compared with the wild type. 
Using a construct containing HIF2α Trp537 instead of Arg537 resulted in intermediate luciferase 
expression (Figure 2.4-2). 
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Figure 2.4-2 HIF2α activity 
Firefly (FF):Renilla luciferase activity in HepG2 cells transfected with an HRE-Firefly luciferase construct and a 
Renilla luciferase construct alongside either: plasmid constructs containing HIF-2α wild type, Arg537 or Trp537 
mutants at the quantities shown in ng in triplicate; or equimolar amounts of the empty vector; or 25ng of the wild 
type and mutant constructs and incubated with 100μM desferrioxamine (DFO). Error bars represent standard 
deviation. 
 
The dose-response ratio can be appreciated by representing the same data as a line graph 
(Figure 2.4-3) and the differences were statistically significant at a dose of 50 ng (one way 
ANOVA: Figure 2.4-4). Stabilisation of HIF with DFO produced significantly greater firefly:Renilla 
ratios than any of the mutants incubated in the absence of DFO. This effect was independent of 
genotype and there was no significant difference between the different alleles. I repeated the 
experiment using Hep3B cells (a different hepatoma cell line in which HIF and EPO are 
regulated by oxygen) and saw similar results (Figure 2.4-5). 
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Figure 2.4-3 Dose-dependent reporter activity 
Firefly (FF):Renilla luciferase activity ratio increased on transfection of increasing amounts of each HIF-2α 
construct in HepG2 cells. Error bars represent standard deviation. 
 
Figure 2.4-4 Activity of each HIF2α allele 
50 ng of plasmid containing either mutant or wild type HIF-2α was co-transfected into HepG2 cells alongside 
HRE-firefly luciferase and Renilla luciferase reporter constructs. Transfection with HIF-2α Arg537 resulted in 
significantly greater Firefly:Renilla luciferase ratio than transfection with either HIF-2α wild type or HIF-2α Trp537. 
Experiment performed 5 times. Error bars represent standard deviation; p = one way repeated measures ANOVA.  
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Figure 2.4-5 HRE-firefly:Renilla luciferase activity in Hep3B cells 
 
2.4.2 Increased transcriptional activity of HIF2α Arg537 is oxygen-
dependent 
In order to identify whether the increased reporter gene expression (i.e. increased mutant 
HIF activity) was dependent on the presence of oxygen, I performed a further experiment in 
which the transfected HepG2 cells were incubated at various oxygen tensions for 16h 
immediately prior to their lysis. This demonstrated that, as the oxygen level decreased, the 
difference between the genotypes became less marked. At 1% oxygen (a level at which prolyl- 
and asparginyl-hydroxylation of wild type HIF is very inefficient so that HIF is highly active) 
there was no difference between the activities of the different HIF2α proteins (Figure 2.4-6). I 
concluded that the mutation impaired the oxygen-dependent hydroxylation of HIF2α and was 
unlikely to have a significant direct effect on DNA- or HIF1β-binding or co-transactivator 
recruitment. 
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Figure 2.4-6 Effect of hypoxia on HIF2α mutant activity in HepG2 cells 
In hypoxia, activity of all constructs was increased and the difference between the level of activation was no 
longer detectable. 
2.5 HIF2α Erythrocytosis and pulmonary physiology 
The observation that two older members of the pedigree had pulmonary arterial 
hypertension (in the absence of pulmonary thromboembolic disease) was potentially significant 
because evidence already existed which implicates the HIF pathway in the regulation of 
pulmonary vascular tone (see introduction to this chapter). In order to identify whether 
HIF2αArg537 causes elevated pulmonary vascular tone, I studied two unrelated individuals with 
the mutation. The first was individual III-1 who, at the age of 26, was polycythaemic with a 
haemoglobin level of 20 g/dl. He had never been venesected and was generally in good health 
with the exception of occasional headaches.  
The second individual, designated DC, was a 44-year-old man of mixed Indian and Kenyan 
ancestry who had been diagnosed with polycythaemia aged 21 while living in Uganda. He had 
undergone regular venesection to maintain a haematocrit below 50% since then. Sequencing of 
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exon 12 of HIF2α performed by others had demonstrated heterozygosity for G2097A, 
predicting the same Glycine to Arginine change at residue 537 of the protein (Percy, Beer et al. 
2008).  
The experimental protocol was the same as that described previously (Smith, Brooks et al. 
2006). In brief, end tidal partial pressure of oxygen and carbon dioxide (PETO2 and PETCO2) were 
measured by occluding the nose and allowing breathing to occur through a mouthpiece 
connected to a circuit. Continuous monitoring of exhaled respiratory gases was performed 
using a mass spectrometer connected to a computer which also controlled the delivery of 
nitrogen, oxygen and carbon dioxide to the subject, allowing dynamic control of the PETO2 and 
PETCO2. PETCO2 was clamped at the subject’s own baseline level throughout the experiment. 
Each participant was first subjected to 5 minutes of euoxia (PETO2 of 100 mmHg) followed by 10 
minutes of mild hypoxia (PETO2 of 70 mmHg, approximating to the level of hypoxia experienced 
during commercial airline travel). This was followed by 5 minutes of euoxia before a 20 minute 
break breathing room air. Next the protocol was repeated but with the hypoxic stimulus being 
moderate instead of mild i.e. a PETO2 of 50 mmHg, which is approximately equivalent to the 
hypoxia experienced during exposure to an altitude of 3500m above sea level. The protocol 
was performed with the subject in the left lateral position and a Doppler ultrasound machine 
was used to measure the maximum systolic tricuspid regurgitant jet velocity, V. The maximum 
systolic pressure gradient (ΔPmax) across the valve (i.e. the difference between the pulmonary 
arterial pressure and the right atrial pressure) was calculated using Bernoulli’s equation: 
        
  
Since right atrial pressure is not affected by hypoxia (Groves, Reeves et al. 1987), changes 
in ΔPmax can be attributed to changes in pulmonary arterial resistance. 
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This experiment demonstrated firstly that resting ΔPmax was elevated in both individuals 
with HIF2α erythrocytosis at 30 (III-1) and 29 mmHg (DC). Since the cut-off for pulmonary 
arterial hypertension is 25 mmHg (and ΔPmax is likely to underestimate the PA pressure since 
the right atrial pressure is greater than 0 mmHg) both these individuals have pulmonary arterial 
hypertension at rest. In addition, mild and moderate hypoxic exposure provoked an 
exaggerated rise in ΔPmax in both individuals compared with healthy controls (Figure 2.5-1). I 
concluded that activation of HIF2α alone (i.e. in the absence of activation of HIF1α) is sufficient 
to produce exaggerated pulmonary arterial tone in humans.  
 
Figure 2.5-1 Isocapnic hypoxic exposure in HIF2α Erythrocytosis 
Hypoxic pulmonary vasoconstriction responses were exaggerated in individuals with HIF2α Erythrocytosis 
compared with controls.  
 
2.6 Summary 
This investigation resulted in the identification of a novel mutation in the HIF2α gene which 
cosegregated with erythrocytosis and elevated pulmonary arterial pressure. Experiments 
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performed using recombinant mutant and wild-type protein demonstrated that the 
substitution of Arginine (or Tryptophan) in the place of Glycine at residue 537 of HIF2α results 
in a protein in which transcriptional activity in normoxia is enhanced. This is very likely to be a 
consequence of impaired oxygen-dependent degradation of the protein since the difference is 
not seen when HIF prolyl hydroxylation is inhibited (by either iron chelation or hypoxia) and is 
almost certain to cause the disease. 
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2.7 Discussion 
This investigation led to the identification of an activating mutation in HIF2α which was 
responsible for autosomal dominant erythrocytosis and pulmonary arterial hypertension in a 
UK family. Consistent with this, I showed in vitro that the mutation resulted in increased HIF2α 
activity in the presence of oxygen.  
The role of HIF2α in regulating erythropoietin production is supported by several previous 
observations. Firstly, selective knockdown of HIF2α but not HIF1α using RNA interference in 
hepatoma cell lines caused loss of hypoxia-induced upregulation of the erythropoietin gene. 
This contrasted with the dependency of hypoxia-induced expression of most other HIF target 
genes tested on HIF1α (Warnecke, Zaborowska et al. 2004). Secondly, conditional inactivation 
of hif2α but not hif1α in the livers of mice deficient in vhl suppressed hepatic expression of 
erythropoietin and the development of polycythaemia (Rankin, Biju et al. 2007). Thirdly, 
expression of hif2α but not hif1α in ischaemic rat kidneys was localised to the fibroblasts which 
produce erythropoietin (Maxwell, Osmond et al. 1993; Rosenberger, Mandriota et al. 2002). In 
addition, mice homozygous for the vhl R200W mutation which causes Chuvash polycythaemia 
in humans have been shown to have increased haematopoiesis associated with increased hif2α 
protein levels (Hickey, Lam et al. 2007). Together these previous findings are all compatible 
with a crucial role for HIF2α in the control of erythropoietin production in humans. 
While the study presented here was being done, a separate group identified unrelated 
individuals with mutations in the same and nearby codons of HIF2α which are also associated 
with erythrocytosis (Percy, Beer et al. 2008; Percy, Furlow et al. 2008). This proves that 
activation of HIF2α in humans is sufficient to cause erythrocytosis. Although in mice inducible 
silencing of hif2α results in normocytic anaemia (Yamashita, Ohneda et al. 2008), proof of a 
non-redundant role for HIF2α in erythropoiesis in humans would require either the 
identification of a loss-of-function HIF2α allele which is associated with a lower than normal 
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haematocrit, or alternatively observing anaemia in humans following specific targeting of HIF2α 
with a pharmacological agent.  
A genome-wide association study of haemoglobin levels in 16,000 individuals of European 
or Indian ancestry identified a non-synonymous SNP located in TMPRSS6 (which codes for an 
enzyme involved in the regulation of the synthesis of the iron control hormone hepcidin) as the 
most strongly associated with haemoglobin levels, and other SNPs located nearby and within 
the HFE gene (mutations of which cause hereditary haemochromatosis, or progressive iron 
loading) were also significantly associated with haemoglobin levels (Chambers, Zhang et al. 
2009). Importantly, variants of HIF2α or the genes constituting the oxygen sensing pathway 
were not found to be associated with haemoglobin levels in this study. It appears likely that this 
simply reflects lack of common functionally significant variation in these genes in the 
populations examined. This view is supported by recent data obtained from genetic analyses of 
high altitude populations (see below). 
It is well recognised that hypoxia (for instance during altitude exposure) is a risk factor for 
the development of pulmonary hypertension (Preston 2007). The physiological reason for this 
phenomenon may be a short term adaptive response: as regions of the lung in which 
ventilation is impaired (for instance in the context of pneumonia) become hypoxic the 
increasing vascular resistance through these regions reduces the amount of deoxygenated 
blood entering the systemic arterial circulation and prevents shunting of deoxygenated blood 
back to the systemic arterial circulation. 
As discussed above, patients with Chuvash polycythaemia exhibit elevated resting 
pulmonary vascular tone (Bushuev, Miasnikova et al. 2006); exaggerated pulmonary 
vasoconstriction in response to hypoxic exposure (Smith, Brooks et al. 2006); and mice 
engineered to carry the same homozygous substitution (R200W in vhl) exhibit pathological 
features of pulmonary arterial hypertension (Hickey, Richardson et al. 2010). This is compatible 
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with the hypothesis that both the abnormal physiology displayed by patients with Chuvash 
polycythaemia and the normal human pulmonary vascular response to altitude are mediated 
by HIF2α. Further insights into the role of the HIF pathway, and HIF2α in particular, have come 
from studies of individuals and communities exposed to chronic hypoxia which is unavoidable 
at high altitudes. 
2.7.1 Genetic adaptation to altitude 
Humans have adapted to a range of different environments since their dispersal from 
Africa. Behavioural, technological and biological adaptability have all contributed to enable 
human survival in a vast geographical range which spans areas in which temperature, 
ultraviolet radiation, climate and food sources differ enormously. However, of these forms of 
adaptability, only biological (i.e. genetic) adaptation has contributed to the human ability to 
colonise high-altitude territory, because pre-modern technology could not ameliorate the 
pervasive hypoxia which exists at high altitude locations as a consequence of reduced 
atmospheric pressure. Over 140 million people worldwide now live at over 2500m above sea 
level (Moore, Niermeyer et al. 1998; Penaloza and Arias-Stella 2007), and communities have 
lived at altitude in the Tibetan plateau and Andean highlands for many generations (estimated 
at 1100 and 550 respectively). 
2.7.1.1 Chronic Mountain Sickness 
Exposure to high altitude causes a reduction in the partial pressure of oxygen in the alveoli, 
which in turn results in reduced saturation of haemoglobin (Figure 2.7-1). Since the amount of 
oxygen dissolved in the plasma is small compared with the amount bound to haemoglobin, 
most of the oxygen carrying capacity of the circulation is provided by haemoglobin. As the 
partial pressure of oxygen falls below 100 mmHg this is associated with a steepening of the 
oxygen-haemoglobin dissociation curve (Figure 2.7-2), with any further reduction in oxygen 
concentration being associated with a more pronounced decline in haemoglobin saturation. 
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This stimulus is accompanied by a rise in haematocrit and a marked decline in plasma volume, 
presumably as an adaptive mechanism to increase the oxygen carrying capacity of the blood by 
maximising the haematocrit as rapidly as possible. It is notable that the plasma volumes of 22.4 
and 28.0 ml/kg reported by Howarth et al in 1979 in patients with HIF2α erythrocytosis were 
lower than any seen in those authors’ clinical practice (Howarth, Chanarin et al. 1979). In fact 
altitude-induced reductions in plasma volumes (of up to 39% and as low as 29 ml/kg) were 
recorded as long ago as 1964 by LG Pugh who studied the effects of acute altitude exposure on 
Europeans during a Himalayan expedition (Pugh 1964).  
 
Figure 2.7-1 High altitude is associated with reduced barometric pressure 
This results in reduced inspired partial pressure of oxygen 
 
Prolonged exposure to reduced ambient oxygen can result in profound adverse 
physiological effects known as chronic mountain sickness (CMS). CMS is a syndrome which 
occurs in long-term residents at high altitude characterised by excessive erythrocytosis 
Chapter 2: HIF2α Erythrocytosis and Pulmonary Hypertension 
78 
 
(increase in red blood cell count), hypoxaemia and reversibility on descent. It is well recognised 
that the progressive CMS leads to pulmonary arterial hypertension with consequent right 
ventricular enlargement (Moore 2001). This is known as high altitude heart disease (HAHD) and 
autopsy findings in fatal cases of CMS have demonstrated that the main abnormal pathology 
involves hypertrophy of the vessels of the pulmonary circulation (Arias-Stella, Kruger et al. 
1973). Observations in healthy residents of high altitude have demonstrated that right 
ventricular hypertrophy, present at birth in all infants, persists in those raised at altitude 
(Penaloza and Arias-Stella 2007). Importantly, the clinical syndrome of erythrocytosis and 
pulmonary hypertension is also seen in many patients with chronic hypoxaemia owing to, for 
example, chronic respiratory or cardiovascular diseases. The similarity of the features of CMS to 
HIF2α erythrocytosis is compatible with the hypothesis that hypoxic activation of HIF2α 
underlies the pathophysiology of both diseases. 
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Figure 2.7-2 Oxygen-haemoglobin dissociation curve and hypoxia at altitude 
 
Although ventilatory responses to hypoxic exposure show strong familial concordance 
(Fagan and Weil 2001) and familial clustering of HAHD and CMS has been observed, data is not 
complete enough to conclude that this does not result from shared environmental factors 
(Rupert and Koehle 2006). However, comparative studies of Tibetan, Han (lowland Chinese), 
Western and Andean populations have revealed significant differences in haematocrit (Beall 
and Reichsman 1984; Garruto, Chin et al. 2003) and pulmonary vascular musculature studied at 
matched altitudes (Gupta, Rao et al. 1992). These data are consistent with the hypothesis that 
genetic adaptation to a high altitude environment has occurred. In addition, pulmonary artery 
pressure of Aymara children at altitude is significantly lower than that of Caucasian children 
studied at the same altitude (Stuber, Sartori et al. 2008). 
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More robust evidence for genetic factors determining susceptibility to CMS comes from the 
observation that risk of CMS at a given altitude varies between different populations. Carlos 
Monge (who was the first to describe CMS) himself observed that Europeans were more 
susceptible to the disease than indigenous Andean residents (Monge 1943), and Tibetans, 
believed to have the longest high altitude antiquity, have strikingly reduced incidence of CMS 
compared with either Han Chinese or Andeans residing at the same altitude since birth (Pei, 
Chen et al. 1989; Moore 2001). This variation suggests that genetic modifiers of susceptibility to 
the disease may exist. 
2.7.1.2 Reproduction at high altitude 
That lowlanders have impaired ability to reproduce at altitude compared with indigenous 
high altitude populations has been recognised for generations: it is traditional for female Han 
Chinese residents of Tibet to stay with relatives in lowland China during pregnancy, returning 
soon after childbirth. Among the Han infants born at high altitude in Lhasa, Tibet (altitude 
3658m above sea level) there is a higher incidence of subacute infantile mountain sickness 
(which consists of polycythaemia, pulmonary arterial hypertension and right heart failure) 
compared with Tibetan infants (Niermeyer, Yang et al. 1995). In addition, the birth weight and 
oxygen saturation of the Tibetan infants was significantly greater than those of the Han infants 
born at the same altitude. Other studies have shown that high altitude is an independent 
predictor of low birth weight (Keyes, Armaza et al. 2003) and that the susceptibility to this 
effect is different between different ethnic populations, with Andean and Tibetan populations 
displaying less reduction in birth weight at high altitude compared with European and Han 
Chinese (Figure 2.7-3) (Moore, Shriver et al. 2004). Early records show that when the 
Conquistadors (Spanish immigrants) arrived at high altitude regions of what is now Peru in the 
16th Century, they experienced reduced fertility and increased perinatal mortality compared 
with the local Inca population (Gonzales 2007). This ‘Curse on the Conquistadors’ is still evident 
today in Bolivia, where children born to Aymara parents (the indigenous group with the longest 
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high-altitude ancestry in the country), despite significantly more adverse socio-economic 
conditions, are protected against intra-uterine growth retardation and are consistently heavier 
at birth than children with European ancestry in whom poverty is less common (Julian, Galan et 
al. 2008). This suggests that even gross disparities of income cannot overcome either the 
effects of altitude on intrauterine growth or the genetic adaptation this stress has produced in 
high altitude communities (Giussani 2007; Bennett, Sain et al. 2008). 
 
Figure 2.7-3 Birth weight at altitude by ethnicity 
Altitude-associated reduction in birth weight is less pronounced in populations with high altitude ancestry (after 
Moore et al 2004). 
 
Clearly, any genetic trait which has a direct effect on reproductive fitness will have a 
disproportionate propensity for selection, and populations in several parts of the world have 
lived at altitude for many generations, including Tibetans in the Himalayas, Aymara in the 
Andes and the Ambaras in the Ethiopian Highlands. Comparative studies of high altitude 
residents compared with lowlanders living at altitude have shown differences in various 
physiological parameters including lower haemoglobin levels. Importantly, these ancient high 
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altitude populations do not increase their haemoglobin levels at altitude. The Ambaras people 
of the Ethiopian highlands have a particular ability to maintain arterial oxygen saturation which 
is not understood, but is likely to reflect altered pulmonary physiology. The history of human 
settlement in these different regions likely explains why chronic mountain sickness is much 
more common in the Andes. Northern Ethiopia has been inhabited by human beings longer 
than almost everywhere else on Earth. Human habitation of the Himalayan plateaus is thought 
to date back >50,000 years and of the high Andes for significantly less, probably ~10,000 years. 
The Himalayan population has undergone significantly less admixture with lowland groups than 
other high altitude populations, primarily as a result of its isolation and inaccessibility – the 
Tibetan plateau has a diameter of over 750 km, lies 1600 km from the nearest ocean and is 
bounded by the world’s highest mountains and one of its largest deserts. The high Andes, in 
contrast, is a narrow strip which lies within 200 km of the Pacific coastal plain and the 
Amazonian river system and has been subject to European colonisation for the last ~400 years.  
2.7.1.3 Positive selection in Tibetans  
While the case for a genetic adaptation for survival at high altitudes has seemed persuasive 
for a long time, it was not until 2010 that the first strong direct evidence for this effect (and the 
genes involved) was uncovered. Simonson et al used cross-population extended haplotype 
homozygosity (XP-EHH) analysis (Sabeti, Varilly et al. 2007) to identify alleles which have 
increased in frequency to the point of (near) fixation in the Tibetan population (compared with 
control populations from lowland East Asia in which there was variation at these loci). They also 
measured the extent of decay of linkage disequilibrium (the integrated haplotype score, iHS) 
between genomic locations and neighbouring regions in order to identify whether any variants 
are likely to have increased in frequency over a short enough time period to leave detectable 
LD across large distances, suggesting recent selection. While XP-EHH detects alleles which have 
reached or are approaching fixation in a population, iHS allows detection of alleles which have 
not yet reached fixation and can therefore be used to correlate genotype (or number of copies 
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of an allele) with phenotype within a population – a comparison which is robust to 
superimposed genetic differences between populations resulting from either genetic drift or 
selection at other loci. Starting with a panel of 247 a priori candidate genes (which were 
generated using Gene Ontology categories involving biological pathways implicated in  the 
response to oxygenation), 10 of these, including HIF2α and PHD2, showed evidence of positive 
selection in the Tibetan population (Simonson, Yang et al. 2010). While HIF2α was only 
identified on the basis of XP-EHH, PHD2 was identified by both XP-EHH and iHS. This allowed 
the researchers to show that the number of copies of the advantageous allele of PHD2 was 
inversely correlated with haemoglobin level (each copy reducing the haemoglobin 
concentration by approximately 1.7 g/dl), consistent with a model in which downregulation of 
the HIF system is protective against the adverse effects of high altitude living. Since HIF2α was 
detected on the basis of fixation in the Tibetan community a similar quantitative trait analysis 
was not possible for the putatively advantageous allele of this gene, but it seems likely that if 
survival at altitude is enhanced by inheritance of an allele of PHD2 which results in reduced 
haematocrit (presumably by enhancing HIF hydroxylation) then any advantageous HIF2α allele 
will have reduced stability compared with alleles common in the lowland population. Clearly, 
functional characterisation of the selected alleles will be needed to confirm this supposition.  
It is notable that variation in HIF1α has not been found to be associated either with 
Mendelian traits in individuals with polycythaemia nor with positive selection in high altitude 
communities. While this may reflect a lack of an important role of this HIF subunit in 
environmental oxygen sensing and haematocrit regulation (i.e. it is rendered redundant in this 
aspect of oxygen sensing by HIF2α) it remains a possibility that there is such an absolute 
dependence on HIF1α for the normal operation of the oxygen sensing pathway in humans that 
any functionally significant change in the protein is incompatible with survival to reproduction. 
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2.8 Conclusion 
There is now evidence from independent studies of Mendelian human traits, human 
populations, genetically modified model organisms and in vitro systems which implicates HIF2α 
as a central component of environmental oxygen sensing in humans. Understanding the 
mechanisms underlying the biological effects of hypoxic exposure, its physiological responses 
and genetic adaptations, is important not only for physiologists, mountaineers, aviators and 
tourists, but also for physicians: in addition to chronic mountain sickness, many disorders, such 
as cyanotic heart disease, chronic pulmonary disease and obstructive sleep apnoea, are 
associated with prolonged systemic hypoxia. Furthermore, there is evidence that hypoxia plays 
a major role in the aetiology and pathogenesis of pre-eclampsia (Gilbert, Ryan et al. 2008) and 
intrauterine growth restriction (IUGR) which are major causes of pre- and perinatal mortality 
worldwide. Although no therapies currently exist which are able to target selectively specific 
branches of the HIF pathway, it seems logical to predict that significant benefit to large 
numbers of people would accrue from such treatments if they were developed in the future. 
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3.1 Introduction: Renal disease and Complement 
This investigation was undertaken in order to elucidate the cause of an unusual form of 
glomerulonephritis occurring in multiple members of a British Cypriot kindred living in London. 
Consideration of the pathology and phenotype suggested that dysregulation of the 
complement alternative pathway was responsible for the disease and this observation 
informed a combined linkage and candidate gene approach which was used to identify a 
mutation in the Complement Factor H Related protein 5 gene which cosegregated with the 
disease. 
Glomerulonephritis is a leading cause of kidney disease worldwide and can be subdivided 
on the basis of histological appearance or by clinicopathological features. While some 
glomerulonephritides are most often found as sporadic diseases of the kidney, others are now 
appreciated to represent renal manifestations of systemic diseases, which can have genetic or 
environmental aetiologies. 
Mesangiocapillary glomerulonephritis (MCGN, or alternatively membranoproliferative 
glomerulonephritis, MPGN) refers to the light microscopic appearances of glomerular 
mesangial cellular proliferation with thickening of the capillary walls and was observed in 
affected members of the family under investigation. MCGN can occur as a consequence of a 
number of disease processes, but central to its pathophysiology is the deposition of 
complement-containing electron dense material in the glomerulus.  
While MCGN can be subdivided in a number of ways on the basis of light or electron 
microscopic appearance, it can also be categorized on the basis of aetiology. In some 
individuals, MCGN occurs as a consequence of systemic inflammation resulting from chronic 
infection (for example endocarditis, hepatitis or osteomyelitis) or owing to autoimmune 
conditions (such as systemic lupus erythematosus, SLE). In these conditions immunostaining of 
the glomeruli reveals the presence of immunoglobulins as well as complement in the electron 
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dense material and it is likely that it is the immune response and associated immunoglobulin 
production which drives the renal injury in this context. Why some individuals with these 
inflammatory disorders develop MCGN and others do not is poorly understood. 
Rarely, MCGN may occur as a result of dysregulation of complement activation in the 
absence of an antibody-driven inflammatory process. In this situation, immunostaining reveals 
complement but not immunoglobulin deposition within the glomerulus. Recently, it has been 
recognised that these conditions can be divided into dense deposit disease (DDD, or 
alternatively MCGN type 2), in which there is linear dense transformation of the glomerular 
basement membrane, and C3 glomerulonephritis (C3GN) in which there is no dense 
transformation of the glomerular basement membrane but there is C3 deposition in the 
mesangium and along the capillary wall in the absence of immunoglobulins. This can be seen 
with or without light microscopic features of MCGN (for review see (Pickering and Cook 2008)). 
Examination of renal biopsy specimens from affected individuals from the family under 
investigation revealed features compatible with C3GN. 
In addition to MCGN, disorders of complement activation can also cause the Haemolytic 
Uraemic Syndrome (HUS), in which the pathological appearances are of thickening of arterioles 
and capillaries, endothelial swelling and accumulation of protein and cellular debris in the 
widened subendothelial space. In addition there is intravascular haemolysis (with erythrocyte 
fragments visible on a peripheral blood film) with platelet thrombi occluding arterioles. These 
histological features are typically seen in the kidney, although other organs (especially the 
heart and brain) may be affected. HUS may occur as a consequence of exposure to Shiga-like 
toxin which is produced by several Escherichia coli serotypes (particularly O157) and by 
Streptococcus pneumoniae, and the histological lesion is indistinguishable from non-Shiga-toxin 
associated (or atypical) HUS (aHUS), in which host abnormalities in complement regulation 
have frequently been identified. 
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Understanding the aetiology and pathogenesis of these conditions has aided understanding 
of the complement system and it may be that, in the future, diagnostic entities based on 
pathological morphology will give still more ground to those defined by their molecular 
pathophysiology. 
3.2 Complement 
Complement is a key component of the immune system which underlies the long-
recognized ability of serum to “complement” antibodies in their ability to destroy micro-
organisms (von Fodor 1887; Bordet 1895). Complement as a distinct substance was first 
identified in 1901 by Bordet and Gengou who showed that antibody-antigen complexes 
removed the ability of serum to lyse antibody-coated cells – work for which Bordet received 
the 1919 Nobel Prize in Physiology or Medicine. Subsequent discoveries, over the last century 
or more, have revealed that complement is composed of a large number of predominantly 
circulating proteins (with a combined concentration of over 3g per litre in plasma), the central 
components of which are proteases.  
It is now recognised that the complement system has three primary physiological activities: 
defence against pyogenic bacteria; forming an interface between innate and adaptive 
immunity; and disposing of immune complexes and other products of inflammation (Walport 
2001). The nomenclature of the complement system reflects the order of discovery of each 
component, not the order in which they are thought to have arisen over the course of 
evolution or the order in which they interact biochemically. That consideration aside, since the 
advent of molecular biology and its interface with clinical genetics, complement biologists have 
unlocked the secrets of an elegant, important and highly conserved molecular apparatus which 
is central to the immune system. 
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Since microbial attack is potentially lethal and self promoting (once established, microbes 
are able to reproduce, increasing the resources required by the host to clear them) it is 
important that, once a microbial invasion is recognised, the host is able to mount a response of 
appropriate magnitude as quickly as possible. This requirement probably underlies the property 
of activated complement components (particularly C3) to catalyse their own activation, 
providing a positive feedback loop which exponentially amplifies a danger signal. This property 
is shared by other facets of innate immunity such as macrophage activation (for review see (Hu, 
Chakravarty et al. 2008)). Clearly, any system which is both powerful (in terms of its ability to 
destroy cells and organisms) and autocatalytic requires finely tuned regulatory mechanisms in 
order to prevent inappropriate or excessive activation and to terminate the activation once the 
stimulus has been removed. For this reason, defects of complement regulation can have dire 
consequences for the host and contribute significantly to the burden of human disease. 
The complement cascade can be activated in a variety of ways, conventionally considered 
as comprising 3 distinct pathways, known as the classical, mannose-binding lectin and 
alternative pathways, which all converge on (i.e. result in) the cleavage of C3 into C3a and C3b 
which, in turn, results in the activation of a common terminal complement pathway. 
3.3 The terminal pathway 
Activation by cleavage of the terminal complement component C5 produces the C5b and 
the anaphylatoxin C5a. C5a, a 10kDa cleavage fragment, is able to bind with high affinity to 
receptors (termed C5aR and C5L2) on the surface of inflammatory cells, activating and 
recruiting them to sites of complement activation (Peng, Li et al. 2009). In common with other 
anaphylatoxins, the effects of C5a are protean, involving alterations of apoptosis, lipid 
metabolism, innate immune responses and adaptive immune responses through effects on 
antigen-presenting cells and T cells (Klos, Tenner et al. 2009). The larger fragment, C5b, initiates 
Chapter 3: Identification of CFHR5 nephropathy 
90 
 
formation of the tubular Membrane Attack Complex (MAC) by recruitment of C6, C7, C8 and 
polymerised C9. The MAC is able to insert into the surface of a targeted cell leading to its lysis, 
a process which is regulated by CD59, a glycosyl-phosphatidylinositol (GPI)-anchored protein 
ubiquitously expressed on host surfaces (Meri, Waldmann et al. 1991; Davies and Morgan 
1993). The importance of this regulatory protein is indicated by the observation that its 
deficiency (which may be inherited or acquired) results in complement-mediated lysis of host 
erythrocytes and Paroxysmal Nocturnal Haemoglobinuria (PNH) (Yamashina, Ueda et al. 1990). 
 
Figure 3.3-1 The Classical and Mannose Binding Lectin complement pathways 
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3.4 The classical pathway 
The classical pathway was the first to be discovered (hence the name) and in fact underlies 
many of the initial 19th century observations which resulted in the discovery of complement 
system. Initiation of the classical pathway results from binding of the C1 complex (which is itself 
composed of the proteins C1q, C1r and C1s in the ratio 6:2:2) to antibodies bound to bacterial 
surfaces. The C1rs heterotetramer has catalytic activity which results in cleavage of C4 in the 
circulation to produce C4b (and C4a). While C4a is an anaphylatoxin which remains in solution 
and acts as a signal to recruit inflammatory cells, C4b becomes covalently bound to the cell 
surface and is able to bind C2. C4b bound C2 is then cleaved by C1s within the activated C1 
complex, resulting in the formation of C4b2a which is covalently anchored to the cell and itself 
has catalytic activity resulting in cleavage of C3 to produce C3b and the anaphylatoxin C3a 
(Figure 3.3-1). The C4b2a complex is also termed the C3 convertase of the classical pathway 
and, when bound to C3b (to produce C4b2a3b), becomes the C5 convertase of the classical 
pathway which cleaves C5 to activate the terminal pathway. The absence of immunostaining 
for C1q in biopsies from family members under investigation here suggested that the genetic 
defect did not result in antibody or classical pathway deposition in the glomerulus and 
therefore did not suggest a defect of classical pathway activity. 
3.5 The mannose-binding lectin pathway 
The mannose-binding lectin (MBL) pathway is activated by the formation of a complex 
composed of MBL and MBL-associated proteases 1 and 2 (MASP1 and MASP2). The formation 
of this complex is triggered by mannose groups which are present on bacterial cell surfaces. 
The activated MASP2 homodimer (in a similar fashion to the C1rs heterotetramer, see Figure 
3.3-1) is able to cleave C4 and C2 to produce the covalently bound C4b2a C3 convertase, 
although it is now believed that MASPs are promiscuous, with protease activity for substrates 
outwith the recognised complement system (Hajela, Kojima et al. 2002; Dobo, Harmat et al. 
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2009). A key player in the regulation of both the classical and MBL pathways is C1 inhibitor 
which inhibits the activities of a range of soluble proteases, including C1r, C1s, MASPs and 
proteases of the coagulation cascade (Davis 2004; Wallis, Mitchell et al. 2010). The importance 
of this regulatory mechanism is illustrated by the clinical consequences of heterozygous genetic 
deficiency (or acquired loss) of this protein, resulting in life-threatening episodes of angio-
oedema, urticaria, gastro-intestinal mucosal oedema and kinin-mediated capillary leakage. 
 
Figure 3.5-1 Activation of the Alternative and Terminal Complement pathways 
3.6 The alternative pathway 
Central to the alternative pathway (AP) is C3b (see Figure 3.5-1) which is continuously 
generated by low-grade cleavage of C3 (by water hydrolysis (Pangburn, Schreiber et al. 1981)) 
in the plasma – a process known as AP tickover. C3b is able to bind (and is stabilised by) 
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hydroxyl groups of cell-surface proteins and carbohydrates as well as Factor B which can then 
be cleaved by factor D to form C3bBb, also known as the C3 convertase of the AP. C3bBb 
catalyses the cleavage of C3 to form more C3b and the anaphylatoxin C3a which plays an 
important role in the recruitment of inflammatory cells to sites of C3 activation. C3bBb is 
stabilized by properdin and can, in addition, bind free C3b (to form C3bBb3b) which is the C5 
convertase of the AP which activates the terminal pathway. Since these complexes are non-
covalently bound they also dissociate freely, and certain factors (discussed below) can 
enzymatically accelerate this dissociation – a property known as ‘decay acceleration’. Clearly, 
stabilization of C3b or the C3bBb complex (for instance by the presence of an appropriate 
‘protected’ surface, such as a bacterial cell) will result in secondary generation of more C3b in a 
positive feedback loop until either C3 is depleted or the loop is terminated by the inactivation 
of C3b (see below). Furthermore, since cleavage of C3 to form C3b is a consequence of 
activation of both the classical and MBL pathways, activation of either of these pathways 
results in AP activation and hence amplification of the signal. Consequently it can be argued 
that the AP, rather than being a third distinct complement activation pathway, could best be 
regarded as the downstream amplification limb of the other 2 pathways which also has 
autonomous activity itself, rather like the petrol supply to a car engine which ticks over without 
any intervention from the driver but can be increased by depressing the accelerator pedal. The 
observation that, in the family under investigation, metabolites of C3 in the absence of C1q or 
immunoglobulins were seen in renal biopsies of affected individuals suggested that increased 
C3 convertase activity was contributing to the disease – most likely through aberrant activation 
of the alternative pathway. 
3.7 Other mechanisms of AP convertase activation 
In addition to the mechanisms described above, physiological generation of the AP 
convertase (C3b) can also be effected by other enzymes, including microbial proteases, 
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elastase, which is released by neutrophils and normally inhibited by alpha-1-antitrypsin 
(Johnson, Ohlsson et al. 1976), and coagulation factors (see below). Pathological stabilisation of 
the AP convertase can result from the acquisition of an IgG antibody (termed C3 Nephritic 
Factor or C3NeF) which binds to C3bBb, preventing its dissociation or cleavage by other 
components of the complement cascade. This results in uncontrolled C3 consumption and fluid 
phase and surface-bound complement activation leading to dense deposit disease (DDD), and 
C3NeF is the commonest cause of DDD worldwide (Licht and Fremeaux-Bacchi 2009). DDD in 
this setting is also associated with the deposition of a substance, morphologically similar to the 
dense material found in the glomerular basement membrane, in Bruch’s membrane of the eye 
leading to the fundoscopic appearance of drusen (Duvall-Young, MacDonald et al. 1989). It is 
now widely believed that drusen in DDD represent an ocular manifestation of the same 
pathophysiological process as that responsible for the renal disease – namely dysregulated AP 
activation. The question of whether there is a consequently increased risk of visual impairment 
in DDD has not yet been conclusively answered (Colville, Guymer et al. 2003; D'Souza, Short et 
al. 2008). Drusen are also the clinical hallmark of age-related macular degeneration (AMD) and 
determining whether factors which affect systemic complement activation among the general 
population can also modify the risk of AMD is an area of active research. 
Activating mutations in the genes for C3 and Factor B which lead to stabilisation of the C3 
convertase have also been described in association with aHUS (Goicoechea de Jorge, Harris et 
al. 2007; Fremeaux-Bacchi, Miller et al. 2008), demonstrating the importance of the normal 
function of these proteins for complement regulation in humans. Intriguingly, mutations 
resulting in haploinsufficiency (i.e. deficiency) of secreted C3 have also been described in 
association with aHUS, findings not well explained by the current paradigm (Fremeaux-Bacchi, 
Miller et al. 2008).  
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The ability of such a wide range of enzymes and antibodies to activate C3 implied that the 
molecular defect responsible for the family under investigation here could reside in one of a 
number of genes – from either within or beyond the recognised complement system. 
3.8 Breakdown products of C3b 
As described above, C3 is cleaved to form C3b and the anaphylatoxin C3a. In addition to 
contributing to the AP convertase, C3b is able to bind to biological surfaces due to the exposure 
of an internal thiolester bond. This allows C3 convertase and C5 convertase activity to be 
maximised at a bacterial surface. C3b (whether bound or unbound) can be modified by the 
action of an array of AP regulating proteins (discussed below) first into iC3b (by cleavage 
between residues 1281 and 1282, and residues 1298 and 1299) and subsequently into C3c and 
C3dg (by cleavage between residues 932 and 933) (Davis, Harrison et al. 1984) and C3dg is 
cleaved by multiple proteases (including trypsin) to form C3d which can remain covalently 
bound to the surface. 
iC3b and its breakdown products do not have convertase activity (and therefore are not 
able to contribute to amplification of the complement cascade) but are able to act as opsonins. 
In addition, iC3b has pro-inflammatory effects (mediated primarily by its ability to act as a 
ligand for complement receptors on phagocytic cells) which are not all shared by C3dg and C3c. 
There are at least 5 complement receptors (CRs) described to date, termed CR1-4 and CRIg. 
CR1 and CR2 are glycoproteins which contain multiple homologous short consensus repeat 
domains and are products of homologous genes situated near each other on Chromosome 1. 
CR1 acts predominantly as an inhibitory regulator of complement activation and is discussed in 
detail below. CR2 is present on B cells and is the principal CR which, following ligand binding, 
enhances B cell immunity (Weis, Tedder et al. 1984) by increasing B cell receptor signalling and 
promoting survival (Matsumoto, Kopicky-Burd et al. 1991). It is able to bind iC3b, C3d and 
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Interferon-α resulting in an inflammatory pattern of gene expression (Clemenza and Isenman 
2000; Asokan, Hua et al. 2006). Allelic variants of CR2 are associated with altered risk of SLE 
(Wu, Boackle et al. 2007). In addition, CR2 is bound by Epstein Barr Virus during infection 
(Yefenof, Klein et al. 1976).  
CR3 and CR4 are members of the β2-integrin superfamily. CR3, also termed CD11b, 
macrophage-1 antigen (MAC-1) or integrin alpha M (ITGAM), is expressed by leukocytes 
involved in the innate immune system, including monocytes, granulocytes, macrophages, and 
natural killer cells. CR3 stimulation by iC3b contributes to leukocyte adhesion and activation of 
these cells at sites where complement is activated (Solovjov, Pluskota et al. 2005). C3dg is 
unable to stimulate CR3, although cleavage of iC3b by kallikrein (which occurs between 
residues 923 and 924) yields a fragment, known as C3d-k, which is able to stimulate CR3. It has 
also been shown that the synthetic 9-amino acid peptide corresponding to residues 924-932 of 
C3 is sufficient to induce leukocytosis in experimental systems (Hoeprich, Dahinden et al. 1985). 
CR4 (also known as CD11c or alternatively ITGAX) is less well studied but has been shown to 
be present on the surface of neutrophils and platelets where it binds iC3b and C3dg with high 
affinity (Vik and Fearon 1987). CR4 has also been identified on the surface of dendritic cells 
where it plays a critical role in adhesion-mediated phagocytosis following opsonisation by 
activated C3 (Ben Nasr, Haithcoat et al. 2006). It is notable that polymorphic variation at the 
genetic locus of CR4 is also associated with altered risk of systemic lupus erythematosus (SLE) 
(Hom, Graham et al. 2008). 
CRIg is encoded by a gene on the X chromosome and its expression is limited to certain 
tissue macrophages found in the Kupffer cells, heart, synovial lining, alveoli, placenta, adrenal 
gland and foam cells in atherosclerotic plaques (Helmy, Katschke et al. 2006). CRIg has been 
shown to bind the β chain of C3 degradation products and is thought to play a significant role in 
clearing opsonised pathogens and debris from the circulation (Bilzer, Roggel et al. 2006). 
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C3 and its cleavage products therefore have an array of properties ranging from primed 
(uncleaved C3), autocatalytic (C3b), opsonising (C3b, iC3b, C3c and C3dg) and inflammatory 
(C3a, iC3b, C3d-k). 
3.9 Evolution of the AP 
The AP is present in all vertebrates which have been studied and is probably the most 
ancient of the three pathways since, while homologues of the classical pathway and MASP 
genes have to date been identified only in chordates, genes with homology to AP components 
C3 and Factor B have been identified in the sea anemone Nematostella vectensis (Nonaka and 
Kimura 2006) which belongs to the phylum Cnidaria. The Cnidaria share a common ancestor 
with Bilateria not less than 1,300 million years ago, before the divergence of the Protostomia 
(which includes arthropods and nematodes) from the Deuterostomia superphylum (which 
includes the chordates), thought to have occurred approximately 1,000 million years ago 
(Pinto, Melillo et al. 2007). The absence of complement pathway genes in protostome species 
(including Caenorhabditis elegans) has been suggested to be a consequence of secondary loss 
which has occurred numerous times (Nonaka and Kimura 2006), and this theory is supported by 
the detection of a complement-like system in the protostomes Drosophila melanogaster 
(Lagueux, Perrodou et al. 2000) and Anopheles gambiae (Levashina, Moita et al. 2001). 
It is a commonly held view that the complement and the coagulation cascades share a 
common ancestral set of genes and indeed there is ample evidence of cross-talk between the 
two systems: coagulation factor (F) XIIa is able to activate C1q ; Kallikrein can cleave iC3b, albeit 
at a site 9 residues N-terminal to the canonical Factor I mediated cleavage site, to produce C3d-
k (Meuth, Morgan et al. 1983); C1 inhibitor can inactivate Kallikrein, FXIIa, FXIa, plasmin, t-PA 
(Davis 2004; Wallis, Mitchell et al. 2010); FXa, FXIa, thrombin and plasmin can cleave C5 and C3 
to produce active C5b and C3b and anaphylatoxins C5a and C3a (Amara, Rittirsch et al. 2008) 
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and in addition mast cells exposed to C5a are induced to switch from producing the fibrinolytic 
t-PA to the pro-thrombotic PAI-1 (Wojta, Huber et al. 2003). It is not completely clear to what 
extent this cross-talk represents physiologically important adaptive mechanisms which are 
beneficial (in an evolutionary sense) or alternatively maladaptive (or artefactual) consequences 
of ‘accidental’ (or experimental) activation of one pathway by the extreme activation of the 
other owing to the homology between proteins of both pathways. Indeed, many of the most 
serious consequences of bacterial infection, such as septic shock and disseminated 
intravascular coagulopathy, may arise from such cross-talk and would seem, at least in some 
settings, to be detrimental to the host organism.  
There is evidence that genetic variation in humans resulting in ‘deficiency’ of complement 
proteins (potentially resulting in reduced ability to clear microorganisms) could provide a 
survival advantage in some circumstances – particularly those in which microorganisms have 
themselves subverted components of the host complement system to increase their virulence. 
One example of this is the observation that reduced levels of MBL in Ethiopians appears to 
confer protection against lepromatous leprosy, potentially by reducing the ability of the 
mycobacteria to gain entry into macrophages (Garred, Harboe et al. 1994; Schorey, Carroll et 
al. 1997; Walport 2001). There is therefore mounting evidence that, in common with adaptive 
immunity, the innate immune system is dynamic and responsive (in an evolutionary sense) to 
environmental influences and pathogens. An intriguing question is whether genetic ‘defects’ 
which result in increased complement activity could provide enhanced innate immunity – a 
situation which may have provided a survival advantage among children infected with bacteria 
(in whom adaptive immunity is less well developed (Lee, Andalibi et al. 2004)) in the pre-
antibiotic era. 
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Figure 3.9-1 Regulation of the Alternative Complement Pathway 
3.10 Modulation of alternative pathway activation 
As discussed above, the alternative pathway contains significant capacity for autocatalysis 
and runaway activation since C3b can bind to factor B and subsequently cleave C3 to generate 
more C3b. In this context, it is clear that regulatory mechanisms must exist to prevent runaway 
activation which could result in complement-mediated damage to host cells or organs (for 
example as in C3GN) and secondary depletion of C3 leading to impaired ability to destroy 
invading micro-organisms. Conceptually, the AP can be considered to consist of 2 cycles – an 
activation cycle (described above) and a regulation cycle, both of which are active in both the 
circulation and on surfaces (Figure 3.9-1). 
Peter Lachmann has proposed the attractive hypothesis that the development of the 
molecular apparatus able to downregulate AP activity became imperative with the evolution of 
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a pumped circulation, since in smaller organisms (in which diffusion is sufficient to provide 
oxygen and nutrients to tissues) any areas of complement activation will be localised. In 
addition, larger organisms also produce a large range of abundant circulating proteases which 
may be capable of cleaving C3 aberrantly (Lachmann 2009). These factors have probably 
contributed to the evolution of genes coding for a number of proteins which regulate AP 
activity on host surfaces, including Complement Receptor 1 (CR1 or CD35); Decay Accelerating 
Factor (DAF or CD55); Membrane Cofactor Protein (MCP or CD46). In addition the circulating 
proteins Complement Factor I (CFI) and Complement Factor H (CFH) are known to play crucial 
roles in the regulation of C3 turnover in the circulation as well as on surfaces. 
3.10.1 The ‘protected surface’ 
Complement activation is enhanced at biological surfaces – examples being bacterial cells 
and desialated red cells (Kazatchkine, Fearon et al. 1979). This phenomenon is known as the 
‘protected surface’ which is a rather misleading term since it is complement activation which is 
‘protected’ resulting in the surface itself being at increased susceptibility to complement-
mediated damage (i.e. not at all protected!) The biochemical mechanisms underlying the 
protected surface are not well understood but probably include the ability of complement 
components (such as C3b and C4b) to form covalent bonds with hydroxyl groups of cell surface 
proteins. It is likely that the consequent need to shield host surfaces from complement-
mediated self-attack has driven the evolution of genes for the regulatory proteins which are 
expressed on, or preferentially bind to, host surfaces and tip the balance from activation to 
regulation of the AP. Clearly, failure of complement regulation at a host ‘protected surface’ can 
result in disease. An example of this is aHUS in which genetic defects of complement regulation 
at host surfaces have frequently been identified. The deposition of C3 on the glomerular 
basement membrane in the absence of depletion of circulating C3 in affected members of the 
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family under investigation suggested that a specific impairment of complement regulation at 
host surfaces could be responsible for the disease. 
3.10.2 Complement Receptor 1 
Complement Receptor 1 (CR1 or CD35) is a 190 kDa transmembrane glycoprotein 
expressed on the surface of most blood cells (including erythrocytes). CR1 has several 
functions: firstly, it acts as a cofactor for the cleavage of C3b and also iC3b by Complement 
Factor I; secondly it can accelerate the decay of the C3 and C5 convertases (both classical and 
alternative); and thirdly, CR1 is an immune adherence receptor which can bind to C3b and C4b, 
allowing blood cells to bind to serum-exposed foreign particles (Ahearn and Fearon 1989). The 
consequences of this depend on the type of blood cell: CR1 on red cells results in transfer of 
the opsonised antigen to the spleen or liver where they can be internalized and degraded by 
macrophages; CR1 on circulating monocytes/macrophages allows immediate phagocytosis and 
degradation of the antigen; and CR1 on B lymphocytes and dendritic cells enhances localization 
and presentation of complement-coated antigens to the cells of the adaptive immune system.  
The gene for CR1 lies on the long arm of Chromosome 1 (at 1q32) within a group of 
complement regulatory genes (including CR2) termed the Regulators of Complement Activation 
gene cluster (RCA) (Rodriguez de Cordoba, Lublin et al. 1985). In common with other members 
of the RCA, CR1 contains homologous short consensus repeat (SCR) domains which, in CR1, are 
critical for C3b and C4b binding, decay accelerating and cofactor functions (Smith, Mallin et al. 
2002). SCRs consist of 60-70 amino acids and are arranged head-to-tail within complement 
regulatory proteins, usually separated by between 4 and 8 (non-conserved) residues. SCRs can 
vary greatly in sequence but each contains 4 conserved cysteines (producing 2 disulphide 
binds) and a conserved tryptophan. They have a hydrophobic core surrounded by beta sheet 
and each SCR folds independently. SCRs can have a number of biochemical functions, including 
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substrate binding and accelerating decay of complement complexes. In addition, they can have 
cofactor activity for Complement Factor I-mediated cleavage of C3b or iC3b. 
Genetic variants of CR1 have not (to date) been implicated in any Mendelian disorders 
affecting humans, but there is evidence that variation in the gene can confer altered 
susceptibility to infectious diseases. In severe malaria, erythrocytes infected with Plasmodium 
falciparum can bind to uninfected red cells (forming the appearance of ‘rosettes’ on a blood 
film). CR1 plays a role in the formation of these rosettes by binding to a parasite-derived 
membrane protein and CR1 polymorphisms which are common in Africans are associated with 
reduced rosetting and have been suggested to improve resistance to severe disease (Rowe, 
Moulds et al. 1997). Intriguingly, one of these alleles (termed S12 in the Knops blood group 
typing system), while associated with reduced susceptibility to severe falciparum malaria, is 
associated with increased susceptibility to chronic Madurella mycetomatis infection, which 
causes mycetoma and is endemic in Sudan (van de Sande, Fahal et al. 2007).  In addition, 
genetic variants resulting in deficiency of CR1 on the surface of erythrocytes have been 
identified with very high prevalence (up to 80%) in regions of Papua New Guinea in which 
falciparum malaria is endemic (Cockburn, Mackinnon et al. 2004). This is therefore potentially 
another example of environmental exposure producing genetic variation in complement 
activation in humans. 
3.10.3 Decay Accelerating Factor 
Decay Accelerating Factor (DAF or CD55) is a 70kDa glycoprotein composed of 4 
consecutive SCRs tethered to the membrane by a glycosylphosphatidylinositol anchor (Kim and 
Song 2006). DAF is coded for by a gene which lies within the RCA at 1q32, allelic variants of 
which have been associated with altered risk of allergic respiratory diseases (Kawai, Takeshita 
et al. 2009). DAF is expressed by a large number of tissues in humans, acts to inhibit the 
formation of C3 convertases and accelerates their decay (Miwa and Song 2001).  
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3.10.4 Membrane Cofactor Protein 
Membrane Cofactor Protein (MCP or CD46) is expressed by a large number of tissues in 
humans. It is also a member of the RCA cluster and consists of 4 SCRs bound to the membrane 
by a transmembrane domain. MCP has the ability to act as a cofactor for Complement Factor I-
mediated cleavage of C3b and C4b (Lublin, Liszewski et al. 1988), thereby contributing to the 
regulation of complement at host ‘protected’ surfaces which expresses it. In addition, MCP can 
act as the cellular receptor for a number of pathogenic organisms, including measles (Dorig, 
Marcil et al. 1993), adenoviruses (Gaggar, Shayakhmetov et al. 2003), human herpesvirus-6 
(Santoro, Kennedy et al. 1999) and Neisseria species (Kallstrom, Blackmer Gill et al. 2001). It has 
also been demonstrated that antibody-mediated stimulation of MCP can induce regulatory T 
cells to proliferate and release IL10, establishing a potential mechanism by which MCP links 
innate to adaptive immunity (Kemper, Chan et al. 2003). Mutations in the MCP gene have been 
implicated in atypical Haemolytic Uraemic Syndrome (aHUS) (Noris, Brioschi et al. 2003; 
Richards, Kemp et al. 2003; Caprioli, Noris et al. 2006). Whether there is an environmental 
context in which variants of MCP confer decreased susceptibility to infection is not known. 
Importantly, there is a low risk of recurrent renal disease in individuals who have received a 
renal transplant, presumably because the transplanted kidney endothelium predominantly 
expresses normal (i.e. donor-derived) MCP. 
3.10.5 Complement Factor I 
CFI is an ‘induced fit’ enzyme of 88 kDa circulating with a plasma concentration of 
approximately 35 μg/ml (de Paula, Barbosa et al. 2003). CFI requires the presence of a cofactor 
to catalyse the conversion (by cleavage at 2 sites in the C3b α-chain) of C3b to iC3b which is 
unable to bind to factor B and hence is unable to act as a C3 convertase. In addition, CFI can 
catalyse the further degradation of iC3b (by cleavage between residues 932 and 933) into the 
inactive breakdown products C3c, which is soluble, and C3dg, which can remain surface-bound. 
This reaction is accelerated efficiently by CR1 but not by CFH (Ross, Lambris et al. 1982). 
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CFI is coded for by a gene located at Chromosome 4q25 and homozygous deficiency of CFI 
in humans has been described. This is associated with depletion of complement C3 and Factor 
B in the circulation (in fact almost all the C3 present is detected as C3b), reduced AP activity 
and increased susceptibility to infections (Vyse, Morley et al. 1996). In a small proportion of 
individuals, autoimmune diseases and/or glomerulonephritis have been reported (Vyse, Spath 
et al. 1994; Sadallah, Gudat et al. 1999; Amadei, Baracho et al. 2001; Baracho, Nudelman et al. 
2003; Genel, Sjoholm et al. 2005) but, where available, clinico-pathological details in these 
cases suggest that activation of the classical pathway (possibly related to infection-driven 
activation of adaptive immune responses mediated by immunoglobulin production), rather 
than the alternative pathway, is responsible. In this situation, the presence of C3b would be 
predicted to allow formation of both the C3 and C5 convertases of the classical pathway 
provided C4b2a has been formed. Importantly, no cases of DDD in the presence of complete 
CFI deficiency in humans have been reported to date (Licht and Fremeaux-Bacchi 2009). 
Nonetheless, heterozygosity for allelic variants of CFI have been described in association with 
altered risk of atypical haemolytic uraemic syndrome (Fremeaux-Bacchi, Dragon-Durey et al. 
2004; Caprioli, Noris et al. 2006) and C3 glomerulonephritis (Servais, Fremeaux-Bacchi et al. 
2007) adding support to the view that CFI is an important component of the system regulating 
AP activation in humans. 
Recently, mice deficient in CFI have been generated and, in common with the CFI-deficient 
humans, these animals exhibit reduced circulating C3 (with all the detectable C3 circulating as 
C3b) without features of pathological AP activation such as dense deposit disease (Rose, 
Paixao-Cavalcante et al. 2008). This paradox, where removal of a negative regulator of AP 
activation does not result in increased activity downstream of the AP can be explained by the 
theory that it is iC3b (not C3b) which is able to deposit on surfaces and mediate inflammatory 
effects there. This conjecture is supported by the observation that mice deficient in both CFI 
and CFH develop significant renal injury only after exposure to an exogenous source of CFI 
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(Rose, Paixao-Cavalcante et al. 2008). This presumably results in the conversion of (the 
plentiful) C3b into iC3b which is able to bind to the glomerular basement membrane (left 
unshielded by the absence of CFH), stimulate CRs which results in leukocyte recruitment and 
mesangiocapillary glomerulonephritis. 
3.10.6 Complement Factor H 
Complement Factor H (CFH) is a glycoprotein of 155 kDa which is member of the RCA 
cluster, is composed of 20 SCR domains and which circulates at concentrations of 
approximately 400 μg/ml. In the fluid phase, it is able to bind to C3b (blocking the formation of 
the C3 convertase, C3bBb) (Conrad, Carlo et al. 1978), has decay accelerating activity 
(increasing the degradation of the C3 convertase) (Weiler, Daha et al. 1976) and can act as a 
cofactor for Complement Factor I-mediated cleavage of C3b to form iC3b (Pangburn, Schreiber 
et al. 1977). In addition, CFH has the ability to bind to polyanions such as glycosaminoglycans, 
heparin and sialic acid molecules and this allows it to target host (as opposed to foreign) 
biological surfaces. Removal of sialic acid molecules from host surfaces decreases the 
interaction between bound C3b and CFH without impairing the interaction of C3b with Factor B 
or properdin, favouring C3 activation rather than degradation (Kazatchkine, Fearon et al. 1979; 
Pangburn, Morrison et al. 1980).  
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Figure 3.10-1 Complement Factor H domains and mutations associated with disease 
DDD, dense deposit disease, aHUS, atypical haemolytic uraemic syndrome. Adapted from (Boon, van de Kar et 
al. 2009).  
 
The functions of CFH are each conferred by properties of one or more specific regions of 
the protein (Figure 3.10-1) and their physiological importance are demonstrated firstly by the 
pathological consequences of mutations in each region of the gene; secondly by in vitro 
deletion-mutation biochemical studies and thirdly by transgenic murine models (Pickering and 
Cook 2008). These studies have indicated that the C-terminal SCRs 19 and 20 confer firstly the 
ability of CFH to bind to polyanions on host surfaces (Meri and Pangburn 1990) and secondly 
contain C3b and C3d binding sites, suggesting that this SCR confers the ability to recognise C3b 
in the context of self-surface. An independent C3b binding site also exists within the N-terminal 
SCRs 1-4 and, in addition, SCR 7 confers significant heparin-binding ability (Schmidt, Herbert et 
al. 2008). A construct composed only of SCRs 19 and 20 has a dominant negative effect, 
abolishing the ability of full length CFH to bind to surface-bound (but not fluid phase) C3b 
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(Ferreira, Herbert et al. 2006). Heterozygous or homozygous mutations in CFH can produce 
clinically significant aHUS and the observation that these mutations cluster at the C-terminal 
end of the protein (Figure 3.10-1; reviewed in (Boon, van de Kar et al. 2009)), suggests that 
defective complement regulation on host surfaces is an important component of this disease.  
This hypothesis was supported firstly by studies of CFH in which pathogenic amino acid 
substitutions (associated with clinical aHUS) were introduced in SCR 20. In an elegant series of 
experiments the ability of these mutant proteins to protect sheep erythrocytes from 
complement-mediated lysis was impaired but cofactor activity in the fluid phase was 
indistinguishable from that of the wild type CFH protein (Sanchez-Corral, Perez-Caballero et al. 
2002; Sanchez-Corral, Gonzalez-Rubio et al. 2004). A second line of evidence, using mutant 
mouse strains, also supported this paradigm: mice completely deficient in CFH exhibit plasma 
C3 consumption and C3 deposition in the glomerular basement membrane – features highly 
reminiscent of the human dense deposit disease (DDD) (Pickering, Cook et al. 2002). When 
these mice were used to generate transgenic animals in which the C-terminal 5 SCRs of CFH are 
deleted (ensuring that all the CFH present was devoid of SCRs 16-20), there was normal plasma 
C3 regulation but impaired protection of host surfaces, leading to aHUS (Pickering, de Jorge et 
al. 2007). In common with the murine model, complete deficiency of functional CFH in humans 
has been described associated with plasma C3 depletion and DDD and is not associated with 
any alteration in CFI levels (reviewed in (Pickering and Cook 2008; Boon, van de Kar et al. 
2009)), whereas those CFH mutations causing aHUS rarely result in hypocomplementaemia 
(Rodriguez de Cordoba, Esparza-Gordillo et al. 2004). Notably, complete CFI deficiency is 
associated with reduced circulating CFH levels, and this is thought to result from CFH binding to 
C3b on surfaces (Pickering and Cook 2008). 
Recently, a third histological category of renal disease, termed C3 glomerulonephritis 
(C3GN, defined by the presence of immunostaining for C3 (but not immunoglobulins) in the 
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glomerular mesangial areas or capillary walls in the absence of linear dense transformation of 
the basement membrane) has been described in association with genetic variants  of CFH or CFI 
(Servais, Fremeaux-Bacchi et al. 2007). Whether C3GN represents an extreme (presumably 
mild) end of the spectrum of DDD or is genuinely a discrete clinicopathological entity remains 
to be determined.  
3.10.7 Polymorphic variation in CFH and disease 
Allelic variants of CFH have been shown to be associated with a variety of diseases, 
including DDD (Abrera-Abeleda, Nishimura et al. 2006) and age-related macular degeneration 
(AMD) (Hageman, Anderson et al. 2005). Genetic evidence also suggests a heritability of 62% 
for circulating CFH levels (which vary markedly in the population) (Esparza-Gordillo, Soria et al. 
2004) although a relationship between circulating levels (excluding those in null mutants) and 
disease susceptibility has yet to be convincingly demonstrated. Recently, haplotypes within CFH 
associated with altered risk of DDD, AMD and aHUS have been identified and initial evidence 
suggests that those variants associated with increased risk of DDD are also associated with 
increased risk of AMD, whereas aHUS risk may be increased in the presence of variants which 
are not associated with increased risk of AMD/DDD (Pickering, de Jorge et al. 2007). However, 
linkage disequilibrium (LD) across the complex and repetitive RCA is not easily defined and it 
may be that the CFH variants in question are in LD with variants of nearby genes (see below) 
which have much greater functional influence on disease susceptibility.  
3.10.8 CFH-Related Proteins 
CFH lies at the 5’ end of a 360 kbp repetitive genomic region which was found to be linked 
with the disease in the family under investigation. This region also includes 5 additional genes 
known as the CFH-Related genes 1 to 5 (CFHR1-5) and a mutation in one of these (CFHR5) was 
found to cosegregate with the disease in the family. The CFHR proteins were originally 
identified by Western blotting of human serum with polyclonal antibodies raised against CFH 
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(Zipfel and Skerka 1994). Unsurprisingly (in view of how they were identified), all 6 genes are 
homologous, sharing significant sequence similarity, each being composed of multiple SCR 
domains. It is thought that they arose as a consequence of gene duplication events, originally of 
CFH, and it is possible to map many of the SCRs of each of the CFHRs to the homologous SCRs 
of CFH itself (Figure 3.10-2). Whether the CFHRs are expressed pseudogenes (with no non-
redundant functional properties) or represent integral components of the sophisticated system 
regulating complement activity in humans has remained an open question since their 
identification 15 years ago, but recently several lines of evidence which may help to resolve this 
issue have begun to emerge. 
 
Figure 3.10-2 Homology and function of domains of CFH/CFH-Related proteins 
Adapted from (Jozsi and Zipfel 2008).  
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CFHR1 is able to bind to the surface of pathogens (including Borrelia burgdorferi, 
Pseudomonas aeruginosa and Group A Streptococci) and to C3b, suggesting a significant 
complement regulating activity despite the absence of detectable cofactor activity (Skerka and 
Zipfel 2008). Recently, it has been shown that it can inhibit C5 convertase activity and hence 
the formation of the terminal complement complex (Heinen, Hartmann et al. 2009).  
However, while these in vitro findings do suggest that CFHR1 is able to regulate 
complement, persuasive genetic evidence exists showing that SCRs of CFHR1, despite extensive 
sequence identity, have functionally and clinically apparent reduced ability to regulate AP 
activity when compared with the homologous SCRs of CFH: Venables and co-workers identified 
a family in which aHUS was caused by heterozygosity for a hybrid gene in which SCRs 19 and 20 
of CFH were replaced by (the homologous) SCRs 5 and 6 of CFHR1 (Venables, Strain et al. 2006). 
This rearrangement produced a protein identical to CFH with the exception of 2 amino acids, 
and functional studies demonstrated that these substitutions resulted in a CFH protein with 
reduced ability to regulate complement on surfaces, and exhibited impaired binding to C3b and 
heparin (Heinen, Sanchez-Corral et al. 2006). It follows that these SCRs of CFHR1 are not 
required to perform the same function as the homologous SCRs of CFH. 
Deletion of CFHR1 is a common polymorphism which is associated with a reduced risk of 
AMD but (in the homozygous state) an increased risk of the development of autoantibodies 
against CFH which, in turn, are associated with increased risk of aHUS (Abarrategui-Garrido, 
Martinez-Barricarte et al. 2009). The mechanism by which absence of one gene can predispose 
to the generation of autoantibodies against the product of a homologous gene has not been 
conclusively established – possibilities include the generation of a neo-epitope of CFH which is 
present in the native form of CFHR1, or alternatively there may be an immunogenic CFH allele 
which is in LD with the CFHR1 deletion. The second explanation seems less likely since 
additional CFHR1 deletions and truncation mutations (i.e. independent alleles) have been 
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identified in association with the development of CFH antibodies (Abarrategui-Garrido, 
Martinez-Barricarte et al. 2009). 
CFHR5, which is the largest of the CFHR proteins and comprises 9 SCRs, has been identified 
within complement deposits in the rat glomerulus (McRae, Cowan et al. 2001). It has been 
shown to bind C3b and heparin and to have cofactor activity at concentrations of several 
hundred ng/μL (McRae, Duthy et al. 2005). Common variants of CFHR5 are preferentially 
represented in cohorts of patients with DDD (Abrera-Abeleda, Nishimura et al. 2006) and aHUS 
(Monteferrante, Brioschi et al. 2007), consistent with an important and non-redundant role for 
the protein, but in the absence of conclusive functional or genetic data it remained unclear 
whether these observations result from LD leading to the detection of effects of risk variants 
elsewhere within the RCA. The work presented here, which indicates that a mutation in CFHR5 
is responsible for a highly penetrant Mendelian disease, provides direct evidence that CFHR5 
has a non-redundant role in the regulation of complement in humans. 
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3.11 A monogenic cause of C3 Glomerulonephritis 
3.11.1 Family 1 
The index case (designated V-4 in Figure 3.11-1) was born in the UK to Cypriot parents. He 
presented to his GP at the age of 9 with a two year history of headaches. He had had a right 
orchidopexy in infancy and there was no other significant medical or surgical history. The GP 
noted that he had not had urinary tract infections in the past. At the time of this review he was 
noted to be “rather thin and frail” and was found to be pyrexial with an upper respiratory tract 
infection (URTI). The blood pressure was 140/90 and he was referred for a paediatric opinion, 
for which there are no available records. 
 
Figure 3.11-1 Family 1 pedigree 
 
He remained well (with no headaches) until the age of 14 when he was seen by a 
cardiologist for investigation of palpitations. Urinalysis at this time demonstrated a trace of 
blood but no other abnormalities were found and he was reassured. He was referred to the 
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nephrology service at St Mary’s Hospital in London two years later because of hypertension. At 
this time he was symptomatically “very well”. Physical examination was entirely normal with 
the exception of an elevated blood pressure of 165/80 mmHg and urinalysis, which 
demonstrated +++ blood only. Circulating biochemical and haematological indices were all 
within the normal ranges. Serum levels of immunoglobulin (Ig) A, IgG and IgM were normal and 
complement C3 was 1.05 g/l (NR 0.73-1.77). An autoantibody screen, including antinuclear and 
anti-neutrophil cytoplasmic antibodies and C3 nephritic factor, was negative and 51Cr-EDTA 
clearance was 100 ml/min. 
A clinical diagnosis of “likely IgA nephropathy” was documented by his nephrologist at this 
time and he underwent a renal biopsy. Light microscopic examination revealed two glomeruli 
with tuft collapse and thickening of Bowman’s capsule and 10% focal atrophy in the areas 
adjacent to these glomeruli. Immunoperoxidase staining revealed C3 deposition on the 
capillary wall and in a few glomeruli. There was no staining with antibodies for IgA, IgM, IgG or 
C1q. Electron microscopy revealed expansion of the mesangial matrix with some peripheral 
electron dense deposits. There were multiple elongated subendothelial dense deposits in the 
glomerular basement membrane but no subepithelial deposits were observed. 
The blood pressure was controlled with enalapril therapy and he remained well until the 
age of 20 at which time he reported sudden onset of abdominal pain, with dark stools noticed 
one day later. The haemoglobin was 7.8 g/dl and he was admitted to his local hospital. An 
oesophago-gastro-duodenal endoscopic examination revealed no source of bleeding and no 
polyps. Serum creatinine at this time was 89 μmol/l and there were no clinical features to 
suggest Peutz Jeghers syndrome. There have been no further episodes of gastrointestinal 
bleeding.  
At the age of 26 he was found to have proteinuria ++ in addition to haematuria and the 
glomerular filtration rate was 60 ml/min. Urinary protein loss was less than 1 g per day. A 
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second renal biopsy was performed: light microscopic examination revealed increased 
mesangial cells and matrix with segmental capillary wall thickening. Immunostaining revealed 
course granular C3 deposition on the capillary wall and electron microscopy again 
demonstrated elongated subendothelial electron dense deposits with occasional subepithelial 
deposits (Figure 3.11-2). At the time of writing he was well on antihypertensive medication 
aged 31. 
 
Figure 3.11-2 Kidney biopsy in individual V-4 
Arrows show electron dense deposits in the subendothelial and mesangial regions. A single subepithelial hump 
is visible (arrowhead). 
 
IV-5 (the mother of V-4, Figure 3.11-1) was born in the village of Gerakies in the Troodos 
region of Cyprus. She had exhibited perioral and buccal pigmented macules in youth which had 
faded with age, and a small number of irregular, splinter shaped pigmented macules on the 
fingers (Figure 3.11-3). Multiple gastrointestinal polyps had been removed endoscopically over 
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the course of her adult life and histological examination of the polyps had revealed cystic-
glandular hyperplasia, consistent with Peutz Jeghers syndrome (Figure 3.11-4). Bilateral 
oopherectomies were performed at the age of 51 and histological examination revealed a left 
serous cystadenoma. Her father (III-3) had been diagnosed with Peutz Jeghers syndrome prior 
to his death from ischaemic heart disease. 
 
Figure 3.11-3 Clinical features of Peutz Jeghers syndrome 
Pigmented papules visible on the fingers of individual IV-5 (arrows). A faint papule was also visible on the buccal 
mucosa (arrowhead).  
 
 
Figure 3.11-4 Histological features of Peutz Jeghers Syndrome 
Cystic glandular hyperplasia in a histological section from a gastric polyp removed from individual IV-5. 
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IV-5 had been referred to the nephrology service at St Mary’s Hospital, London at the age 
of 40 with persistent microscopic haematuria. Biochemical and haematological parameters 
were all within the normal ranges with a serum creatinine of 90 μmol/l. Circulating 
complement C3 level was 1.08 g/l. Neither autoantibodies nor C3 nephritic factor were 
detected in the serum and immunoglobulin levels were normal. She underwent renal biopsy 
which demonstrated slight mesangial expansion with occasional capillary loop occlusion. There 
was 5% tubular atrophy. Electron microscopy demonstrated scattered, small subendothelial 
electron dense deposits and a few larger subepithelial deposits. There were occasional 
mesangial electron dense deposits with mesangial cell interposition. 
A paternal relative (III-1 in Figure 3.11-1), who had emigrated from Gerakies to London 
some years previously with his parents had presented to the nephrology service of Charing 
Cross Hospital with haematuria and proteinuria. A renal biopsy was performed at the age of 43 
which showed mesangiocapillary glomerulonephritis (MCGN) with immunostaining for C3 but 
not immunoglobulins or C1q. He commenced haemodialysis at the age of 46 and received a 
cadaveric renal allograft one year later. He died 10 years subsequent to this from a myocardial 
infarction at which time there was good allograft function – the graft was never biopsied and 
serum creatinine prior to death was 89 μmol/l. There was a history of haemorrhagic gastritis 
but no features of Peutz Jeghers syndrome were documented. Of note, his father (II-1) had 
developed end-stage renal disease and was receiving haemodialysis prior to his death, however 
further clinical details are not available.  
3.11.2 Independently identified patient from Cyprus 
An unrelated individual was referred from Nicosia to Hammersmith Hospital for a second 
opinion. At the age of 31 he had been found to have microscopic haematuria, with 
hypertension first noted at age 35, at which time his serum creatinine was 103 μmol/l. Over the 
following 4 years he reported recurrent episodes of synpharyngitic macroscopic haematuria, 
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one of which directly preceded a sharp rise in his serum creatinine to 237 μmol/l, recovering to 
172 μmol/l some months later. Urine protein loss was relatively constant at around 400 
mg/day. Tests for circulating antibodies including antinuclear and anti-neutrophil cytoplasmic 
antibodies and C3 nephritic factor, were negative. At age 38 a renal biopsy was performed. 
Light microscopic examination revealed expansion of mesangial cells and matrix and 10% focal 
tubular atrophy. Immunostaining was positive for complement C3 and C9 but negative for 
immunoglobulins. Electron microscopy revealed mesangial, subendothelial and a few scattered 
subepithelial electron dense deposits. The histopathologist (Professor Terry Cook) considered 
the biopsy findings highly unusual but noticed the similarity with those seen in individuals from 
family 1. No features of Peutz Jeghers syndrome were observed and a family history of renal 
disease was not documented. 
In summary, I have described a multiply affected kindred with ancestry in the Troodos 
Mountains of Cyprus in which there is autosomal dominant inheritance of renal disease 
characterised by glomerular C3 deposition in the absence of significant immunoglobulin or C1q 
– appearances consistent with C3 glomerulonephritis (C3GN). There are characteristic C3-
containing subendothelial, mesangial and occasional subepithelial deposits visible on electron 
microscopy and all affected individuals have microscopic haematuria. Sub-nephrotic range 
proteinuria and renal impairment are observed in some individuals. The clinico-pathological 
features were strikingly reminiscent of IgA nephropathy with the exception of a) autosomal 
dominant inheritance and b) a lack of IgA staining on renal biopsies in all affected individuals. 
Peutz Jeghers syndrome is also present in the family although it did not appear to cosegregate 
with the renal disease. In addition, an unrelated individual from Cyprus was also found to have 
C3GN, with renal biopsy findings remarkably similar to those seen in family 1. In addition to 
microscopic haematuria, hypertension and renal impairment, he reported repeated episodes of 
synpharyngitic macroscopic haematuria which appeared to coincide with stepwise 
deterioration of kidney function.  
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3.12 Investigation strategy 
The aim of this investigation was to identify the gene responsible for the kidney disorder 
affecting this family. While the phenotype described is not of a well-recognised Mendelian 
disorder, the deposition of C3 in the glomerulus (in the absence of immunoglobulins and C1q) 
that was present in all 4 affected individuals who were biopsied suggested that a defect of 
complement alternative pathway regulation was present. Genes implicated in other disorders 
of complement regulation which result in kidney disease include Complement Factor H (CFH), 
Factor B, Complement Factor I (CFI), Complement C3, Membrane Cofactor Protein (MCP). The 
exons and flanking intronic sequences of these genes were sequenced in IV-5 and V-4 from 
family 1 prior to my involvement in this investigation by colleagues of Dr Pickering, and no likely 
pathogenic variants were identified. 
Review of the available clinicopathological information highlighted the following salient 
points: 
1.  Glomerular deposition of C3 in the absence of immunoglobulins in the observed 
pattern (i.e. C3GN) is exceedingly rare, and coincidental occurrence of these biopsy 
appearances in multiple members of a single family, in the absence of a shared genetic 
or environmental aetiological agent, was unlikely enough to be discounted. The 
possibility that the independently identified individual from Cyprus was a relative of 
family 1 was intriguing and would potentially strengthen a linkage study. 
2. V-4 (family 1) was born and brought up in the UK so I considered an environmental 
factor restricted to the Troodos Mountains unlikely to explain the observations. 
3. The independently identified individual from Cyprus reported synpharyngitic 
macroscopic haematuria – a symptom considered almost pathognomonic of IgA 
nephropathy. Furthermore, histological features were compatible with IgA 
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nephropathy in all cases, with the obvious exception of the absence of detectable IgA 
deposition. 
4. Peutz Jeghers syndrome (PJS) is a rare condition (affecting between 1 in 60,000 and 1 in 
300,000 of the population). Coincidental occurrence of 2 unrelated rare disease, while 
not impossible, appeared unlikely. Notably, PJS was not present in III-1 and V-4 from 
family 1, nor in the independently identified patient from Cyprus. 
In order to answer these questions, I proceeded with the following steps: 
1. Interview affected individuals to identify the presence of: 
a. synpharyngitic macroscopic haematuria 
b. additional relatives with renal disease and/or PJS  
2. Screen relatives of affected individuals for the presence of digital, perioral or buccal 
pigmentation; a history of gastrointestinal bleeding or intussusceptions; urinary 
abnormalities (haematuria and proteinuria); or renal impairment 
3. Perform retinal photography in affected individuals to look for extra-renal 
manifestations which might be expected in the presence of a defect of AP regulation 
4. Candidate gene sequencing: 
a. Amplify and sequence exons of STK11 in IV-5 and V-4 from family 1 
b. Amplify and sequence exons of CFHR5 in IV-5 and V-4 from family 1 
5. Collect DNA and serum from consenting family members, whether affected, unaffected 
and unknown affection status, genotype 6000 SNPs across the genome and perform a  
linkage study in order to inform the selection of additional candidate genes to 
investigate 
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3.13 Family screening and DNA collection 
3.13.1 Family 1 
On direct questioning, individual V-4 reported repeated episodes of brown-red 
discolouration of the urine which occurred immediately preceding or within 1-2 days of the 
onset of upper respiratory tract infections. These episodes of synpharyngitic macroscopic 
haematuria usually lasted for between 2 and 5 days and had occurred approximately once or 
twice each year since the age of 14. Individual IV-5 could recall having experienced one or two 
similar episodes over the course of her life. 
IV-5 from family 1 reported that her father’s cousin’s daughter (IV-1 in Figure 3.11-1) also 
had kidney disease. Individual IV-1 had been referred to Charing Cross Hospital 20 years 
previously at the age of 25 because of persistent microscopic haematuria with a trace of 
proteinuria. Renal biopsy at that time had demonstrated focal interstitial fibrosis and some 
collapse of glomerular capillary loops. Immunostaining demonstrated the presence of diffuse, 
intense granular deposition of C3 along the capillary loops with scanty staining for IgM and IgA 
but not IgG or C1q. Electron microscopy revealed conspicuous, elongated subendothelial 
electron dense deposits with a few discrete subepithelial deposits. Deposits were also present 
in the mesangial regions which were otherwise normal. Immuno-gold electron microscopy 
demonstrated that the electron dense deposits were bound by antibodies directed against 
complement C3 (Figure 3.13-1). She had remained entirely well during this period, with no 
hypertension, renal impairment or episodes of macroscopic haematuria reported. She had no 
clinical stigmata of Peutz Jeghers Syndrome. 
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Figure 3.13-1 Immuno-gold electron microscopy 
Immuno-gold electron micrograph of a kidney biopsy from individual IV-1. Black dots indicate immunoreactivity 
for Complement C3 in a subendothelial electron dense deposit 
 
At the invitation of IV-5, I travelled to Cyprus to meet additional relatives who reside there. 
Urinary dipstix testing identified + haematuria and trace proteinuria in individual IV-7. He also 
exhibited perioral pigmentation and had been diagnosed with Peutz Jeghers syndrome. 
Individual IV-2 (sister of IV-5, Figure 3.11-1) had died from disseminated intra-abdominal 
malignancy in her early forties. One of her sons (V-1) had been diagnosed with PJS owing to the 
presence of digital, buccal and perioral pigmentation (Figure 3.13-2) and numerous 
gastrointestinal hamartomas which had been removed endoscopically. Urinalysis was normal. 
His brother (V-2) exhibited no stigmata of PJS and was entirely well. Urinalysis revealed a trace 
of blood only. IV-4 (also sister to IV-5, Figure 3.11-1) had subtle perioral pigmentation 
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gastrointestinal polyps and had been diagnosed with PJS some years previously. Urinalysis was 
normal. None of these individuals reported any episodes of macroscopic haematuria. 
 
Figure 3.13-2 Pigmented macules on the lips and buccal mucosa of individual V-1 
 
3.13.2 Family 2 
On direct questioning, the unrelated individual from Cyprus (III-2 in Figure 3.13-3) reported 
that, while his father was from Larnaca in Eastern Cyprus, his mother’s family was from 
Kalopanagiotis, which lies approximately 3km from, and in the same valley as, Gerakies in the 
Troodos Mountains (Figure 3.13-4). Her father (I-1) had died from kidney failure at the age of 
65 in 1953 and her brother (II-3) had recently died with many medical problems, including 
‘severe’ kidney disease in his 60s. Further details from these individuals were not available. III-2 
invited me to Cyprus where I was able to meet and screen additional relatives. This revealed 
microscopic haematuria in his mother, aunt and 2 cousins (individuals II-1, II-4, III-4 and III-5). 
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All these individuals had recent serum creatinine measurements which were within the normal 
range and no evidence of proteinuria. None had been biopsied. In addition, the daughter of 
one of the cousins (IV-1) was subsequently found to have microscopic haematuria. None of 
these female relatives could recall any episodes of macroscopic haematuria. Furthermore, no 
individuals from family 2 exhibited abnormal pigmented macules and there was no history of GI 
bleeding, polyps or intussusception. 
 
Figure 3.13-3 Family 2 pedigree 
 
None of the known surnames of ancestors of family 2 were shared by known ancestors of 
family 1 and neither family could trace ancestry to the other village. Several members of the 
family pointed out to me that marriages between the residents of the two villages were 
extremely common. In addition, individual III-4 from Family 2, informed me that the Kikkos 
Monastery was situated near the villages and that it was common folklore that many of the 
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residents of the valley were the product of (illegitimate) liaisons between monks and villagers. I 
could find no evidence to lend direct support to this speculation and therefore considered that, 
if the two families did have an affected common ancestor, this individual had probably lived 
before living memory. 
All individuals from both families were eager to participate in the research. 
 
Figure 3.13-4 Satellite photograph of the Troodos region  
Showing the region from which the families reported ancestry, and their location on the island of Cyprus (inset). 
Images downloaded from www.google.com. 
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3.14 Retinal photography 
Since defects of complement regulation have been associated with retinal abnormalities 
(particularly drusen in dense deposit disease (Duvall-Young, MacDonald et al. 1989)), retinal 
photography was performed in IV-5 and V-4. This demonstrated no abnormality (Figure 
3.14-1). 
 
Figure 3.14-1 Normal retinal appearance of IV-5 and V-4 (family 1) 
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3.15 Candidate gene sequencing:   
3.15.1 STK11 
Peutz Jeghers syndrome (PJS, OMIM #175200) is a rare, autosomal dominant disorder 
characterised by perioral, buccal and digital pigmented macules and multiple gastrointestinal 
hamartomas. It was first described in 1921 and extra-intestinal polyps recognised as a feature 
of the disease in the 1960s. Affected individuals are at increased risk of a large number of 
neoplasms, both intra- and extra- intestinal, including rare ovarian, cervical and testicular 
tumours and breast carcinoma. Mutations in the Serine Threonine Kinase 11 (STK11) gene on 
chromosome 19p13.3 have been identified cosegregating with PJS in numerous families, with 
loss of heterozygosity (i.e. somatic inactivation of the second allele) detectable in 70% of polyps 
studied (Gruber, Entius et al. 1998). At the time this part of the investigation was performed 
(summer 2007), no families with PJS had been reported in the published literature in which a 
mutation in a gene other than STK11 had been implicated in causing the disease. However, in 
2008, A single individual with clinical features reminiscent of PJS was reported in whom a 
mutation in the Myosin Heavy chain 11 (MYH11) gene on chromosome 16p13.13 was identified 
(Alhopuro, Phichith et al. 2008). 
Intriguingly, the gene for Complement C3 lies 5 megabase-pairs (Mbp) downstream of 
STK11 on the short arm of chromosome 19. It therefore seemed possible that a large inversion 
had occurred resulting in disruption to the two genes and causing both the renal disease and 
PJS, with incomplete penetrance of each phenotype. Other possibilities included: 
1. The presence of an STK11 mutation linked to a C3 mutation in family 1 with a 
recombination event having occurred since families 1 and 2 diverged 
2. Both PJS and the renal disease were caused by a single mutation with incomplete 
penetrance of both diseases 
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3. Completely coincidental inheritance of 2 unlinked mutations in some members of 
family 1 only, with the PJS mutation absent in family 2. 
Possibility 2 (the same mutation in an unknown gene causing both diseases) was hard to 
envisage because the biology of PJS (which results from a defect of intracellular energy sensing) 
and complement (predominantly a cascade of circulating proteins secreted by the liver) seem 
so diverse. Nonetheless, it would not be impossible for a trafficking, gain-of-function or gene 
fusion mutation to have effects on such disparate systems. 
In order to disentangle these possibilities, firstly cytogenetic analysis (with particular 
emphasis on chromosome 19p) of lymphocytes from individual IV-5 was performed at the 
Kennedy-Galton centre for clinical genetics, Northwick Park Hospital. This was reported as 
normal. Second, IV-5 and V-4 were screened for STK11 mutations. This was clinically important 
because V-4 had experienced a gastrointestinal bleed, yet had no clinical evidence of PJS and a 
molecular diagnosis might therefore be valuable in guiding decisions on further gastro-
intestinal surveillance in him (as well as other ostensibly unaffected relatives). As a 
consequence, exons of STK11 in were amplified from genomic DNA from IV-5 and V-4 and 
sequenced. This revealed a novel single C to A substitution at a position 1262 base pairs from 
the transcription start site in exon 1 of the gene (C1262A), present only in IV-5 (Figure 3.15-1). 
This predicts a change from Tyrosine 49 to a premature termination codon (Tyr49X), and is 
therefore highly likely to be pathogenic. V-4 only had evidence of the database allele at this 
position. 
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Figure 3.15-1 Premature stop codon in exon 1 of STK11  
Detected in DNA from individual IV-5 from family 1. 
 
C1262A is predicted to abolish an AfaI restriction site in a PCR amplicon generated by 
amplification of exon 1 of STK11. This allowed screening of clinically affected and unaffected 
members of the families which identified the mutation in all and only individuals with a clinical 
diagnosis of PJS (Figure 3.15-2). This allowed calculation of a logarithm of odds ratio (LOD 
score) of 2.1 for segregation with PJS among descendants of III-3. It was not identified in any 
members of family 2 or individuals IV-1 and V-4 from family 1, proving that the renal disease 
did not result from this STK11 mutation.  
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Figure 3.15-2 Screening for STK11 mutation 
Restriction digest showing heterozygosity for abolished Afa1 restriction site only in individuals with clinical 
evidence of PJS. 
 
In addition, this pattern of recombinations made it unlikely that the mutation responsible 
for the renal disease was located near to STK11, since 1 or more recombinations would have 
had to occur between III-3 and IV-1 (5 meioses) AND there would have had to be at least 1 
recombination between III-3 and V-1 (2 meioses) AND 1 recombination between III-3 and IV-4 
(1 meiosis) AND 1 recombination between IV-5 and V-4 (1 meiosis) AND no recombinations 
between III-3, IV-5 and IV-7 (2 meioses). 
The likelihood of this occurring at a given recombination fraction, θ, can be calculated as 
follows: 
                                              
 It follows that: 
                
             
               
 
This can be plotted graphically (Figure 3.15-3) 
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Figure 3.15-3 Linkage of renal disease with STK11 
The LOD score is -0.97 at θ=0.185, the predicted position of the C3 gene (arrow). 
 
Since the C3 gene is situated 5 megabases (corresponding, in this region of the genome, to 
18.5 cMa) from STK11 the predicted recombination fraction is approximately 0.185, which 
yields a LOD of -0.97, indicating that linkage between the renal disease and C3 was unlikely. 
3.15.2 CFHR5 
As discussed above, the coding and flanking regions of genes previously implicated in 
complement alternative pathway dysregulation leading to renal disease (namely CFH, CFI, CFB, 
C3, MCP) had been sequenced without indentifying any likely pathological variants. Recent 
work (Abrera-Abeleda, Nishimura et al. 2006; Monteferrante, Brioschi et al. 2007) had 
implicated variation in CFH Related protein 5 in modifying the risk of dense deposit disease 
(DDD) and haemolytic uraemic syndrome respectively. These were both case-control studies in 
which certain SNP alleles were over-represented in cases compared to controls. While this sort 
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of study is unlikely to confirm an aetiological role of a particular variant (firstly because the 
effect of other alleles in linkage disequilibrium with those directly measured could mediate any 
biological effect and secondly because, since the variants are present in a significant proportion 
of healthy controls, any functional effect on protein function or expression is likely to be subtle 
and hence difficult to study in vitro), this work does provide evidence that CFHR5 could play a 
role in AP regulation and therefore I considered sequencing the gene worthwhile. 
Sequencing was first attempted by amplification of exons of CFHR5 using the primers 
published in (Abrera-Abeleda, Nishimura et al. 2006), however this was unsuccessful and I 
selected new primers which did allow amplification and sequencing of the gene. This was 
performed in IV-1 and IV-5 from family 1 and in 2 unrelated controls. No likely pathogenic 
coding sequence or splice-site variants were detected and heterozygosity for a database SNP 
was observed in IV-1 (although IV-5 was homozygous for all). This excluded loss of one copy of 
the entire gene in an individual with biopsy-proven C3GN. 
Further candidate genes (such as CFHR1-4) were not sequenced at this time as I took the 
view that a linkage study would be a more efficient way of targeting continued efforts. In 
particular, since there was no evidence of circulating complement activation/depletion and no 
indication of complement deposition outside the kidney, it seemed possible that an 
abnormality of a gene which is usually expressed in the kidney (i.e. which is outwith the 
complement pathway) could be responsible for localised complement activation there. 
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3.16 Genome-wide linkage study 
Simulation analysis (using FastSLink) indicated that, with the samples available, the 
maximum predicted LOD score (assuming linkage would be identified at the same locus in both 
families) would be 3.67 (Figure 3.16-1). While a LOD of 3.67 would be considered significant for 
linkage by conventional criteria, this information was not critical in determining whether a 
linkage study was worthwhile. In fact, the prime rationale for performing the linkage analysis 
was to exclude genes which had been prior candidates (and had no coding/splice site mutations 
detected so far). This is because the two most likely options were a) a mutation in a gene not 
previously considered (in which case all the candidate genes might be excluded on the grounds 
of linkage) or b) a mutation in a gene previously shown to have no coding/splice site mutations 
in this family (i.e. some form of copy number variation too large to be captured in a single PCR 
amplicon). This eventuality would result in at least one locus containing a candidate gene being 
linked to the renal disease. 
 
Figure 3.16-1 Simulation analysis  
Simulation using FASTSLINK indicated maximum predicted LOD score of 3.67 for families 1 and 2. 
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SNP genotyping was performed using the Illumina Linkage IV array which comprises 6008 
SNPs distributed across the genome with an average spacing of 0.32 cM. The cost-benefit 
analysis of using this chip was favourable at the time the experiment was performed.  
Family members were scored as unaffected if they married into one of the families, or if 
they had a normal urinalysis and no renal impairment. Individuals were scored as affected if 
they had renal impairment or microscopic haematuria. Renal biopsies showing C3GN were 
available from 4 individuals for whom DNA was available. 
46 SNPs with Mendelian errors were identified across the families. These SNPs were 
removed from subsequent analyses. This represents less than 0.1% of all genotypes and was 
consistent with accurate sample labelling, genotyping and data transfer. 
Genome-wide linkage analysis excluded linkage with renal disease with a LOD of < -2 in 
89.6% of the genome. This included the loci containing CFI, CFB, MCP, C3, STK11. Of the 10.4% 
of the genome remaining, 5.7% lay in regions with a LOD score for linkage to the renal disease 
of below 0 (indicating that it was more likely than not that the observed pattern of segregation 
was by chance rather than due to linkage at this locus). 3.6% of the genome lay at regions 
linked with LOD between 0 and 1 and 0.7% were linked with LOD > 3 with the renal disease. 
This 0.7% comprised one locus on each of chromosomes 1, 2 and 16 (Figure 3.16-2). 
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Figure 3.16-2 Genome-wide LOD scores for linkage with renal disease 
A single locus (circled) approached the maximum possible LOD score (LOD was 3.4) in families 1 and 2. 
 
Linkage analysis in multiple families generates a LOD score based on the transmission of 
alleles within each family. The presence of linkage with a disease at the same locus in multiple 
families does not imply that there is identical-by-descent (IBD) inheritance of an allele at this 
locus. Rather, the LOD score approach was developed specifically not to assume this – allowing 
the analysis of multiple unrelated families each with a private mutation at the same locus (i.e. 
in the same gene) causing a particular disease. Assuming IBD inheritance would prevent 
simultaneous analysis of multiple such families with a shared phenotype.  
However, I considered it likely that there was IBD inheritance of the disease-causing 
mutation for two reasons. Firstly, the phenotype (autosomal dominant inheritance of C3GN) is 
exceedingly rare and has not previously been recognized, so coincidental identification of 2 
families with independent mutations was correspondingly unlikely (note that this argument 
would not apply if I had started the investigation by screening a very large number of families 
with kidney disease and selected another family with C3GN). Secondly, both families could 
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trace ancestry to a defined geographical area and the prior probability of a common ancestor 
was therefore high. It followed that, if linkage at a particular locus in both families was a 
consequence of the presence of a single disease-causing mutation at that locus, the haplotype 
surrounding it would be shared, with the size of the shared region dependent (in a statistical 
sense) on the number of recombinations (i.e. generations) between the families. Therefore, I 
inspected haplotype plots (inferred by GENEHUNTER and visualised using HAPLOPAINTER) to 
identify which of these loci was likely to have been inherited from a common ancestor in all 
affected individuals of both families. This demonstrated that only part of the chromosome 1 
linked interval was inherited IBD in both families (Figure 3.16-3).  
 
Figure 3.16-3 Identical By Descent (IBD) inheritance  
An identical haplotype on chromosome 1 was inherited by all affected members of both family and family 2. 
 
The common haplotype comprised 17 SNPs and encompassed 8.74 cM, a region which included 
the CFH/CFHR1-5 gene cluster (Figure 3.16-4). 
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Figure 3.16-4 Linkage, IBD haplotype and genes of the RCA cluster 
RCA, Regulators of Complement Activation on Chromosome 1q32 
 
I concluded that the allele (i.e. mutation) responsible for causing the renal disease lay 
within this region which had been inherited from a common (presumably affected) ancestor by 
all affected individuals from both families. 
3.17 Further investigation of CFH/CFHR1-5 gene cluster 
Having amplified and sequenced exons and flanking intronic sequences of CFH and CFHR5, I 
considered there to be 2 likely possibilities. The first was that the mutation responsible for 
causing the disease lay in a different gene in this region (obvious candidates being CFHR1-4) 
and the second was that the mutation was a copy number variation (CNV) in either CFH or 
CFHR5 which was too large to be identified by single-exon amplification and sequencing. 
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In order to address this, I first inspected the sequence traces of CFH and CFHR5 from 
affected individuals and identified heterozygosity for at least one database SNP in each of these 
genes in at least one affected individual, effectively excluding heterozygosity (or homozygosity) 
for a whole-gene deletion of either of these genes. Clearly, other types of CNV (for instance 
whole-gene or sub-whole-gene duplications, hybrid genes and sub-whole-gene deletion events) 
could not be excluded so simply. I therefore proceeded with direct exon sequencing of other 
genes in the interval and, in parallel, assays for copy number variation. 
3.17.1 Sequencing of CFHR1 
Since commonly encountered polymorphic deficiency of CFHR1 is associated with increased 
risk of disease as a consequence of complement activation, it seemed possible that a mutation 
in CFHR1 might cause autosomal dominantly inherited C3GN. Consequently, this gene 
appeared to be the most attractive of the ‘unexplored’ genes in the candidate locus. I therefore 
designed primers in order to amplify and sequence the gene. Because of the high degree of 
sequence identity present in this region, amplification of the exons of CFHR1 required PCR 
primers of high specificity. I designed the primers by inserting the database genomic sequence 
800bp flanking CFHR1 into the web-based PRIMER3 program and specifying coordinates of 
each of the 6 exons. Potential primer sequences generated by PRIMER3 were then aligned with 
the 360 kilobase-pair genomic sequence encompassing all 6 genes of the CFH/CFHR1-5 cluster 
(and 1600 flanking base pairs). Any primers with multiple alignments were rejected. In addition, 
alignment was attempted at reduced stringency. Any primer which had multiple alignments 
when 4 or fewer mismatches were allowed were rejected, and primers which had multiple 
alignments when fewer than 5 mismatches were allowed were rejected unless 2 of the 
mismatches were at the 3’ end (predicting inefficient amplification). Therefore, primers were 
selected to be selective for the desired amplicon. The exception to this was exon 1, which has 
100% sequence identity with exon 1 of CFHR2. However, 187 bp downstream of the exon (i.e. 
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within intron 1) the database sequence for CFHR1 is C, whereas the corresponding position in 
CFHR2 is A (Figure 3.17-1).  
 
Figure 3.17-1 Genomic sequences of CFHR1 exons 1 and 2 
The sequences in these regions are identical except for 2 nucleotides (red) which do not lie within the coding 
sequence (bold). Position of primers used to amplify this region are shown in blue. 
 
Therefore, amplification of both exons simultaneously would be predicted to produce 
apparent heterozygosity for a C/A ‘pseudoSNP’ (i.e. chain termination with ddC is just as likely 
as termination with ddA following equal amplification of both exons. This results in overlying 
curves of reduced amplitude on a sequencing electropherogram, exactly as would be produced 
by the presence of heterozygosity at a particular base-pair in a diploid organism). I therefore 
used primers predicted to amplify both exons equally efficiently and used the presence of this 
pseudoSNP to confirm amplification of exon 1 of both genes. In both patients tested apparent 
heterozygosity at this position was observed (Figure 3.17-2), with all other positions 
demonstrating homozygosity for the database nucleotide (clearly, heterozygosity in only one of 
the 2 genes would be predicted to result in 2 overlying peaks, one ¼ the amplitude of the 
other). This demonstrated firstly no mutations within exon 1 of either gene and secondly that 
there was not homozygous deletion of either gene in affected individuals. The similar size of 
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the peaks of the pseudoSNP suggested that there was not a duplication or heterozygous 
deletion involving one of these exons (but could not indicate if a single CNV involving both 
genes had occurred). Sequencing of all the other exons demonstrated no mutations in the 2 
affected members of family 1 sequenced. 
 
Figure 3.17-2 CFHR1 exon 1 pseudoSNP 
 
In parallel with PCR-amplification and sequencing, analysis of CNV across the locus using 2 
independent approaches was performed: Comparative Genomic Hybridisation (CGH) and 
Multiplex Ligation-dependent Probe Amplification (MLPA) analysis. 
3.17.2 Comparative Genomic Hybridisation (CGH) 
CGH is a way of detecting changes in copy number by competitive annealing of 
fluorescently labelled patient and control DNA to a tiled array of probes which are fixed to a 
glass slide. The ratio of patient to control DNA binding at each position on the slide is related to 
the strength of fluorescence, detected by a charge couple device. This is then plotted against 
genomic location to determine the copy number at each location. 
Since the genomic region of interest had been defined by the linkage study, I commissioned 
a targeted array which used 385,000 probes spanning the region inherited IBD in both families. 
This analysis was performed by Nimblegen in Iceland and the data are summarized in Figure 
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3.17-3. This analysis revealed heterozygous deletion of CFHR1 and CFHR3 in III-2 from family 2, 
but not in IV-5 from family 1. This is a common polymorphism, present in 14.2% of healthy 
controls (Dragon-Durey, Blanc et al. 2009) and could not account for the renal disease. 
Furthermore, since it was absent in an affected individual from family 1 I inferred that 
individual III-2 in family 2 had inherited it from his unaffected father (i.e. was on the other, 
unlinked, chromosome). I concluded from this analysis that a significant region of CNV was 
unlikely to cosegregate with (and hence cause) the disease. 
 
Figure 3.17-3 Comparative Genomic Hybridisation (CGH) array  
CGH across the CFH/CFHR gene cluster showing evidence for a deletion of CFHR1 and 3 in III-2 from family 2 
only. No other significant copy number variation was identified. 
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3.17.3 Multiplex Ligation-dependent Probe Amplification (MLPA) 
analysis 
MLPA is a specific, PCR-based method for determining copy number. A pair of probes, 
complementary to adjacent oligonucleotides, are allowed to anneal to the target DNA. Only 
when both are annealed (with no mismatch at the 3’ end of the upstream probe or the 5’ end 
of the downstream probe) will they be ligated by DNA ligase. Attached to the 5’ end of the 
upstream probe and the 3’ end of the downstream probe (i.e. flanking the ligated double 
probe) are sequences complementary to PCR primers (the forward one of which is 
fluorescently labelled) which are added to the reaction mixture. Geometric amplification by 
PCR therefore only occurs of probe-pairs which are exactly complementary (at the ligation 
point) with target DNA. Since the length of each probe (and its non-complementary tail) can be 
set experimentally, multiple target sequences can be assayed in a single reaction, utilizing the 
same amplification primers and separating the amplicons electrophoretically (Figure 3.17-4). 
Commercial MLPA kits are available for regions of the genome in which CNV has previously 
been considered important, including the CFH/CFHR1-5 gene cluster and include validated 
probe pairs with ligation points at sites of unique base-pairs in homologous regions. 
Chapter 3: Identification of CFHR5 nephropathy 
142 
 
 
Figure 3.17-4 Multiplex Ligation-dependent Probe Amplification (MLPA) analysis  
 
The gene dosage quotient (DQ) is determined by measuring the signal from the amplicon in 
question (A) and dividing by the signal from a reference amplicon (B). The ratio of this quotient 
to the quotient of the same amplicon (a) and same reference amplicon (b) in a control subject 
is determined to yield a relative copy number (Yau, Bobrow et al. 1996). 
Hence:            
 
 
   
 
 
  
The experiment was performed by Dr Rubén Martinez-Barricarte in Madrid. Gene dose 
across the region is indicated in Figure 3.17-5. This confirmed that the heterozygous deletion of 
CFHR1and CFHR3 which had been identified in the CGH array was present in family 2, and that 
it had been inherited by III-2 from his father, with the other allele (conferring the disease) 
inherited from his mother (who also – coincidentally – carried the same common CFHR1/3 
deletion on her other chromosome). This duplication was not present in the individuals tested 
from family 1. 
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Figure 3.17-5 MLPA analysis in individuals from families 1 and 2  
Confirming CFHR1 and 3 deletion in family 2 (in both affected and unaffected individuals) and indicating 
increased copy number of CFHR5 exons 2 and 3 in all affected individuals tested. 
 
In addition, there was evidence of an increased number of copies of exons 2 and 3 (but not 
exon 1) of CFHR5 and this was present in affected individuals from both families, consistent 
with it residing on the disease-linked haplotype. This variant was not previously described and 
it seemed possible that this was the mutation responsible for causing the disease. 
3.18 Confirmation and delineation of CFHR5 internal 
duplication 
While the MLPA was consistent with a duplication of these 2 exons, there was no evidence 
of this on the CGH array, even on inspection of the signal from individual probes at this 
genomic location (Figure 3.18-1). In view of this disparity, I attempted to verify (and delineate 
the extent of) the putative duplication using three different approaches. Firstly by amplification 
and sequencing of cDNA of CFHR5 obtained from affected individuals, secondly by Southern 
Blotting of genomic DNA in order to define the exact genomic extent of the duplication and 
thirdly by Western blotting of patient sera to detect an aberrant protein band. 
Chapter 3: Identification of CFHR5 nephropathy 
144 
 
 
Figure 3.18-1 CGH in detail 
Careful inspection of individual CGH probe signal data from affected individuals of both families revealed no 
evidence of increased copy number at CFHR5 exons 2 and 3. 
 
3.18.1 CFHR5 cDNA sequencing 
Consultation of a gene expression database (Su, Wiltshire et al. 2004) predicted low levels 
of the transcript from cells of peripheral blood (Figure 3.18-2). While the transcript is 
abundantly expressed in normal human liver, I considered that invasive sampling of this organ 
(i.e. performing a liver biopsy) for the purpose of this investigation would be too high-risk and 
unpleasant to be ethically justifiable. Nonetheless, I collected fresh blood from individuals IV-5 
and V-4 from family 1 and immediately extracted RNA from peripheral lymphocytes. The RNA 
was retrotranscribed and amplification was attempted using a number of primer pairs for 
regions of CFHR5, but in no case was a product detectable, in either patient or control samples. 
I concluded from this that the quantity of CFHR5 transcript in circulating blood was too low to 
allow this strategy, with the techniques employed, to work. 
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Figure 3.18-2 CFHR5 expression 
CFHR5 transcript abundance in publicly available genome-wide expression database, by organ. Data were 
downloaded from the website specified in (Su, Wiltshire et al. 2004).  
 
3.18.2 CFHR5 Southern Blotting 
Consultation of the database sequence surrounding exons 2 and 3 of CFHR5 indicated that 
there was an EcoR1 site 439 basepairs (bp) 3’ to exon 1 (i.e. in intron 1) and a second site 7934 
bp downstream, lying 1958 bp 3’ to exon 3 (i.e. in intron 3) (Figure 3.18-3). I therefore 
considered it likely that a duplication involving exons 2 and 3, but not exon 1, would either be 
flanked by or contain one (but not both) of these sites and that therefore probing a membrane 
blotted with EcoR1-digested genomic DNA from an affected individual with a radiolabelled PCR 
amplicon containing exon 2 of CFHR5 would yield a second band (reflecting the existence of a 
genomic fragment which contains CFHR5 exon 2 which migrates at a different rate to the wild-
type allele due to altered size). Clearly, there was the possibility that the duplication was large 
enough to include both sites, in which case no aberrant band would be detected. 
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Figure 3.18-3 Restriction sites in relation to exons of CFHR5  
Predicted restriction fragment lengths are shown (green lines). 
 
Initial Southern blotting of EcoR1-cut genomic DNA from IV-5 and V-4 demonstrated, in 
addition to the predicted 7.9 kbp band, a band of 6.3 kbp which was not present in 2 unrelated 
control individuals (Figure 3.18-4). I considered this the crucial experiment proving the 
existence of genuine CNV cosegregating with the disease (since this allele would have to lie 
within the shared haplotype in order to be transmitted from IV-5 to V-4). Nonetheless, it was 
still not clear what the topography of the duplication was.  
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Figure 3.18-4 Southern blot for CFHR5 
Southern hybridization of a sequence containing exon 2 of CHFR5 with genomic DNA cut with EcoR1 from 2 
affected (IV-5 and V-4) and 2 control individuals (C1 and C2) showing an additional 6.3 kbp band in affecteds only. 
 
The MLPA had indicated that the CNV was a duplication (rather than a deletion) and this 
suggested that one of the EcoR1 sites was included inside a 6.3kbp duplication (if the EcoR1 
sites flanked the duplication a slower migrating band of the size of the duplication plus 7.9kbp 
would be predicted). In order firstly to confirm this result in both families and secondly to 
delineate the topology of the duplication, I repeated the Southern analysis using DNA from 
multiple affected individuals from both families, digesting each individual with EcoR1 and a 
second enzyme. These were selected from the restriction map (Figure 3.18-3) in the hope of 
providing the most accurate estimation of the duplication size and position. I selected BamH1 
because there was one site 1.2 kbp upstream of exon 1 and a second site 5.2 kbp downstream 
of exon 2 (and 4.1 kbp downstream of exon 3) – positions I judged likely (although not certain) 
to flank a 6.3 kbp duplication which included both exon 2 and exon 3 (but not exon 1) of CFHR5. 
I also selected Nco1 because there was a restriction site within exon 2 and further sites 
2.3kbp upstream (in intron 1) and 3.8 kbp downstream (in intron 3). Therefore, a 6.3 kbp 
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duplication including exon 2 would be likely to result in duplication of 2 of these restriction 
sites, producing a new band, the size of which may be helpful in determining the insertion 
point. Finally I included digestion with Pst1 which has one site 278 bp upstream of exon 2 and 
second site 8.6 kbp downstream. This was likely to result in duplication of either no sites 
(resulting a product larger than the wild-type fragment) or the upstream site only (resulting in 
an additional band smaller than the wild-type band). This would confirm the size of the 
duplicated region and further limit the possible insertion point. This experiment confirmed 
firstly inheritance of a 6.3 kbp duplication in affected individuals in both families, secondly that 
the duplication included one (but not both) Pst1 sites and thirdly that the duplication was 
flanked by the BamH1 sites (Figure 3.18-5). The absence of additional bands resulting from 
Nco1 digestion implied either that the duplication included all 3 Nco1 sites or else that the 
distance between the 5’-most duplicated site and the site immediately upstream of the 
duplication insertion point was either 3.8 or 2.3 kbp. 
 
Figure 3.18-5 CFHR5 Southern blot in both families 
Southern hybridization of a sequence containing exon 2 of CFHR5 with genomic DNA from multiple family 
members and controls digested with various restriction enzymes. Aberrant bands present only in affected individuals 
are marked (red arrows). 
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There were, however, 2 possible topologies (with respect to these restriction sites) for the 
new allele. Either there was duplication of a 6.3 kbp fragment which included the 5’ EcoR1 and 
Pst1 sites, or else the duplication included the 5’ Pst1 and 3’ EcoR1 sites. In order to determine 
which of these possibilities was correct I designed primers in which the forward primer was 
downstream (in the wild type chromosome) of the reverse primer. These would fail to amplify 
the wild-type sequence but would produce a product if the duplication resulted in a second 
copy of the reverse primer downstream of the forward primer (Figure 3.18-6). A product was 
observed following amplification with primers designed to amplify a duplication involving the 5’ 
Pst1 and 3’ EcoR1 sites. This product was 4.8 kbp in size and I performed multiple sequencing 
reactions (with primers every 700 bp within this product) in order to reveal the sequence of 
this fragment .  
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Figure 3.18-6 Selective amplification of duplication 
This confirmed its topology with respect to restriction sites and exons. Positions of primers are shown by arrows 
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Figure 3.18-7 Exact sequence and position of duplication 
Determined by amplification and sequencing of insertion point. Sequence positions are colour-coded and have 
the order pink-blue-green-yellow and pink-blue-green-blue-green-yellow in the wild-type and mutant alleles 
respectively. 
 
Comparison of this sequence with the database revealed the exact genomic location of the 
new sequence and this information allowed me to infer the precise size and location of the 
entire duplicated region (Figure 3.18-7). Interestingly, there was not significant sequence 
identity between the regions flanking the beginning and end of the duplication, with only a 
single shared TC pair immediately preceding the start and end of the duplicated region (Figure 
3.18-8). Blasting the 600bp flanking the start and end of the duplicated section revealed no 
significant sequence identity, implying that the non-allelelic recombination event which gave 
rise to the duplication was also non-homologous. 
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Figure 3.18-8 Local sequences at the exact insertion point of the duplication 
Only 2 base pairs (underlined) are duplicated in the sequence immediately prior to the beginning and end of the 
duplicated section. 
 
3.19 Rapid assay for CFHR512123-9 allele 
Knowledge of the exact genomic sequence of the duplication was important because it 
allowed me to design a specific PCR reaction which would amplify both the mutant and the 
wild-type allele at the same time. This reaction was a 1-step diagnostic test for the duplication 
which would allow its presence to be confirmed in the other members of the family and also 
allow me to test for the allele frequency in the general population. While it would have been 
possible to use the presence of a 4.8 kbp fragment as the ‘diagnostic’ test for the duplication 
this was suboptimal for two reasons. Firstly, 4.8 kbp is a rather large fragment of DNA to 
amplify and it is possible that genomic DNA which has become degraded or fragmented would 
fail to amplify even if the duplication were present; and secondly there was no control, in this 
reaction, for amplification failure so it would not be possible to determine whether failure to 
observe a product was due to absence of the duplication in the individual being tested or 
simply to failure of amplification. I therefore designed a reaction which used 3 primers to 
produce 2 differently sized products – one as a result of amplification of a wild type sequence 
in this region, and a second (smaller) product as a result of amplification of the mutant 
sequence. This ensured the test was as sensitive as possible, since small amplicons are more 
likely to be amplified than larger ones during a PCR reaction, and therefore absence of the 
small product, in the presence of the larger product, would exclude the presence of the 
duplication. The positions of these primers are shown in Figure 3.19-1. 
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Figure 3.19-1 Duplication-specific 3-primer diagnostic PCR 
3 primers (arrowheads) are predicted to amplify a 298-bp fragment in the presence of the wild type allele 
(green) but an additional 222-bp fragment in the presence of the duplication. 
 
This assay allowed screening of the families and confirmed that the duplication 
cosegregated with the disease-linked haplotype in both families (Figure 3.19-2). 
 
Figure 3.19-2 Family screen by diagnostic 3-primer PCR 
Demonstrating the smaller fragment (arrow) produced by amplification across the duplication insertion point in 
all and only affected individuals from both families. The band produced by amplification of the wild-type sequence 
(arrowhead) is present in all individuals, indicating that the PCR reaction did not fail. 
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In addition, I tested 100 individuals from the UK 1958 birth cohort for the presence of the 
duplication. It was not detected in any of these individuals (Figure 3.19-3), implying that this 
duplication is not a common polymorphism in the general Caucasian (and specifically the UK) 
population.  
 
Figure 3.19-3 CFHR5 duplication is absent in UK controls 
Only the band produced by amplification of the wild-type allele was detected among 100 individuals from the 
UK 1958 birth cohort. 
 
3.20 Detection of CFHR5 mutant protein 
Inspection of the database sequence indicated that exon 2 is 195 bp (i.e. exactly 65 codons) 
and exon 3 is 177 bp (i.e. exactly 59 codons) in length. Therefore, duplication of these exons is 
not predicted to result in a shift of the reading frame of subsequent exons which were 
therefore predicted to be translated as normal. This would result in a protein of 693 amino 
acids, 124 amino acids longer than the wild-type CFHR5 protein. The molecular mass of such a 
protein can be estimated to be ~66 kDa, compared with 54 kDa for the wild type allele (McRae, 
Duthy et al. 2005). However, there was still the possibility that the mutant protein would be 
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unable to be exported from the cell or alternatively that it would be too unstable to be 
detectable in the circulation.  
CFHR5 consists of 9 short consensus repeat (SCR) domains, each coded for by 1 of exons 2-
9 of the gene respectively. SCRs 1 and 2 (coded for by exons 2 and 3 respectively) are 
homologous with corresponding SCRs of CFHR1 and CFHR2. SCRs 3-7 and 8-9 share homology 
with SCRs 10-14 and 19-20 of CFH (see Figure 3.10-2). Therefore, duplication of exons 2 and 3 
would be predicted to produce a protein consisting of SCRs 12123456789 (denoted    
CFHR512123-9, where the wild-type protein is CFHR5123-9). 
Western blotting was performed on patient and control sera by Dr Elena Goicoechea de 
Jorge using polyclonal antiserum directed against CFHR5. This demonstrated the presence of an 
aberrant band sharing immunoreactivity with wild type CFHR5 only in individuals with genetic 
evidence of the CFHR5 duplication. This new band migrated at a rate consistent with a 
molecular mass of 65 kDa, compared with 54 kDa for the wild-type protein (Figure 3.20-1). This 
was interpreted as most likely resulting from the presence of the mutant protein in detectable 
quantities in the circulation. 
 
Figure 3.20-1 CFHR5 Western blot of serum  
Western blot for CFHR5 of serum from affected individuals (IV-5 and V-4) revealed an additional band migrating 
more slowly (arrow). This was not seen in controls (C1-4) and is consistent with expression of the mutant allele. 
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3.21 Discussion 
3.22 Copy Number Variation and Human Disease 
Copy number variation (CNV) refers to an increased or decreased number of copies of a 
particular sequence of DNA, which can be of anywhere between a few base pairs or many 
millions of base pairs in length. It is now known that CNV accounts for a significant amount of 
the genetic variation between human beings, with some estimates suggesting that 
approximately twice the number of base pairs of difference between any two individuals being 
accounted for by CNV compared with SNPs (Korbel, Urban et al. 2007).  
3.22.1 How does CNV occur? 
CNV usually results from non-allelic recombination, where two previously separated 
chromosomal segments line up incorrectly and are joined to produce a new sequence. This can 
occur either in the presence of homology (called non-allelic homologous recombination, NAHR) 
or in its absence (non-allelic non-homologous recombination). It follows that where a 
duplication has already occurred this will result in homologous sequences arranged end-to-end 
on the chromosome (termed a low copy number repeat or LCR). Conventionally, LCRs are 
defined as regions of >1 kbp sharing >95% sequence identity (Hastings, Lupski et al. 2009) and 
because of their extensive sequence identity, they provide the substrate for further NAHR 
events – leading to the development of highly complex genomic regions.  
Homologous recombination underlies several mechanisms of DNA repair, where a 
homologous sequence (presumably most often from the undamaged sister chromosome) is 
used to repair a damaged sequence (reviewed in (Hastings, Lupski et al. 2009)). Homologous 
recombination requires sequence identity of 300 bp in mammalian cells (Liskay, Letsou et al. 
1987) because smaller (or less perfect) regions of sequence identity are prevented from 
participating in NAHR by mismatch repair mechanisms which are present in prokaryotic and 
Chapter 3: Identification of CFHR5 nephropathy 
157 
 
eukaryotic cells (Rayssiguier, Thaler et al. 1989; Kim, Krasieva et al. 2002). Novel genetic 
variants generated by NAHR arise with increased frequency in regions of complex genomic 
architecture (such as the CFH/CFHR1-5 gene cluster) (Lupski 1998) and it seems likely that the 
homology between the different CFH SCR domains and between the CFH and CFHR genes is a 
result of non-allelic recombination events over time, and that once a duplication has occurred 
further non-allelelic recombination events become more likely at this locus due to the 
proximity of multiple homologous sequences. However, while explaining how CNV can be 
increased in a region of the genome, NAHR cannot account for the initial generation of CNV and 
nor can it explain CNVs in which the flanking regions (i.e. the breakpoint) are not homologous. 
Non-homologous non-allelic recombination can occur as a consequence of repair 
mechanisms which do not require homologous sequences, such as non-homologous end 
joining, where the two ends of a double strand break are ligated – either accurately or with any 
missing sequence filled in with random nucleotides (Lieber 2008) or by microhomology-
mediated end joining, in which a double strand break undergoes end-resection until 5-25 bp 
homologous sequences are revealed (McVey and Lee 2008). Other non-homologous 
recombination mechanisms include replication slippage, in which sequence identity exists 
within an Okazaki fragmenta (100-200 bp in eukaryotes) and the replication machinery ‘slips’ 
between the sequences resulting in small insertions or deletions (Albertini, Hofer et al. 1982); 
or fork stalling and template switching, in which, during replication, secondary structure  in the 
lagging strand template (or nucleotide shortage) stalls replication leading to a free 3’ end of the 
new DNA molecule which can align with another exposed single-stranded template sequence 
on another replication fork leading to a duplication, deletion, inversion or translocation 
(Hastings, Lupski et al. 2009). Interestingly, non-homologous recombination events, although 
they do not coincide with LCRs or they would be indistinguishable from NAHR events, are also 
                                                          
a
 The discontinuously synthesised piece of DNA on the lagging strand during DNA replication 
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more common in the areas of complex genomic architecture (such as the CFH/CFHR gene 
cluster), possibly owing to increased frequency of double strand breaks (Lee, Inoue et al. 2006). 
3.22.2 Why does CNV occur? 
Although mechanistically CNV appears to occur as by-product of inaccurate DNA repair 
mechanisms, it has been suggested that in some circumstances CNV may confer adaptive 
advantages on the host, for example by allowing gene expression levels to be higher than can 
be achieved purely through transcriptional control (Hastings, Lupski et al. 2009). This view is 
supported firstly by the observation that genes involved in olfaction, secreted proteins and 
innate immunity (all with functions relevant to interactions with the environment) appear to be 
over-represented among regions of CNV and secondly by the observation that human 
populations which traditionally consume more dietary starch tend to have more copies of the 
gene for salivary amylase AMY1 suggesting an adaptive mechanism in response to an 
environmental challenge (Perry, Dominy et al. 2007).  However, it could also be argued that 
CNV is rapidly purged from the population if it occurs in genes for which precise copy number is 
important for function and that those genes for which CNV commonly exists are genes for 
which selection on this basis is less potent (Nguyen, Webber et al. 2008). While it has been 
suggested that most CNV polymorphisms have been observed at low frequency in the 
population and that this indicates that they are not tending towards fixation (i.e. are 
detrimental rather than neutral or beneficial), ascertainment of CNV is not straightforward and 
a recent analysis has suggested that over 80% of CNV between pairs of humans occurs as a 
consequence of CNV polymorphisms with allele frequency >5% (McCarroll, Kuruvilla et al. 
2008). 
CNV can favour increased diversity at a locus in at least 2 ways: firstly by increasing the 
probability that further CNV will arise and secondly by making it less likely that any mutation 
which does occur will be detrimental (since a mutation which disables or confers a new 
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function on one copy of a duplicated gene will have no effect on the sequence of the original 
gene which will be unchanged). It may be that for genes involved in combating microbial 
infection, the presence of ‘spare copies’ of a gene may confer an advantage by allowing more 
rapid evolutionary change which in turn allows complex organisms to cope with selection by 
rapidly evolving microbial pathogens. While a possible evolutionary benefit of CNV remains 
unproven, it has been shown that humans and chimpanzees have more LCRs than mice and rats 
(Tuzun, Bailey et al. 2004; Dumas, Kim et al. 2007) and it may be that this has allowed faster 
evolution (over a given number of generations) in primates. 
While a potentially beneficial role of CNV is the subject of much speculation, in the 
CFH/CFHR1-5 gene cluster CNV is well recognized, common in the general population and is 
usually associated with increased risk of disease. Examples include deletion of CFHR1 and 
CFHR3; deletion of CFHR1 and CFHR4 (Schmid-Kubista, Tosakulwong et al. 2009); and gene 
conversions involving CFH and CHFR1 (Venables, Strain et al. 2006). As discussed above, there is 
mounting evidence for pathogenic role for deletion of CFHR1: individuals with homozygous (or 
compound heterozygous) deletions of this gene are overrepresented in collections of patients 
with aHUS compared with collections of healthy individuals (although the pathophysiology is 
not fully understood). However, although this is consistent with a detrimental effect of these 
variants, it must be remembered that since the introduction of antimicrobial therapy and 
modern medicine the cost-benefit balance of genetic changes which combat microbial infection 
in the human population have shifted substantially towards the cost side: individuals who lack 
variants conferring increased resistance to microbial infection can often be protected 
pharmacologically more effectively than those with variants which are protective against 
infection but at the same time increase the risk of autoimmune attack. 
While gene dosage effects such as these and others (Aitman, Dong et al. 2006; Schaschl, 
Aitman et al. 2009) are well recognized in determining risk of ‘sporadic’ (i.e. non-Mendelian) 
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disorders, the proportion of highly penetrant inherited (i.e. Mendelian) diseases which result 
from CNV of the sub-gene scale, compared with longer-recognized mechanisms of variation 
identifiable by PCR-amplification and sequencing (such as small insertions and deletions or 
missense and nonsense single base-pair substitutions), has yet to be ascertained. Studies in the 
Mendelian disorders phenylketonuria and long QT syndrome indicate that whole exon 
duplications or deletions currently account for a small proportion of such cases (Gable, 
Williams et al. 2003; Eddy, MacCormick et al. 2008). As more powerful new techniques 
(including whole-genome sequencing) are used to investigate more people it is probable that 
the full extent of CNV, as a mode of inter-individual variation within a species, will become 
appreciated. 
3.23 “CFHR5 nephropathy” 
The results presented here demonstrate the existence of a mutant, expressed CFHR5 
variant present in individuals from 2 ostensibly unrelated families from the Troodos region of 
Cyprus affected with synpharyngitic macroscopic haematuria, C3GN and renal failure. These 
findings therefore potentially define a new clinical and pathological entity (designated “CFHR5 
nephropathy”) but further information was needed – firstly to confirm the pathogenic nature 
of the CFHR5 mutation; secondly to elucidate the mechanism by which it causes disease; and 
thirdly to define the prevalence and geographical distribution of the disease. This is the subject 
of Chapters 4 and 5. 
  
 
 
 
 
Chapter 4: CFHR5 functional 
studies 
  
Chapter 4: CFHR5 functional studies 
162 
 
4.1 Introduction 
In the previous chapter I described the identification of a novel, expressed variant of CFHR5 
(an in-frame duplication of exons 2 and 3, coding for a protein denoted CFHR512123-9) which 
cosegregates with renal disease in 2 ostensibly unrelated families. Histological examination of 
kidney biopsy specimens from affected members of both families revealed C3 
glomerulonephritis, in which complement C3 is deposited in the kidney in the absence of any 
deposition of immunoglobulins or C1q. This suggested a defect of complement alternative 
pathway regulation.  
As discussed in the previous chapter, the physiological function(s) of the CFHR proteins are 
not well understood and, prior to the identification of a Mendelian trait cosegregating with a 
CFHR5 mutation, the evidence of an important biological role for any of these proteins was 
somewhat circumstantial. However, recent work has revealed genetic evidence that complete 
deficiency of CFHR1 is a risk factor for the development of antibodies directed against CFH 
which in turn predispose to atypical haemolytic uraemic syndrome (aHUS) (Abarrategui-
Garrido, Martinez-Barricarte et al. 2009; Moore, Strain et al. 2010). This suggests that at least 
some CFHR proteins have a non-redundant biological role in humans. 
4.1.1 Genetic epidemiology of CFHR5 
Three studies in which the question of whether variation in CFHR5 could contribute to risk 
of disease have been published to date, investigating dense deposit disease (DDD), haemolytic 
uraemic syndrome (HUS) and age related macular degeneration (AMD). (Abrera-Abeleda, 
Nishimura et al. 2006) showed in 22 patients affected with DDD and 131 controls (unaffected 
by either DDD or age related macular degeneration, AMD) that the minor alleles of 2 SNPs 
(rs9427661 and rs9427662, located in the promoter region of CFHR5) were significantly less 
common in the patients (1 out of 44 compared with 28 out of 206 alleles reported, p = 0.033 
for both SNPs). In addition, the minor allele of a non-synonymous coding SNP, rs12097550 
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(which codes for P46S, a Proline to Serine substitution at codon 46 in exon 2) was significantly 
more common in people with DDD compared with controls (3 out of 44 compared with only 1 
out of 206 controls, p = 0.00023).  
Monteferrante et al (Monteferrante, Brioschi et al. 2007) observed that uncommon genetic 
variants of CFHR5 were more frequently identified in people with HUS compared with controls. 
In 80 blood donor controls and 45 patients with HUS and no mutations identified by direct exon 
sequencing of CFH, PCR amplification and sequencing identified a number of polymorphisms of 
CFHR5. Although 17.5% patients compared with only 5% controls (p = 0.02) harboured CFHR5 
variants, all of these variants were present in at least one unaffected individual. The authors 
conclude that the data were consistent with variation in CFHR5 playing a ‘facilitative but not 
causative’ role in the pathogenesis of HUS.  
Importantly, neither of the above studies employed techniques capable of detecting copy 
number variation and so would not have detected the CFHR512123-9 allele or other similar 
variants. In addition, the extent to which the associations reported in both the above studies 
could have arisen as a consequence of linkage disequilibrium (where an undetected allele of 
the same or a nearby gene is inherited more often than would be expected by chance with the 
observed allele of CFHR5) rather than owing to a functional effect of the observed variants was 
not addressed. Abrera-Adeleba et al conclude in their paper that “functional studies would be 
required to resolve this question.” 
More recently, an additional study did not identify (by exonic amplification and sequencing) 
any pathogenic mutations in CFHR5 in a cohort of 639 unrelated patients with AMD, and the 
authors argue against an important contribution of variation in CFHR5 in this condition 
(Narendra, Pauer et al. 2009). Clearly, this study does not prove that CFHR5 does not play a role 
in protecting the retina against damage, but it does show that SNPs in CFHR5 are not a 
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common contributor to genetic risk of this disease. The methods reported by these 
investigators would not be expected to detect CNV within CFHR5. 
The identification of a highly penetrant Mendelian disease linked to CFHR5 therefore 
provides a completely new line of evidence that CFHR5 plays an important role in humans. The 
aim of the work presented in this chapter was to identify whether duplication of SCRs 1 and 2 
(predicted to result from duplication of exons 2 and 3 of the gene) results in any detectable 
change in the known biochemical functions of the CFHR5 protein. It should be emphasised that, 
in the absence of a complete understanding of the function of the normal protein, only some of 
those biochemical properties (related to the known functions of CFH) which had been 
identified in previous work, were interrogated. 
The work presented here was the result of a collaborative venture with Dr Elena 
Goicoechea de Jorge and Dr Matthew Pickering who performed a substantial number of the 
experiments described. 
4.1.2 Established properties of CFHR5 
Since its identification in 2001 as a circulating plasma protein, relatively little work has been 
published describing the function(s) of CFHR5, and has mostly interrogated the biochemical 
interactions of CFHR5 with reference to CFH – only those properties known to be displayed by 
CFH have been tested. It has been shown that CFHR5 is almost invariably present when C3 is 
deposited in glomerular tissue and also that it is able to bind C3b in vitro (McRae, Cowan et al. 
2001; Murphy, Georgiou et al. 2002). Subsequently, a number of experiments have been 
performed by McRae et al (McRae, Duthy et al. 2005) indicating some biochemical properties 
of recombinant CFHR5, including cofactor activity, heparin binding, binding to C-reactive 
protein and lipoprotein association.  
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4.1.2.1 Cofactor activity 
Recombinant CFHR5 was shown to be able to act as a cofactor for Factor I-mediated 
cleavage of C3 in the fluid phase, and this activity is dose-dependent. Whether this reflects a 
significant function of CFHR5 in vivo remains uncertain for two principal reasons: Firstly, the 
concentration of CFHR5 required in this experiment was 8 μg/ml whereas CFH displayed 
detectable cofactor activity at a concentration of 0.4 μg/ml. Since CFHR5 circulates at levels of 
3-6 μg/ml and CFH is present at concentrations of approximately 500-800 μg/ml it would be 
predicted that, in the healthy human circulation, CFH is in massive excess with respect to its 
function as a cofactor for Factor I mediated cleavage of C3. Secondly, genetic deficiency of CFH 
in humans is associated with C3 activation and reduced levels of circulating C3 (Boyer, Noel et 
al. 2008; Montes, Goicoechea de Jorge et al. 2008), implying that the ability of CFH to regulate 
C3 in the circulation is not redundant in the presence of CFHR5.  It therefore remains to be 
proven whether this property of CFHR5 is physiologically important or if it simply represents a 
vestige of a common evolutionary origin with CFH. 
4.1.2.2 C3 convertase inhibition 
Addition of factor D to a mixture containing C3, C3i, Factor B and magnesium chloride 
results in the generation of C3a, which can be measured by ELISA. Addition of CFHR5 to this 
mixture produced a dose-dependent reduction in C3a production over the range 8-80 μg/ml, 
consistent with inhibition of the C3 convertase. CFH exhibited a similar effect, although of 
greater magnitude. For the same reasons as those discussed above with respect to cofactor 
activity, it is unclear whether C3 convertase inhibition in the circulation is a physiologically 
important function of CFHR5. Importantly, CFHR5 was found not to reduce the rate at which 
factor B is recruited by immobilised C3b in the presence of properdin, factor D, NiCl2 and NaCl, 
suggesting that CFHR5 does not have decay accelerating activity or C3 convertase inhibitory 
activity at a surface (see Chapter 3). 
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4.1.2.3 Heparin binding 
CFHR5 was shown to bind to solid phase and column-immobilised heparin. Notably, a 
higher NaCl concentration was required to elute CFHR5 than CFH, suggesting a higher affinity 
for heparin. The investigators went on to use recombinant CFHR5 fragments comprising either 
SCRs 1-4 or SCRs 3-7 to show that, while CFHR534567 required NaCl concentration of 250mM for 
elution from heparin columns, CFHR51234 was detected in the flow-through and wash fractions, 
indicating that none of domains 1-4 are sufficient to confer detectable affinity for heparin in 
this experimental setup. 
4.1.2.4 Binding to C-reactive protein 
Recombinant CFHR51-9 was also shown to bind to immobilised C-reactive protein (CRP), a 
property inhibited by addition of heparin. Binding was not observed using the CFHR51234 
fragment, however significant binding was exhibited by the CFHR534567 fragment (albeit at a 
reduced level compared with the complete CFHR51-9 protein). 
4.1.2.5 Association with lipoprotein 
CFHR5 was also detected in high (but not low or very low) density lipoprotein purified from 
human plasma.  
Together, these functional data provide good evidence that CFHR5 can co-localise with C3 
in vivo and suggest a mechanism by which CFHR5 can target to host surfaces (owing to high 
affinity for polyanionic moieties such as heparin found there) but leave unanswered the 
question of what the primary functions of CFHR5 are. In addition, elucidation of these 
functional properties has allowed researchers to propose the pairing of domains of CHFR5 with 
their likely homologous domains of CFH (Figure 4.1-1).  
Chapter 4: CFHR5 functional studies 
167 
 
 
Figure 4.1-1 Proposed homologous domains of CFH and CFH-Related proteins 
Positions of CFH mutations associated with dense deposit disease (DDD) and atypical haemolytic uraemic 
syndrome (aHUS) are shown. Adapted from (Jozsi and Zipfel 2008) and (Boon, van de Kar et al. 2009).  
 
As discussed in Chapter 3, aHUS is believed to result from defective complement regulation 
at host surfaces and is commonly associated with mutations in the C-terminal 2 domains of 
CFH. This, combined with the absence of any reported association between mutations in the 
(functionally) homologous domains of any of the CFHR proteins and aHUS, has two corollaries: 
firstly, normal levels of functional CFHR proteins are not sufficient to protect the host from 
aHUS in the presence of abnormalities of the C-terminal SCRs of CFH; and secondly that 
functionally normal levels of CFH are sufficient to prevent aHUS. In support of this, and despite 
extensive screening, the only CFHR alleles which have been shown to be associated with aHUS 
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are those which are also associated with reduced CFH activity – either owing to the 
development of autoantibodies against CFH (Moore, Strain et al. 2010) or as a consequence of 
a likely dominant negative effect on CFH (CFHR1*B in (Abarrategui-Garrido, Martinez-Barricarte 
et al. 2009). 
In summary, while the known biochemical properties of CFHR5 seem to most closely 
resemble those physicochemical properties which are necessary in CFH to prevent aHUS (i.e. 
Factor I cofactor activity, C3 convertase inhibition and heparin binding), these properties have 
not been shown, in any CFHR protein, to be necessary to prevent disease. It can therefore be 
concluded that, while the biochemistry is partially understood, the physiological role of CFHR5 
remains almost completely unknown. Interestingly, none of the published experiments 
interrogate whether CFHR5 is able to play a role in regulating the terminal complement 
pathway, although recent work has shown that CFHR1 is able to inhibit C5 convertase (and 
hence terminal pathway) activity (Heinen, Hartmann et al. 2009). 
4.1.3 How might CFHR512123-9 cause disease? 
In principle, an autosomal dominant disease can result from a mutation by at least 4 
different mechanisms:  
1. Loss-of-function: mutations resulting in the production of insufficient quantity of 
functional protein (i.e. haploinsufficiency) – for example mutations in CBFA1 which 
result in cleidocranial dysostosis. 
2. Gain-of-function: inheritance of an allele for which the protein has either impaired 
degradation and is constitutively more active (for example impaired breakdown of the 
epithelial sodium channel due to a mutation in the ENaC gene in Liddle syndrome) or 
else has acquired new physico-chemical properties leading to a new ‘function’ of the 
protein which itself causes disease (for example transthyretin mutations in familial 
amyloidosis) 
3. Dominant negative: the mutant allele is able to impair the function of the wild-type 
allele resulting in disease – an example of this is Marfan syndrome resulting from 
inheritance of certain defective fibrillin alleles 
4. Somatic second hit: germline loss of one allele results in complete absence of the 
functional protein when a mutation (or deletion) occurs in the other copy during 
mitosis in a somatic cell. While autosomal dominant clinically, these disorders can be 
regarded as recessive on a cellular level – examples include inherited tumour 
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syndromes, such as mutations in STK11 in Peutz Jeghers Syndrome or VHL in von Hippel 
Lindau disease 
CFHR5 nephropathy appeared most likely to result from either a loss-of-function or a 
dominant negative mutation in CFHR5, although a gain-of-function mutation could also be 
responsible. 
Understanding the mechanism by which the observed duplication in CFHR5 might cause 
renal disease is potentially important for two main reasons. The first is in optimising the 
approach to treating affected individuals: in a simple haploinsufficiency (i.e. loss-of-function 
mutation) model, it would be predicted that administering wild-type protein (either a pure 
preparation or as a plasma infusion) to affected individuals may be sufficient to delay the 
progression of renal impairment. However, if the mutation had a dominant negative or gain-of-
function effect then a rational treatment approach would involve removal or neutralisation of 
the circulating mutant protein – an approach likely to present significantly greater barriers to 
success than simply supplementing the quantity of the circulating normal protein. 
In addition to informing rational design of treatment strategies for individuals CFHR5 
nephropathy, it is possible that understanding the mechanism of the disease might provide 
significant insight into the role of CFHR5 in the normal human kidney, and also its role in other 
diseases. A disease resulting from haploinsufficiency or dominant negative effects would imply 
that CFHR5 plays an important physiological role in protecting the kidneys from complement-
mediated attack. It follows that supplementing CFHR5 activity in individuals with MCGN as a 
result of other underlying conditions (such as infection, autoimmunity or IgA disease) may 
provide a novel therapeutic avenue for the future. A gain-of-function mutation would provoke 
a more circumspect interpretation of the role of wild-type CFHR5.  
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4.2 Properties of CFHR512123-9  
4.2.1 Predicted effects of SCR 1 and 2 duplication 
Knowledge of the nucleic acid sequence of the mutant allele allowed prediction of the 
amino acid sequence of the mutant protein. In addition to predicting the molecular mass (by 
summation of the molecular mass of each amino acid), knowledge of the amino acid sequence 
allows estimation of the overall charge (and pI) of a protein, using the following equation: 
     
      
           
    
    
           
  
 
where Ni is the number and pKai the pKa values, of the N-termini and the side chains of the 
Arginine, Lysine, and Histidine residues; and Nj and pKaj are the number and pKa values, of the 
C-termini and side chains of the Aspartate, Glutamate, Cysteine and Tyrosine residues. This 
equation can be solved for any peptide chain at a given pH using an online calculator (for 
example at www.innovagen.se) and can also be used to generate the predicted pI or isoelectric 
point  (i.e. the pH at which the charge is zero). While wild-type CFHR5123-9 has a predicted 
charge of 1.8 at pH 7.0 (and a pI of 7.3), CFHR512123-9 has a predicted charge of -3.2 at pH 7.0 
and a predicted pI of 6.6 (see Figure 4.2-1).  
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Figure 4.2-1 Predicted charge and pI of wild type (WT) and mutant CFHR5 proteins 
 
This suggests that, while the wild type protein is likely to be positive or uncharged at a 
physiological pH, duplication of SCRs 1 and 2 is predicted to produce a negatively charged 
protein – potentially reducing the overall affinity of the protein to negatively charged host 
surfaces. However, it is important to note that this method of modelling is relatively crude: for 
instance, it assumes each residue is independent and takes no account of the presence of post-
translational modifications or disulphide bridges (of which there are at least 18 in CFHR5123-9 
and 22 in CFHR512123-9). 
In addition to the relatively large (from a physico-chemical point of view) change predicted 
by duplication of 2 whole exons, the duplication also predicts the existence of a novel peptide 
sequence within the protein which it is possible could confer altered biological properties on 
the mutant protein. Exon 1 codes for the 5’ untranslated region (UTR) and a 42-amino acid 
sequence upstream of the first short consensus repeat (SCR) domain, ending in the first base of 
codon 43, a Guanine (G). The remainder of codon 43 (consisting of Guanine and Adenine (A)) is 
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encoded by exon 2, yielding Glycine (encoded by GGA) as the first amino acid of SCR 1. Exon 3 
ends with the first base of codon 168, an Adenine. Splicing of another copy of exon 2 
immediately downstream of exon 3 (as predicted by the genomic duplication in CFHR5 
nephropathy) produces the codon AGA, predicting Arginine as the first amino acid of duplicated 
SCR 1 – see Figure 4.2-2. The remaining residues of duplicated SCRs 1 and 2 (and the remaining 
SCRs 3-9) are identical to the wild type sequence. While Glycine is small, uncharged (at pH 7.4) 
and hydrophobic (with a hydropathy index of -0.4 (Kyte and Doolittle 1982)), Arginine is large, 
carries a positive charge and is the most hydrophilic amino acid (with a hydropathy index of -
4.5). Although such a change could have functional consequences, possibly owing to altered 
conformation, if it occurs at or close to a functionally important site of a protein (indeed HIF2α 
erythrocytosis results from exactly this substitution in the region of a critical reactive proline 
residue, see Chapter 2), it seems somewhat less likely that this single amino acid substitution is 
responsible for altering function of the protein compared with the change in overall charge of 
the protein predicted by duplication of the whole of SCRs 1 and 2.  
 
Figure 4.2-2 Amino acid sequence of first 6 exons of the translated mutant CFHR5 
Note the duplicated exon 2’ begins with Arginine (R, in red) rather than Glycine (G). 
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In addition to the electrostatic effects it is also possible that the critical functional change 
caused by the mutation arises from altered conformation of the protein. Perhaps the 2-SCR 
duplication or the glycine to arginine substitution reduces substrate accessibility to another 
part of the protein, impairing function. Conversely, it is possible that the mutant protein binds 
more strongly to an interacting partner owing to the presence of one or more binding sites 
within SCRs 1 and 2. Nonetheless, whatever the mechanism, this in silico prediction of the 
biochemical effect of the mutation was consistent with altered function of the protein, and 
hence provided a theoretical basis for CFHR5 nephropathy to result from this mutation. 
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4.2.2 Erythrocyte lysis  
Since CFHR5 has biochemical properties which allow it to target to host surfaces (and is 
found co-localised with complement C3 in immune deposits in vivo) and the mutation could be 
predicted to impair this function, an experiment was performed which aimed to test the ability 
of mutant CFHR5 to localize with C3 on the surface of chick erythrocytes. Chick erythrocytes are 
spontaneously lysed by complement in human serum, resulting in C3 (and terminal pathway 
components) being deposited on the erythrocyte membrane fragments which can be isolated 
by centrifugation. Components of the serum which bind to C3 (and other deposited 
complement components) will therefore be depleted from the supernatant and enriched in the 
pellet. These components can be separated by electrophoresis and identified by 
immunoblotting. This experiment is summarized in Figure 4.2-3, and the result demonstrated 
that, while the wild type CFHR5 protein is found predominantly in the pellet, the mutant 
CFHR512123-9 species was almost entirely found in the supernatant. This indicated that, in the 
relative proportions in which these proteins are found in the circulation of patients, the wild-
type allele has a greater affinity for complement-lysed chick erythrocytes than does the mutant 
allele. 
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Figure 4.2-3 Chick erythrocyte lysis experiment 
The mutant (Mut) CFHR5 protein is less abundant in the erythrocyte membrane pellet than it is in the 
supernatant. This contrasts with the wild type (WT) protein of which most is present in the pellet. 
 
As a negative control, the experiment was performed in the presence of EDTA, which 
inhibits complement activation. In these conditions, there was complete absence of CFHR5 
(wild type or mutant) from the pellet (which was composed of unlysed erythrocytes), providing 
evidence that non-specific binding of CFHR5 to the outside of the erythrocyte membranes was 
not occurring. In addition, immunoblotting confirmed the presence of C3 in the pellet (Figure 
4.2-4). 
Clearly, this experiment cannot determine which component(s) of the complement cascade 
CFHR5 is binding to, but it did provide the first direct evidence that the altered physico-
chemical properties of mutant CFHR5 are sufficient to affect the ability of the protein to localize 
with complement to a surface.  
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I also observed that, when examining patient sera, the band corresponding to the mutant 
CFHR5 protein was of consistently greater intensity than that corresponding to the wild type 
CFHR5 protein. The antibody used for this analysis was monoclonal and raised against the 
whole protein. McRae et al demonstrated that this antibody recognized both the CFHR51234 and 
CFHR534567 peptides, suggesting that it recognized an epitope residing in SCR 3 or 4. This implies 
that higher affinity of the antibody for the mutant (compared with the wild type) protein is less 
likely to explain this discrepancy. One attractive possibility was that, in affected individuals, the 
wild type protein is preferentially bound to the glomerular electron dense deposits leaving 
relatively little of this species in the circulation. Conversely, since the mutant CFHR5 protein has 
lower affinity for surface-fixed complement, it would remain relatively abundant in the 
circulation, manifesting as more intense staining of the relevant band on Western blotting.  
 
Figure 4.2-4 C3 is detectable in the lysed erythrocyte pellets 
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4.2.3 Heparin Binding – CFHR5 from serum 
The observation that CFHR5 is able to bind to heparin (McRae, Duthy et al. 2005) raised the 
possibility that the mutant allele had altered ability to bind to heparin. In addition, heparin is 
among the most strongly negatively charged biological molecules – the change in charge 
predicted by the mutation (which is likely to render the mutant allele negatively charged at 
physiological pH) can be expected to result in an electrochemical force which opposes heparin 
binding. In order to test this, patient serum was passed through a heparin column (HiTrap, GE 
Healthcare Ltd, Buckinghamshire). The column was then washed and the bound components 
eluted with various concentration of NaCl. At each NaCl concentration, the eluate was blotted 
for CFHR5. While the wild type protein was only detected in the fraction eluted by 350 mM 
NaCl solution, the mutant band was more abundant in the fraction eluted at 300 mM (Figure 
4.2-5), indicating that affinity for the heparin column of the mutant protein was reduced. In 
common with the erythrocyte lysis experiment, this experiment directly compared the affinity 
of the alleles to heparin in the relative concentrations in which they are present in the 
circulation of patients. The result supported the hypothesis that (and provided a potential 
mechanism by which) the mutation results in reduced ability of the protein to localise to host 
cells, which commonly express heparin-like moieties. 
 
Figure 4.2-5 Elution of serum-derived CFHR5 from heparin columns 
The mutant CFHR5
12123-9
 is eluted at 300 mM NaCl whereas the wild type CFHR5
123-9
 protein only becomes 
dissociated from the heparin column at 350 mM NaCl. 
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4.2.4 Generation of recombinant CFHR512123-9  
While the assays of patient-derived serum indicated that the mutant protein had reduced 
affinity for complement-coated erythrocytes and for heparin, the possibility remained that a 
change other than the duplication of SCRs 1 and 2 was responsible for this altered behaviour – 
this possibility was unlikely because Western blotting allowed specific detection of the protein 
product of each allele and the behaviour of each was directly compared. Nonetheless, in order 
to understand better the functional effect of the mutation, and to exclude the possibility that 
the altered behaviour of the alleles was a consequence of an unidentified abnormality 
(presumably of a gene on the disease-linked haplotype) I performed in vitro mutagenesis of 
cloned cDNA of CFHR5 in order to allow expression of the recombinant alleles. 
4.2.4.1 CFHR5 cDNA 
CFHR5 cDNA was purchased from Open Biosystems (Thermo Scientific, Huntsville AL, USA) 
in the vector pCR-BluntII-TOPO which also contains a kanamycin resistance gene. Chemically 
competent DH5α E. coli were transformed with the plasmids, grown on agar plates 
impregnated with kanamycin and 5 colonies were picked for expansion. Plasmid DNA was 
extracted using a miniprep kit (QIAGEN) from aliquots of each culture and DNA from a single 
colony (which was subsequently used for all further experiments), was sequenced using 
primers complementary to the T7 (forward) M13 (reverse) promoter sequences upstream and 
downstream (respectively) of the cDNA for CFHR5. This confirmed firstly that the cDNA was 
identical to the database sequence for CFHR5 and secondly demonstrated the exact insertion 
site within the vector (Figure 4.2-6). 
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Figure 4.2-6 CFHR5 cDNA and vector  
Showing unique restriction sites (blue) including the NdeI site and also the 3 NcoI sites (orange) 
4.2.4.2 Amplification of the duplicated exons 
Knowledge of the exact gene and vector sequence allowed identification of a unique 
restriction site (NdeI) which lay 15-bp from the 3’ end of exon 3. I selected primers which would 
amplify exons 2 and 3 of the cDNA, but at the 5’ end of the upstream primer (labelled 
“Exon_2_start”) I inserted an oligonucleotide with the same sequence as the 25-bp at the 3’ 
end of exon 3 (underlined in blue in Figure 4.2-7).  
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Figure 4.2-7 Plasmid sequence section 
Showing: T7 promoter site (grey); CFHR5 coding sequence (orange); CFHR5 exons 2 and 3 (within the black box); 
and the sequences of the forward (blue arrow) and reverse (red arrow, 3'→5' complementary) are shown, as is the 
unique NdeI site. 
 
This 5’ overhang contained the NdeI site. Amplification of the CFHR5 plasmid with these 
primers was predicted to produce a 446-bp product containing the last 25-bp of exon 3, 
followed by the whole of exons 2 and 3 and the first 49-bp of exon 4 (Figure 4.2-8). Since there 
is an NdeI site 15-bp from the 3’ end of exon 3, I subjected this PCR product to overnight 
digestion with this enzyme. This was predicted to remove the 5’ 10-bp and the 3’ 64-bp, 
producing a 372-bp product consisting of the last (i.e. 3’) 15-bp of exon 3, followed by the 
whole of exon 2, followed by all but the last 15-bp of exon 3, with (identical) “sticky” ends 
suitable for ligation into an NdeI-digested template. I next digested the pCR-BluntII-TOPO-
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CFHR5 plasmid with NdeI overnight, and treated the product with alkaline phosphatase which 
results in loss of the 5’ terminal phosphate moieties of the linearised plasmid, preventing their 
self ligation in the presence of DNA ligase. Both digests were electrophoresed on a 2% agarose 
gel and the bands were purified (QIAGEN).  
 
Figure 4.2-8 Plasmid PCR-amplicon 
Amplicon resulting from amplification of CFHR5 cDNA using forward primer consisting of the 3’ 25-bp of exon 3 
(red box) placed 5’ to the first 12-bp of exon 2 (forward arrow) and a reverse primer which was the reverse-
complement of an oligonucleotide present in exon 4 (purple arrow). Digestion of this amplicon with NdeI produced a 
372-bp fragment (between green arrows) consisting of the last 15-bp of exon 3 followed by all of exon 2 followed by 
all but the last 15-bp of exon 3. Note the NcoI site 44-bp from the 5’ end (and 328-bp from the 3’ end) of this 
fragment (black arrow). 
 
4.2.4.3 Ligation of amplified exons 2 and 3 into gene 
Since a single restriction enzyme had been used both to generate sticky ends on the insert 
and to linearise the plasmid, a number of possible outcomes could be anticipated to result from 
ligation. Firstly, self ligation of the linearised plasmid to form the wild-type CFHR5 in the vector; 
secondly, correct insertion of the digested PCR product to form the desired mutant in the 
vector; thirdly, incorrect insertion of the digested PCR product inverted with respect to the 
plasmid; fourthly, insertion of multiple copies of the PCR product into the plasmid. I considered 
that the first possibility was unlikely to occur owing to the prior treatment of the digested 
plasmid with alkaline phosphatase – lack of the 5’ phosphate group on both the sense and 
antisense strands would prevent formation of a covalent bond between the hydroxyl group on 
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the 3’ end and the 5’ end of the linearised plasmid. I predicted that ligation of the insert would 
occur in the desired and inverted orientation with equal likelihood, but that insertion of 
multiple copies of the insert would be unlikely unless the insert was in significant excess with 
respect to the vector.  
I therefore performed the ligation reactions and PCR product:plasmid molar ratios of 3:1  
and 10:1. The ligated products were then used to transform chemically competent DH5α E. coli 
which were then plated onto kanamycin-impregnated agar plates. 10 individual colonies were 
picked for each molar ratio, allowed to replicate and plasmid DNA was extracted from an 
aliquot of each one. 
4.2.4.4 Diagnostic digestion of mutant construct 
Diagnostic digestion with NcoI was predicted to produce 4 bands of size 372, 439, 1645 and 
3924-bp if the insert was correctly inserted (with 372-bp band being lost in the absence of an 
insert). Inversion of the insert was predicted to produce bands of sizes 439, 654, 1645 and 
3634-bp respectively (Figure 4.2-9).  
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Figure 4.2-9 The desired and inverted ligation products 
The desired product contains NcoI restriction sites at positions 1280, 1719, 3364 and 3736, predicting bands of 
size 372, 439, 1645 and 3924-bp following NcoI digestion. The inverted product contains NcoI sites in positions 1280, 
1719, 3364 and 4064, predicting bands of 439, 654, 1645 and 3634-bp respectively. 
 
This was performed and confirmed the presence of the predicted bands in none of the 10 
colonies transformed with product of ligation at a 3:1 molar ratio, but 3 of the 10 colonies 
transformed with 10:1 molar ratio ligation product (see Figure 4.2-10). In the remaining 7 
colonies, the 372-bp band was absent – consistent with failure to ligate the PCR product into 
the vector. One colony with the desired diagnostic digest was selected and the gene sequenced 
(again using T7 and reverse M13 primers), confirming that the desired recombinant mutant 
allele had been generated. 
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Figure 4.2-10 Predicted and observed gels 
The 372-bp fragment (white arrow) is only predicted to be present when the insert is present in the correct 
orientation. Inversion of the insert is predicted to produce an aberrant band of 654-bp (red arrow). 
 
The subcloning, heparin and glomerular binding and cofactor assays were performed by Drs 
Matthew Pickering and Elena Goicoechea de Jorge. The experiments are included in this thesis 
because I was involved in the experimental design and interpretation, and because the insights 
they give into the functional effects of the CFHR5 mutation are important considerations for 
material presented later. 
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4.2.4.5 Sub-cloning into pCI-Neo and expression in Cos7 cells 
In order to allow efficient expression of the mutant protein in mammalian cells expressing 
the SV-40 large T antigen, the recombinant CFHR5 alleles which I had made were cloned into 
pCI-Neo vector (obtained from Promega) which contains an SV40 enhancer/promoter. This was 
achieved by amplification of the wild type and mutant genes in pCR-BluntII-TOPO using primers 
incorporating (in their 5’ ends) a SalI restriction site (5’ end of the gene) and a NotI restriction 
site (3’ end of the gene – i.e. the reverse primer). Amplification was performed using Platinum 
Taq High Fidelity (Invitrogen), which has proof-reading ability via its 3’ to 5’ exonuclease 
activity. The PCR products were digested with SalI and NotI to produce sticky ends and the 
resulting digested amplicons ligated into the pCI-Neo vector which had been cut with SalI and 
NotI to produce the products shown in Figure 4.2-11. These constructs were used to transform 
competent E. coli bacteria and amplified in culture. The plasmid DNA was extracted and the 
inserts sequenced using T7 (forward) and T3 (reverse) primers. This confirmed correct insertion 
of the alleles into the vector and excluded the presence of substitutions, insertions or deletions 
which might have occurred during the PCR amplification procedure. 
 
Figure 4.2-11 CFHR5 in expression vector pCI-Neo 
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pCI-Neo-CFHR5 wild type and mutant plasmid DNA was transiently transfected into Cos7 
cells using calcium chloride and grown under serum-free media. After incubation for 48 hours, 
aliquots of the media were blotted for CFHR5 and this demonstrated the presence of 
immunoreactive bands corresponding to the size predicted for CFHR5123-9 and CFHR512123-9 
respectively (Figure 4.2-12). Next, an enzyme-linked immunosorbent assay was performed 
using rabbit polyclonal and mouse monoclonal antibodies. This demonstrated similar levels of 
expression of both alleles in the supernatant, consistent with the result from Western blotting 
(Figure 4.2-13). 
 
Figure 4.2-12 Expression of CFHR5 wild type and mutant proteins in Cos7 cells 
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Figure 4.2-13 Enzyme-linked immunosorbent assay for CFHR5 
ELISA was performed on serum and culture medium from Cos7 cells transfected with wild type or mutant 
CFHR5 
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4.2.5 Heparin-binding – recombinant CFHR5 
Culture media containing each protein was passed through HiTrap heparin columns and 
eluted at increasing NaCl concentration (Figure 4.2-14). While the wild type CFHR5 was 
predominantly eluted at 350mM NaCl, the CFHR512123-9 protein was detectable in the eluate of 
250 mM NaCl and was predominantly released in the 300 mM fraction. This protein was not 
detected in the 350 mM fraction.  
 
Figure 4.2-14 Elution of recombinant CFHR5 proteins from heparin columns 
Recombinant CFHR5 proteins were allowed to bind to heparin columns and eluted with increasing NaCl 
concentrations. The mutant protein is eluted at a lower concentration than the wild type, consistent with lower 
affinity for the column. 
 
We concluded that the mutation causes CFHR5 to have reduced affinity for heparin. 
4.2.6 Glomerular binding – recombinant CFHR5 
Since CFHR5 is present in the glomerular deposits of C3 (McRae, Cowan et al. 2001) and the 
theoretical and heparin binding data were consistent with impaired ability of the mutant 
protein to bind to anionic surfaces, an experiment was performed which compared the ability 
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of the recombinant proteins to bind to glomerular sections coated with C3. The substrate used 
for this experiment was glomerular sections from mice deficient in CFH (cfh-/-). These animals 
spontaneously develop C3 accumulation along the glomerular basement membrane (Pickering, 
Cook et al. 2002). The sections were first incubated with 5% normal human serum, washed and 
then incubated with mouse monoclonal anti-CFHR5 antibody. The sections were then 
incubated with fluoroscein isothiocyanate-labelled goat anti-human IgG antibodies in order to 
visualise and quantify any deposition of CFHR5 in the glomeruli. For comparison of the 
distribution, adjacent sections (from the same animal) were stained with fluorescein 
isothiocyanate (FITC)-labelled mouse anti-C3 antibodies, and as a negative control, sections 
from mice deficient in both cfh and c3 were stained for CFHR5. This revealed that CFHR5 from 
human serum bound to the mouse glomeruli in a similar distribution to C3, but did not bind in 
the absence of C3 (Figure 4.2-15). This result was expected in view of the previous observation 
that CFHR5 co-localizes with C3 in human glomeruli (Murphy, Georgiou et al. 2002) and 
provided proof of concept that the mouse complement system could act as a model for (at 
least some of) the biochemical functions of human CFHR5. 
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Figure 4.2-15 CFHR5 in complement-coated mouse glomerular sections 
Human CFHR5 is detected in CFH-deficient mouse glomerular sections following incubation with normal human 
serum in a similar distribution to C3. Human CFHR5 is not detected when the mouse is deficient for both CFH and C3, 
or if the glomerular sections are not incubated with human sera. 
 
The erythrocyte lysis and heparin binding assays were both consistent with reduction in 
affinity of the mutant protein for negatively charged host surfaces and it was therefore 
predicted that the mutant protein would bind less well to the mouse glomeruli. Serial dilutions 
of supernatant were tested and the supernatant containing the mutant protein resulted in 
significantly lower fluorescence intensity compared with that containing the wild type protein 
(Figure 4.2-16). 
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Figure 4.2-16 Impaired binding of mutant CFHR5 to complement-coated glomeruli 
Significantly less fluorescence was detected when recombinant mutant CFHR5 was incubated with CFH deficient 
mouse glomerular sections compared with the wild type, at various concentrations of recombinant protein. 
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4.2.7 Cofactor activity – recombinant CFHR5 
The functional data reported above were consistent with a reduced ability of the mutant 
protein to localize to host surfaces but did not address the question of whether the mutant 
protein had altered ability to regulate C3 turnover, in addition to the altered ability to localize 
to surfaces. 
Since CFHR5 had previously been shown to have the ability to act as a cofactor for Factor I-
mediated cleavage of C3b to iC3b, the ability of the mutant protein to perform this function 
was assessed. C3b (Calbiochem, CA, USA) was generated from C3 by partial digestion with 
trypsin. 50 ng of C3b was added to 10 ng Factor I (Calbiochem, CA, USA) and serial dilutions of 
wild type or mutant CFHR5 were added to a total volume of 16.5 μL in 20 mM phosphate buffer 
(pH 6.0). The mixture was incubated overnight at 37°C, the reaction then stopped with 5 μL SDS 
sample buffer and the solution blotted for C3 (using goat anti-C3c polyclonal antibodies). 
Surprisingly, while no cleavage of the C3α chain was detected in solution containing 7 nM or 
less wild type CFHR5, cleavage was detected with as little as 3.5 nM CFHR512123-9 and no intact 
C3α chain was detected in the presence of 7 nM CFHR512123-9. A representative blot is shown in 
Figure 4.2-17. This experiment indicated that, rather than coding for a simple loss-of-function 
variant of CFHR5, duplication of exons 2 and 3 produces a protein which has enhanced cofactor 
activity (at least in this assay). 
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Figure 4.2-17 Recombinant CFHR5 cofactor activity 
Cleavage of C3α in the presence of complement factor I was detected with lower concentrations of the mutant 
CFHR5 protein (lanes 5 to 8) compared with the wild type protein (lanes 1 to 4) 
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4.2.8 Insights from clinical observations 
While experiments using CFHR5 and CFHR512123-9 isolated from serum or generated from 
recombinant DNA can provide some evidence of the biochemical effects of the mutation, two 
clinical observations have provided particular insight into the pathophysiology of the disease 
and have implications for its treatment. 
4.2.8.1 Transplant recurrence 
To date, 3 individuals with CFHR5 nephropathy have undergone renal transplantation. The 
first was individual III-1 from family 1 (see Chapter 3). This individual was born in Cyprus and 
was an obligate carrier of the CFHR5 duplication. A native renal biopsy performed in his fifth 
decade revealed C3GN and he reached end stage renal failure and received a cadaveric renal 
allograft at the age of 49. He died 11 years later from a myocardial infarction at which time his 
serum creatinine was 89 μmol/l. The allograft was never biopsied. The second individual (III-2 
from family 3, see Figure 5.2-4, Chapter 5) resided in Cyprus and had presented at end stage 
renal disease and hence had never been biopsied. Molecular analysis (performed on stored 
genomic DNA post mortem) confirmed the presence of duplication of exons 2 and 3 of CFHR5 in 
him. This individual had undergone cadaveric renal transplantation but lost the (well-
functioning) graft and his right leg 10 years later to cholesterol embolic disease following 
coronary angiography. He died 6 years after that. Both of these individuals therefore had no 
clinical or histological evidence of disease recurrence following transplantation. 
The third individual was a Cypriot man (designated 115301, see Chapter 5) with end stage 
renal failure secondary to CFHR5 nephropathy (diagnosed by the presence of synpharyngitic 
macroscopic haematuria, C3GN on native renal biopsy aged 34 and heterozygosity for the exon 
2/3 duplication of CFHR5) who underwent cadaveric renal transplantation at the age of 53 with 
a kidney from a 66-year-old donor. There were no surgical complications and 
immunosuppression was with alemtuzumab and corticosteroids in the perioperative period, 
Chapter 4: CFHR5 functional studies 
195 
 
and tacrolimus which was continued after discharge on postoperative day 8. Serum creatinine 
stabilised at 186 μmol/l and there was persistent microscopic haematuria with a single episode 
of macroscopic haematuria which was not related to instrumentation of the urinary tract. 
Allograft biopsy performed on postoperative day 46 demonstrated subendothelial and 
mesangial electron dense deposits (Figure 4.2-18). There was C3GN, with isolated granular 
staining for C3, but no detectable deposition of immunoglobulins. In this biopsy, there was no 
mesangiocapillary glomerulonephritis, and the impression of the histopathologist (Professor 
Cook) was that the suboptimal allograft function could not be explained by the glomerular 
changes. 
 
Figure 4.2-18 Recurrent disease following transplantation 
Kidney allograft biopsy performed in an individual with CFHR5 nephropathy 46 days after transplantation 
showing subendothelial electron dense deposits. 
 
Whatever the direct implications for this patient, this observation demonstrates that C3GN 
in CFHR5 nephropathy can recur in an allograft and proves that the disease results from an 
abnormality of a circulating factor, as opposed to a defect of local complement regulators 
synthesised within the kidney.  
The systemic nature of the disease has two major clinical implications: firstly that organs 
other than the kidneys might be susceptible to the disease; and secondly that therapeutic 
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interventions which modulate circulating CFHR5 levels may be of benefit in CFHR5 
nephropathy. 
4.2.8.2 Therapy in CFHR5 nephropathy: anecdotal experience 
An individual (designated 116301, see Chapter 5) had been diagnosed with MCGN following 
a renal biopsy performed to investigate macroscopic haematuria at the age of 18 years. 
Subsequent review was consistent with C3GN (i.e. there was immunostaining for C3 but not 
immunoglobulins and no dense transformation of the basement membrane) and molecular 
testing confirmed that the underlying disease was CFHR5 nephropathy. Ten years later there 
was the first evidence of renal dysfunction and proteinuria and the biopsy was repeated – again 
revealing C3GN but now with some tubular and mesangial scarring. He remained well until the 
age of 32, at which time there was a further rise in serum creatinine to approximately 200 
μmol/l. Treatment with mycophenolate mofetil was commenced, but over the following 6 
months the renal function deteriorated progressively and renal replacement therapy was 
commenced. 
A 44-year-old individual (III-2 from family 2, for clinical history see Chapter 3) exhibited a 
rising creatinine during the first half of 2009, from a baseline of approximately 180 μmol/l in 
2008. He was diagnosed with a urinary tract infection and subsequently underwent a bladder 
neck incision operation in March 2009. Following this procedure, the creatinine progressively 
rose to approximately 230 μmol/l and he was administered 1 g of cyclophosphamide 
intravenously at the start of June, with a further 1 g one month later. Immediately after the 
first dose was administered there was macroscopic haematuria and blood tests revealed a 
rising creatinine (see Figure 4.2-19). The macroscopic haematuria became more severe after 
the second dose of cyclophosphamide and no further doses were given. The creatinine 
continued to rise, reaching 270 μmol/l prior to the second dose, with a continued gradual rise 
over the next 2 months. During this period the patient experienced persistent macroscopic 
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haematuria, nausea, weight loss and poor appetite. In September 2009 he was admitted to 
hospital with non-specific symptoms (feeling ‘very unwell’ with a presumed bacterial infection) 
and an acute deterioration in renal function, with a serum creatinine which peaked at 
approximately 620 μmol/l. Following treatment with intravenous rehydration and antibiotics 
the creatinine fell and at discharge it was 375 μmol/l. Over the ensuing 8 weeks, the creatinine 
fell slowly, however the macroscopic haematuria persisted. 
 
Figure 4.2-19 Treatment of CFHR5 nephropathy 
Rising serum creatinine in an individual with CFHR5 nephropathy in the context of macroscopic haematuria. 
There was no response to immunosuppression with corticosteroids and cyclophosphamide, and admission with a 
presumed bacterial infection was associated with sudden deterioration in renal function. Macroscopic haematuria 
ceased and recovery of function to baseline was seen immediately following plasma exchange. 
 
In view of the known abnormal circulating protein (i.e. CFHR512123-9) and the recently 
observed recurrence of the disease in a transplant, I considered that normalising the circulating 
concentrations of complement proteins using plasma exchange would have a good chance of 
therapeutic benefit, similar to other genetic diseases of complement regulation (Noris, 
Bucchioni et al. 2005). Because it was not possible to be certain whether supplementation of 
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wild type CFHR5 or removal of mutant CFHR5 would be needed to provide the maximum 
chance of benefit, in consultation with the clinician  looking after him (Dr Pierides), the patient 
underwent 4 cycles of plasma exchange, each against 1.5 l fresh frozen donor plasma and 1.5 l 
5% human albumin solution. On completion of this treatment there was a very marked clinical 
improvement with cessation of the macroscopic haematuria and an abrupt fall in the serum 
creatinine to under 180 μmol/l. Over the following 6 months, the serum creatinine has 
gradually risen, with a most recent reading of 223 μmol/l. 
Western blotting of serum samples before and after each exchange revealed reduction in 
the levels of the mutant protein, more apparent after the third and fourth exchanges. There 
was no obvious change in the intensity of the band corresponding to the wild type protein 
(Figure 4.2-20). 
 
Figure 4.2-20 CFHR5 protein before and after plasma exchange 
Western blot of serum for CFHR5 immediately before and after treatment with plasma exchange on 4 
consecutive days. There is a detectable reduction in the amount of the mutant protein following exchanges, with 
apparent recovery to pre-treatment levels within 24 hours. 
   
Chapter 4: CFHR5 functional studies 
199 
 
4.3 Discussion 
The full range of biochemical properties, interactions and physiological functions of CFHR5 
are incompletely understood. In this context, a complete appreciation of the biological effects 
of the observed duplication of 2 SCR domains is impossible. However, it is clear that previously 
reported biochemical properties of CFHR5 are altered by the presence of the mutation: 
CFHR512123-9 displays reduced affinity for negatively charged molecules and surfaces (namely 
heparin and complement-coated eukaryotic surfaces); appears to be more abundant than the 
wild-type CFHR5 protein in the circulation of patients; and has increased ability to act as a 
cofactor for factor I-mediated cleavage of C3b. 
It is worth noting that, even though the methods of detection and quantification of the 
CFHR5 alleles (i.e. ELISA and Western blotting) relied on antibody binding, a significant 
difference in the affinity of the antibody for the protein products of the two alleles would not 
explain the differences observed: for both the erythrocyte lysis and heparin binding 
experiments, the quantity of each protein in different fractions of the same experiment was 
compared (i.e. pellet versus supernatant in the erythrocyte assay and each eluate in the 
heparin binding assay) and this ratio was compared between the two proteins.  
If the explanation of the reduced glomerular staining for CFHR512123-9 in the mouse kidney 
sections treated with recombinant CFHR5 alleles was reduced affinity for the antibody (rather 
than reduced affinity for the glomerular deposits) then the quantity of CFHR512123-9 
administered to the sections would have been similarly underestimated, which would tend to 
oppose this error. A similar argument can be deployed in the case of a hypothetically increased 
affinity of the antibody for the mutant protein. 
Finally, in the original publication describing the antibody, it was shown to detect both 
CFHR51234 and CFHR534567 peptides (McRae, Duthy et al. 2005), implying that it recognised 
epitope(s) other than those found in SCRs 1 and 2. I therefore consider it impossible for all the 
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observed differences between the two alleles in the binding assays to be an artefact of a 
difference in antibody affinity, and unlikely for any of them to have resulted from this type of 
artefact. 
4.3.1 CFHR512123-9: A gain-of-function mutation? 
It is not immediately obvious how increased cofactor activity (leading to enhanced ability to 
degrade C3b) could be the mechanism by which CFHR512123-9 is responsible for CFHR5 
nephropathy. One possibility is that this observation resulted from a flaw in the design of the 
experiment: since the read-out for the cofactor reaction was degradation of C3b (rather than 
quantification of CFHR5), interpretation of the assay is highly dependent on the accuracy of 
quantification of CFHR5 administered. Nonetheless, it seems unlikely (given, for instance, the 
strong staining for the mutant band in patient sera) that the concentration of recombinant 
mutant protein used in the experiment was inadvertently so much higher (requiring a reduced 
affinity for the antibody) than that of the wild type band – especially in view of the greater than 
2-fold increase in concentration of the wild type allele required for the reaction to proceed. It 
therefore seems more likely that the observed enhanced cofactor activity reflects a genuine 
difference in the properties of the proteins. 
While iC3b (the product of factor I-mediated cleavage of C3b) does have pro-inflammatory 
effects (via its ability to act as a ligand for complement receptors on phagocytic cells), it lacks 
C3 convertase activity (see Chapter 3). Therefore, an abnormality which resulted (purely) in 
increased cleavage of C3b to form iC3b would not result in increased C3 turnover – in fact 
accelerated clearance of C3b would tend to reduce alternative pathway activation by reducing 
the levels of C3 convertase. Importantly, evidence from both humans and mice with genetic 
complement abnormalities has shown that CFI activity (and presumably therefore iC3b 
generation) is required for complement-mediated renal damage. As discussed in Chapter 3, 
humans with homozygous deficiency in CFI, while manifesting C3 deficiency (with what is 
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detected predominantly present as C3b, presumably owing to the uncontrolled conversion of 
C3 to C3b via the alternative pathway), do not always exhibit glomerulonephritis and in 
particular, no cases of C3GN or DDD have been reported in these individuals (Rose, Paixao-
Cavalcante et al. 2008; Licht and Fremeaux-Bacchi 2009). In addition, mice deficient for both cfi 
and cfh, do not exhibit glomerular damage until after the administration of exogenous source 
of cfi which allows iC3b to be generated (Rose, Paixao-Cavalcante et al. 2008). Together these 
data are most likely to be explained by a pathogenic role of iC3b in mediating glomerular 
damage. Although it is true that circulating C3 levels were normal in all affected individuals 
studied, compatible with the absence of generalised C3 consumption, the hypothesis that 
enhanced C3b cleavage alone (i.e. without autocatalytic upregulation of C3b production by 
alternative pathway dysregulation) is sufficient to cause glomerulonephritis owing purely to 
increased iC3b production is intriguing but intuitively unlikely: iC3b may be necessary but has 
never been shown to be sufficient to cause C3-mediated glomerular damage in the absence of 
excessive C3b generation. Nonetheless, the fact that the evolution of the complement system 
has resulted in the requirement of CFI for a cofactor in order to cleave C3b suggests that 
regulation of this step is of critical importance in the pathway, implying that abnormal kinetics 
of this reaction could result in disease.  
The question of what would be the effect of isolated CFI overactivity could be answered by 
the generation of a model organism which overexpressed a constitutively active form of cfi (i.e. 
a mutation which abrogated the requirement for a cofactor) or else the identification of 
humans in which a gain-of-function mutation of CFI caused disease. Individuals with 
heterozygous mutations in CFI are well-represented in individuals and families with aHUS and 
C3GN (Fremeaux-Bacchi, Dragon-Durey et al. 2004; Caprioli, Noris et al. 2006; Servais, 
Fremeaux-Bacchi et al. 2007) but, where reported, the functional effect of these mutations has 
been to inhibit CFI protease activity. 
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Clearly, a defect which resulted both in alternative pathway dysregulation and iC3b 
generation would provide an attractive mechanism to explain the pathogenesis of CFHR5 
nephropathy, however no data exist which support this, and the absence of C3 depletion in 
affected individuals argues against it. 
In addition, since normal CFHR5 is not sufficient to regulate C3 turnover in the circulation in 
the absence of CFH and there is no abnormality of circulating complement C3 levels in 
individuals with CFHR5 nephropathy, it is intuitively unlikely that the primary mechanism is one 
of dysregulation of complement in the circulation, although clearly increased production of a 
C3 metabolite which has particular affinity for the glomerulus is not impossible. 
4.3.2 CFHR512123-9: A reduced function mutation? 
The data presented here demonstrate that both recombinant and patient-derived mutant 
CFHR5 have impaired ability to bind to heparin and complement-coated eukaryotic surfaces. 
However it is important to emphasize that, in these assays, CFHR512123-9 displayed reduced but 
not absent binding and should therefore be regarded as a hypomorphic rather than a complete 
loss-of-function allele – at least with respect to surface/heparin binding. 
If the observed reduction in the binding affinity of mutant CFHR5 for host surfaces is indeed 
the sine qua non of CFHR5 nephropathy then there are three important corollaries: Firstly that 
CFHR5 must play a non-redundant role in the protection of glomerular surfaces, since its failure 
to localise there results in disease (see Figure 4.3-1); secondly that administration of (wild-type) 
CFHR5 to people with CFHR5 nephropathy would effectively treat the disease by 
supplementing the deficient protein; and thirdly that in humans two normally functioning 
copies of the CFHR5 gene are required to prevent glomerulonephritis.  
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Figure 4.3-1 Proposed model for CFHR5 
Showing a non-redundant role for CFHR5 in regulating C3 activity at glomerular endothelial surfaces (left panel). 
When CFH is deficient in the circulation (middle panel), uncontrolled C3 activation leads to runaway C3 deposition, 
overwhelming the ability of CFHR5 to regulate (or clear) C3 from the glomerular surfaces. When CFHR5 is deficient or 
mutated (right panel), circulating C3 regulation is normal but regulation at glomerular surfaces is impaired leading to 
disease. GBM, glomerular basement membrane. 
 
While normal CFH function is necessary and (in the absence of a significant abnormality of 
C3, CFI or CFB) sufficient to regulate complement activation in the circulation (illustrated by the 
low C3 seen in humans and mice with CFH deficiency or depletion), both CFH and CFHR5 
appear to be required for the normal regulation of complement activation at the glomerular 
surface. 
If substitution of one normal allele of CFHR5 with one hypomorphic allele is sufficient to 
cause disease, then the normal circulating levels of CFHR5 are not in massive excess with 
respect to preventing C3 deposition in the glomerulus in normal humans. This is compatible 
with the observations that a) normal copies of CFHR5 are not sufficient to protect the 
glomerulus from damage in the presence of genetic or acquired causes of pathological 
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alternative pathway activation (for example C3 nephritic factor or complete CFH deficiency 
which cause DDD) and b) that activation of the classical pathway by antibodies (produced in 
response to infections or in autoimmune diseases such as systemic lupus erythematosus) can 
lead to complement deposition in the kidney and MCGN in individuals without abnormal CFHR5 
alleles. In addition, the hypothesis that CFHR5 levels in healthy humans are only a little higher 
than that required to prevent spontaneous C3GN is not an a priori unlikely proposition since 
complement activation must remain finely balanced between the need to destroy invading 
microorganisms and the need to protect host surfaces (see Chapter 3); it is easy to imagine how 
an allele conferring reduced complement activation (for example a gain-of-function mutation or 
increased gene dose of a complement regulator) could result in death from infection during 
infancy, especially in the pre-antibiotic era. Following this line of reasoning, the issue of 
whether CFHR512123-9 might (in some environmental context) actually confer a survival 
advantage (notwithstanding the risk of kidney disease in adulthood) is discussed in Chapter 5. 
The pattern of disease seen in patients with CFHR5 nephropathy is compatible with a 
partial impairment of the ability to tolerate activation of the immune system. The disease is 
characterised by episodes of macroscopic haematuria accompanied by acute deterioration in 
renal function which coincide with infections (often of the upper respiratory tract). It may be 
that, while in health complement regulatory activity of CFHR5 at the glomerular surface is 
sufficient to prevent disease, when complement turnover is increased owing to increased 
antibody production in response to infection, the complement-regulating capacity of the locally 
subnormal level of CFHR5 is overwhelmed and glomerulonephritis results. Consistent with this, 
it is recognised that mutations in or deficiency of other complement regulatory proteins 
(particularly CFH) most commonly produce clinical disease only in the context of an 
environmental immunological trigger such as a viral infection (Goodship and Kavanagh 2010). 
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This model has two exciting implications. The first is that, administration of CFHR5 to 
people with CFHR5 nephropathy would potentially correct the molecular defect, curing the 
disease, and might only be required during episodes of immunological stimulation (i.e. 
intercurrent infections). Secondly, if CFHR5 levels in genetically normal human beings are not in 
sufficient excess to protect the kidney in situations in which there is extreme complement 
activation via the classical pathway (for example lupus nephritis, IgA nephropathy or MCGN 
resulting from chronic infections) then CFHR5 supplementation in people with these (sporadic) 
diseases may provide a therapeutic benefit by enhancing the negative regulation of 
complement at the glomerular surface.  
4.3.3 CFHR512123-9: A dominant negative mutation? 
Since the physiological function of CFHR5 is not known, it is quite possible that CFHR5 is 
actually an antagonist of CFH and that the CFHR512123-9 mutation enhances this effect, either by 
being cleared less effectively by the kidney (owing to its more negative charge preventing 
transit across the glomerular basement membrane) or by more effective competition for 
binding to CFI. In support of this hypothesis is the observation that the cofactor activity of 
CFHR5 is several fold weaker than that of CFH (with CFH being effective in the 1-2 ng/μL range, 
compared with 300-400 ng/μL CFHR5 required for detectable cofactor activity (McRae, Duthy 
et al. 2005)) – it may therefore be that its physiological function is to antagonise (by competing 
with) CFH-mediated cofactor activity and that impaired clearance of CFHR512123-9 results in 
increased levels of an inhibitor of the negative regulation of C3 by CFH. Although conceivable, 
this hypothesis is rather unlikely for 2 reasons: Firstly, the site of C3 deposition in CFHR5 
nephropathy is the kidney, precisely the location which CFHR512123-9 is less able to bind (see 
Figure 4.2-16) rendering a dominant negative action at this site unlikely; and secondly, 
CFHR512123-9 actually has enhanced cofactor activity compared with wild type CFHR5, implying 
that it would it be less effective as a competitive antagonist of CFH. 
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Clearly, CFHR5 and CFHR512123-9 may have additional activities (perhaps relating to 
interactions with C5 or other complement proteins) which have not been interrogated, and it is 
possible that CFHR512123-9 has activity or activities which are completely absent in wild type 
CFHR5. If this is the case then inhibition of CFH by CFHR512123-9 would not imply that wild type 
CFHR5 is also capable of acting as an inhibitor of CFH. 
4.3.4 CFHR5 nephropathy: lessons from therapy 
The observation of recurrent C3GN post transplantation proved that the disease results 
from an abnormality of a circulating factor, since proteins which regulate complement which 
are synthesised by the allograft can be predicted to be normal. 
In the two cases for which clinical data are available, use of immunosuppressive therapy 
which targeted the cellular/adaptive immune system (i.e. mycophenolate mofetil and 
cyclophosphamide) provided no evidence of benefit and in both instances was accompanied by 
acceleration in the rate of decline of renal dysfunction. The mechanism by which 
immunosuppression could exacerbate renal damage in CFHR5 nephropathy is not immediately 
obvious, but one possibility is that impairment of the adaptive immune system results in 
impaired clearance of colonizing microorganisms from the nasopharynx, skin and urinary tract. 
These organisms therefore are more likely to cause infections which are cleared by the innate 
immune system – especially complement, perhaps by the alternative and mannose binding 
lectin pathways. The increased complement turnover produced in this scenario would provide 
the substrate for increased C3 deposition in the kidney in CFHR5 nephropathy. Consistent with 
this hypothesis are the observations firstly that macroscopic haematuria and renal dysfunction 
is commonly triggered by respiratory tract infection, and secondly that in 2 individuals (both of 
whom were subsequently shown to have CFHR5 nephropathy) persistent macroscopic 
haematuria accompanying tonsillitis was terminated by tonsillectomy (Dr A Pierides, personal 
communication). 
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Although plasma exchange did seem to provide clinical evidence of benefit, with abrupt 
cessation of macroscopic haematuria, it should be appreciated that the creatinine was falling at 
the time the treatment was instituted and, although the rate of improvement in renal function 
appeared to be increased, this is a single therapy in a single individual. Nonetheless it is unlikely 
that plasma exchange (in contrast with conventional immunosuppression) had a detrimental 
effect. Clearly, further prospective studies are needed to determine whether this therapy offers 
a way of modifying the natural history of CFHR5 nephropathy. 
Inhibition of C5 with the humanised monoclonal antibody Eculizumab has been shown to 
be effective in treating haemolysis in paroxysmal nocturnal haemoglobinuria (Parker 2009), 
which usually results from a bone marrow somatic mutation in the PIGA gene causing impaired 
expression of Decay Accelerating Factor (DAF, CD55) and other complement regulators on the 
surface of red cells. However, it has recently been shown that treatment with Eculizumab does 
not completely correct the half-life of red blood cells and does not prevent the deposition of C3 
on their surfaces, suggesting mechanisms of disease in PNH which do not require C5 (Risitano, 
Notaro et al. 2009). Although C5-9 is detectable in the kidney in CFHR5 nephropathy, the 
question of whether renal injury in this disease is a consequence of C5 activation, or results 
from other consequences of C3 deposition has yet to be answered. In this context, while 
Eculizumab therapy is an attractive option (similar to its potential value in aHUS), clinical 
studies will be required to determine whether therapy with this agent improves outcome in 
CFHR5 nephropathy. 
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4.4 Conclusion 
While the physiological function of CFHR5 is unknown, the mechanism by which 
heterozygosity for the CFHR512123-9 allele causes disease will be open to question. I have 
discussed 3 potential mechanisms and have taken the view that it is most likely (judging by the 
currently available evidence) that renal disease in CFHR5 nephropathy results from impaired 
targeting of the CFHR512123-9 protein to the glomerulus resulting in local insufficiency for a 
negative regulator of complement. Immunosuppression does not appear to result in significant 
benefit in the disease and treatment strategies which result in either normalisation of CFHR5 or 
inhibition of complement activation seem to hold more promise for successful treatment of 
CFHR5 nephropathy. 
This work has raised a number of questions, the most interesting of which are as follows: 
1. Biochemistry and physiological properties of CFHR512123-9 
a. Does CFHR512123-9 interact with C3b, immobilised or in the fluid phase, and how 
does its affinity compare with that of wild type CFHR5?  
b. What is the structure of CFHR5, alone or in complex with C3b or CFI? 
c. What is the structure of CFHR512123-9, alone or in complex with C3b or CFI? 
d. Is CFHR5 excreted in the urine and if so is the excretion of CFHR512123-9 
impaired? 
2. Variation in humans 
a. Do people with other mutations in CFHR5 exist, and if so what effects do these 
mutations have? 
b. Are genetic variants of CFHR5 differentially represented in cohorts of people 
with complement deposition in the kidney (e.g. those with lupus nephritis, 
IgAN, or MCGN) compared with controls? 
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c. Do people homozygous or heterozygous for complete deficiency for CFHR5 
exist and if so, what is their phenotype? 
d. Do levels of CFHR5 correlate with renal injury in people with autoimmune or 
infectious diseases associated with increased antibody production? Is CFHR5 
depletion a biomarker for glomerular injury? 
3. Model organisms 
a. Can administration (or transgenic expression) of CFHR5 in mice deficient for cfh 
ameliorate renal injury and/or C3 consumption in the circulation? If so, at what 
dose and is this ability shared by CFHR512123-9? 
b. Can administration of CFHR512123-9 (exogenous or transgenic) to mice cause 
renal injury?  
4. Treatment of CFHR5 nephropathy 
a. Does plasma exchange in people with CFHR5 nephropathy prevent injury? 
b. Is inhibition of C5 protective in CFHR5 nephropathy? 
c. Would depletion of C3 be protective in CFHR5 nephropathy? 
d. Can administration of CFHR5 in humans with CFHR5 nephropathy, C3GN or 
MCGN ameliorate renal injury? 
 
Clearly, addressing these questions will require a significant amount of further work. 
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5.1 Introduction 
The previous chapters describe the autosomal dominant inheritance of microscopic and 
synpharyngitic macroscopic haematuria, C3 glomerulonephritis (C3GN) and (in affected males) 
renal failure occurring in 2 ostensibly unrelated families with ancestry in the Troodos 
Mountains of Cyprus. A genome-wide linkage study followed by haplotype analysis and 
molecular dissection of the linked region allowed identification of a novel, expressed mutation 
of the Complement Factor H Related protein 5 (CFHR5) gene which cosegregated with the 
disease. Additional work demonstrated that the mutant protein (recombinant or from patient 
serum) exhibited impaired ability to bind to heparin, complement-coated erythrocytes and 
complement-coated glomerular basement membranes. The ability of the mutant protein to 
degrade C3b in solution was increased compared with wild type CHFR5 and it remains unclear 
whether it is impaired targeting of the mutant protein to the glomerulus or increased iC3b 
production (or both) which leads to the disease. The possibility also existed that an undetected 
mutation, present on the cosegregating haplotype, was responsible for causing the disease and 
the CFHR512123-9 mutation just happens to reside on the linked chromosomal segment and is 
unrelated to disease pathogenesis. Notwithstanding this possibility, I considered that the 
CFHR512123-9 mutation was likely to be causative for 2 principal reasons: 
1. CFHR5 was among the 6 genes identified as a candidate gene prior to the linkage study 
(in which only 0.7% of the genome was linked with the disease, and only 0.3% of the 
genome was inherited by affected individuals in both families from a common 
ancestor). The prior probability of the causative mutation residing in CFHR5 was 
therefore high. Bayesian logic dictates that invoking an additional (hypothetical) 
mutation in some other gene (by definition not a prior candidate since all the prior 
candidates were sequenced before the linkage study) is very much less likely to explain 
the data than is the detected CFHR5 mutation. 
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2. The mutation was associated with the expression of a novel CFHR5 variant which had 
altered function (i.e. reduced binding to the glomerular surface) in a way compatible 
with causing the disease. 
Clinical genetics is essentially a probabilistic science, inasmuch as proof (to a level 
comparable with fulfilment of Koch’s postulates in microbiology) is seldom possible. 
Specifically, to prove that a mutation causes a human disease beyond all doubt would require 
specific, targeted introduction of the mutation in a human being of known genetic background 
(for example one of identical twins). This is an undertaking which is beyond the capability of the 
current state of the art and is, in any case, unlikely to be ethically acceptable under any 
foreseeable circumstances. Instead, there are accepted to be several types of evidence which 
can lead to a novel genetic variant which is linked with a disease being accepted (i.e. proven 
beyond reasonable doubt) to be responsible for causing a disease. 
1. The identification of a similar genetic variant in the same gene causing the disease in an 
unrelated individual: while not completely proving the case, this would raise the 
likelihood that the disease is caused by a mutation in the gene in question by several 
orders of magnitude. In the context of CFHR5 nephropathy, ongoing work aims to 
sequence CFHR5 in other individuals with C3GN, but since this is such a rare disease 
(fewer than 40 cases previously described in the world literature) this approach 
appears to have a rather low probability of resolving the issue in a realistic timeframe. 
2. The identification of individuals inheriting a mutation from the same ancestor with 
recombinations flanking the mutation closely enough to exclude inheritance of all other 
genetic variants – in other words if the common haplotype is small enough to be 
sequenced in its entirety then mutations in other genes in the interval can be excluded, 
proving the case by elimination. Conventionally, this has been viewed as likely only to 
occur in mutations which have been present in a population for a great many years (i.e. 
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usually autosomal recessive conditions), however advances in sequencing technology 
have meant that sequencing larger genomic regions is becoming increasingly practical 
as a solution to this problem. 
3. A clear demonstration, using recombinant proteins, that the mutation affects the 
function of the protein sufficiently to provide a molecular mechanism for the disease. 
In the case of whole-gene deletions or early premature termination codons, or where 
the function of the gene is well understood, this is readily achievable (see Chapter 2: 
HIF2α erythrocytosis and pulmonary hypertension), but where the function and 
biochemical interactions of the wild type protein are less well understood and the 
altered structure and function of the gene resulting from the mutation are not easily 
predictable, this may be difficult to achieve. The physiological role of CFHR5 is not 
understood, and the homology with other members of the CFH/CFHR1-5 gene cluster 
adds significant complexity to this undertaking. It is likely that for this approach to 
resolve the issue for CFHR5 nephropathy, a range of unbiased assessments of the 
biochemical and physiological functions of the protein in vitro and in vivo will be 
necessary. 
4. Introduction of the mutation in the orthologous gene in an animal model causing a 
phenotype sufficiently similar to the human disease. The level of proof that this type of 
experiment provides is crucially dependent on the similarity of the model organism to 
humans in relation to the system being interrogated. 
Given that the approaches likely to prove beyond reasonable doubt that the mutation 
identified in CFHR5 was responsible for the disease were beyond the time and resources 
available for this project, I therefore considered the evidence that would disprove this 
hypothesis. Although the CFHR512123-9 allele was not detected in control individuals from the UK 
population, the possibility remained that it was a common variant in Cyprus: demonstrating its 
presence in large numbers of unaffected individuals in Cyprus would cast significant doubt on 
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its role as the pathogenic mutation in CFHR5 nephropathy and prompt the search, within the 
segregating haplotype, for another putative causative genetic change. Conversely, it seemed 
possible that identification of further (unrelated) individuals with the mutation who also had 
the disease would support the hypothesis and reduction of the size of the shared haplotype 
may allow proof by elimination (see 2 above) of the pathogenic role for the mutation. 
The observation that the disease was cosegregating in two ostensibly unrelated families 
raised the possibility that it may be present in other individuals in Cyprus. Since the onset of 
clinically significant renal impairment was after the 4th decade in all individuals, and because 
the mutation is predicted to increase the activation of the complement system, it did not seem 
impossible that the mutation (perhaps in a certain environmental context) could actually 
enhance survival by increasing the ability to resist infection by pathogenic micro-organisms in 
childhood. 
In this chapter I will present data demonstrating a high prevalence and wide distribution of 
the mutation within Cyprus and show that it has probably been present in the Cypriot 
population for at least two millennia. 
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5.2 CFHR512123-9 in the Cypriot population 
5.2.1 Estimation using healthy controls 
In order to measure the frequency of the allele in the general Cypriot population accurately 
(i.e. without introducing bias for inclusion of people with renal disease) I aimed to identify a 
collection of appropriate DNA samples from the Cypriot population. In order to achieve this, I 
performed a pubmed search using the terms “Cyprus” and “DNA.” This identified a recent 
paper (Loizidou, Michael et al. 2008) describing the results of a breast cancer study (the 
“MASTOS” study) which used 1109 Cypriot women and 1177 age-matched healthy controls. I 
contacted Dr Andreas Hadjisavvas, the corresponding author, and he agreed to screen 1015 of 
the control subjects for the presence of the allele using PCR primers which I sent to him. This 
experiment identified a single individual (out of 1015) who carried the allele – a finding which I 
confirmed by (blinded) analysis of 15 samples (including the individual in whom he had 
detected the mutation) from this cohort which he provided (Figure 5.2-1). 
 
Figure 5.2-1 CFHR5 duplication in a control individual 
3-primer PCR reaction diagnostic for CFHR5 duplication (see Chapter 3: Identification of CFHR5 nephropathy) in 
15 Cypriot individuals from the MASTOS study. A single individual (arrow) was found to be affected among 1015 
Cypriot control individuals (1000 unaffected individuals not shown). 
 
Under the terms of the ethical approval under which the MASTOS study was performed, it 
was not possible to obtain any further clinical or demographic details for this single anonymous 
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affected individual. Nevertheless, I concluded firstly that the duplication is not a common 
variant in Cyprus and secondly that at least one additional affected family was likely to exist.  
Although identification of only a single individual in a sample of ~1000 does not allow a 
robust estimation of the actual frequency in the population, EB Wilson (Wilson 1927) proposed 
a method of estimating a 95% confidence interval of the true frequency from an observed 
proportion (Newcombe 1998). Using an online statistical calculator (VassarStats 2010) to 
calculate this yielded an interval of 0.0002 to 0.0056 (equating to 1:5000 to 1:179) for the 
estimated proportion of the Cypriot population who harbour the mutation. This suggested that, 
rather than being a vanishingly rare condition affecting only those individuals already 
identified, CFHR5 nephropathy might be a relatively common genetic condition in Cyprus. For 
comparison, estimates of the frequency of adult polycystic kidney disease in Caucasian 
populations range from 1:1000 (Dalgaard 1957) to 1:2500 (Davies, Coles et al. 1991).  
Clearly, refining this estimate using this method to improve the statistical certainty of the 
allele frequency would involve sampling a very large number of the general Cypriot population, 
an undertaking which would require significant resources. I therefore pursued alternative 
approaches to estimate the frequency of the allele and the disease in Cyprus.  
5.2.2 Estimation using family data 
In order to predict how likely it was that additional mutation carriers would exist, I 
attempted to estimate the allele frequency in the local population from which Family 1 and 
Family 2 were drawn. In order to do this I first estimated how many generations were likely to 
have separated the families. Since the families could not trace their ancestry to a single 
ancestor genealogically, this implied that at least 4 generations separated them (unless more 
recent undocumented extra-pair paternity had occurred) and further information was unlikely 
to be gained from documentary evidence. However, the size of the shared haplotype between 
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the families could be used to estimate how many generations had elapsed, following the 
reasoning of Genin et al (Genin, Tullio-Pelet et al. 2004): 
5.2.2.1 Minimum age of the allele 
The genetic distance between 2 loci is determined from the recombination fraction θ 
(which is the observed proportion of meioses resulting in a recombination between the two 
loci) according to a mapping function, such as that developed by Kosambi (Kosambi 1944): 
  
 
 
   
    
    
  
where S is the distance in hundreds of cM (abbreviated to M below). 
For a distance S M, the expected recombination frequency, θS, is given by the inverse of the 
mapping function: 
   
 
 
       
     
 
It follows that the likelihood that no recombinations occurred between a mutation and a 
marker x which is k M distant in n meioses is given by: 
           
  
The likelihood that a recombination occurred between marker x and the adjacent marker x-
1 is given by: 
                 
If marker x is the marker in the haplotype shared between members of both families most 
distant (e.g. farthest centromeric) from the mutation, it follows that either one or both 
individuals (from the two different families) must have inherited a recombination in this region 
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in the n generations since their most recent common ancestor. Therefore, the likelihood that 
this occurred is given by: 
                     
and the likelihood of the observed haplotype being transmitted from an ancestor n 
generations ago is given by combining the likelihood for the centromeric- AND telomeric-most 
shared markers: 
                                    
The value of n for which L(n) is maximized is therefore an estimate of the number of 
generations which has elapsed since the most recent common ancestor of individuals sharing a 
common haplotype. Clearly, L(n) tends towards 0 as n becomes large. 
Plotting the number of generations against the likelihood of the observed haplotype 
allowed estimation of the most likely number of generations to have passed since the most 
recent common affected ancestor of the individuals from the two families (MRCAfamilies) (Figure 
5.2-2). This yielded a figure of 10 generations, equating to roughly 250 years, which was 
therefore the likely minimum age of the mutation (clearly the mutation could have arisen 
earlier – prior to the divergence of families 1 and 2).  
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Figure 5.2-2 Estimated time since most recent common ancestor of families 1 and 2 
 
Genin et al also determined 95% confidence interval for this estimation using Bayes’ 
theorem, where the posterior probability of the observed haplotype being shared across m 
generations is L(m) divided by the sum of all the likelihoods for all other number of 
generations: 
     
    
         
 
Where r is very large (and hence L(r) is very small). The 95% confidence interval is 
determined by finding the values for nlow and nhigh for which                   , and 
                   . This yields a 95% confidence interval of between 3 and 32 generations. 
5.2.2.2 Likelihood of further affected relatives existing 
The valley containing Gerakies and Kalopanagiotis also contains 3 other villages: 
Moutoullas (which is contiguous with Kalopanagiotis), Oikos and Pedoullas (Figure 5.2-3). The 
combined populations of these villages, according to the 2001 census, is 1081 (Cyprus Ministry 
of Finance 2001). The past thirty years has seen a reduction in the population of the valley – the 
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population of the valley fell by approximately 25% between 1992 and 2001 (Cyprus Ministry of 
Agriculture Natural Resources and Environment 1991) and it is likely that the pre-1950 
population was of the order of 2000 people. 
 
Figure 5.2-3 Satellite image of the valley in the Troodos mountains  
Families 1 and 2 reported ancestry from this valley. The position of the valley on the island of Cyprus is shown 
(inset). Images downloaded from www.google.com. 
 
In an isolated, randomly mating population, as genealogies are traced back in time there 
comes a point when every currently existing member of the population is descended from a 
single individual – this individual is termed the Most Recent Common Ancestor (MRCApopulation). 
There may be more than one MRCA alive at this point, and with each generation one goes back 
beyond this the number of common ancestors (as a proportion of the population) increases. 
This is in part because all the ancestors of the MRCA must be common ancestors of the whole 
present-day population. Eventually, a generation is reached in which all the individuals in this 
generation are either ancestors of everybody living today or else they left no descendants – this 
is the Identical Ancestors (IA) point. 
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It has been shown that, for a randomly mating population of size n, the time since the 
MRCApopulation is sharply distributed about log2(n) generations in the past, with the number of 
generations since the IA point distributed about 1.77 x log2(n), at which time the probability 
that a randomly chosen individual is a common ancestor of the entire present population is 
approximately 0.8 (Chang 1999).a  
In order to make some estimate of whether it is likely that other affected families exist, I 
made several assumptions: 
1. The effective population, n, of the valley was approximately 2000 people  
2. That random mating occurred within the valley – anecdotal reports from the family 
support this assumption in general, however it should be noted that the model 
proposed by Chang takes no account of the fact that an individual usually produces 
offspring with a single partner multiple times, rather than each offspring being the 
result of an independent random mating event. Nonetheless, for small family sizes the 
approximation is likely to be valid  
3. Reproductive fitness of individuals harbouring the mutation is not significantly reduced 
compared with the general population. I viewed this as a reasonable assumption 
because symptomatic or morbid renal impairment had not been observed in any 
individuals younger than 40 years of age 
4. Migrants into the valley did not contribute much to the gene pool. This is supported by 
the observation that, historically, migration has been out of the valley. The notable 
exception to this is the presence of the monastery (discussed in Chapter 3) and this 
issue clearly places a limit on the validity of this estimation since the model takes no 
account of an influx of new founders 
                                                          
a
 A startling corollary of this is that, given that he is known to have living descendants, Charlemagne 
(742-814) is predicted to be an ancestor of all people of recent Western European descent 
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5. The MRCA of families 1 and 2 (MRCAfamilies) resided in the valley approximately 10 
generations ago 
It can therefore be estimated that, while the MRCA of the whole valley (MRCAvalley) is likely 
to have lived approximately 11 generations ago, and that 80% of the population 19 generations 
ago were ancestors to the whole of the current population, the MRCAfamilies lived more recently 
than this and hence is unlikely to have been ancestral to the whole valley. However, 
considering that the MRCAfamilies likely lived so long ago (i.e. relatively close in time to the IA 
point) and had given rise to at least 2 families in existence now, there appeared to be at least a 
reasonable chance that other descendants of this individual would exist. This result is intuitively 
correct since even people from societies with small family sizes can be expected to have a very 
large number of 9th cousins. Furthermore, there is no evidence to suggest that the MRCAfamilies 
was the first individual to harbour the mutation and clearly with each preceding generation the 
likelihood increases that an affected individual was ancestral to a greater proportion of the 
current residents of the valley. 
Since humans are diploid organisms, the probability of inheriting a particular allele from an 
ancestor within a randomly mating population depends on the frequency of that allele in the 
population (because descent within a finite population can be by more than one possible 
intermediate in each intervening generation – contrasting with the completely outbred 
situation where the probability of inheriting a given allele from a given ancestor is 1/2n where n 
is the number intervening of generations), so while having an affected ancestor is necessary it is 
certainly not sufficient to result in an individual being affected. In conclusion, it appeared likely 
that further individuals from the valley with the CFHR5 duplication would be identified if an 
appropriate population were tested. The obvious questions were firstly whether such 
individuals manifested renal disease, and secondly what the frequency of the allele was.  
  
Chapter 5: CFHR5 nephropathy: clinical spectrum, prevalence and distribution 
223 
 
5.2.3 Identification of additional affected individuals 
This reasoning supported the hypothesis that further investigation of the Cypriot 
population was likely to identify other people with the disease. I therefore contacted Dr Alkis 
Pierides, a nephrologist in Cyprus who had looked after the index case from family 2 (see 
Chapter 3) and who, in collaboration with Professor Constantinos Deltas, had studied inherited 
renal disease, identifying mutations in the Col4A3 and Col4A4 genes segregating with 
autosomal dominant inheritance of microscopic haematuria and focal segmental glomerular 
sclerosis  (Voskarides, Damianou et al. 2007).  
Dr Pierides and colleagues used the diagnostic PCR reaction to screen a cohort of 84 
Cypriot patients with advanced or end-stage chronic renal disease. 23 of these individuals had 
presumed glomerulonephritis with no histological diagnosis; 19 had biopsies reported as 
membranoproliferative or mesangioproliferative glomerulonephritis or focal sclerosis; and the 
remaining 42 patients had end-stage renal failure of unknown cause. This identified 1 female 
and 3 male patients who harboured the duplication, proving the supposition that other 
individuals with the allele would be identified, and additionally extending the evidence for an 
association of the allele with renal disease. None of these individuals initially reported descent 
from the Troodos region.a 
In addition, 2 families were identified in which the duplication cosegregated with 
microscopic haematuria (Figure 5.2-4). One of these families, designated family 3, was 
identified from a proband in the cohort described above. In addition to microscopic 
haematuria, individuals from these families exhibited synpharyngitic macroscopic haematuria 
and/or renal impairment. Neither of these additional families could trace their ancestry to the 
Troodos Mountains and one of them (family 4) reported ancestry in Deftera which is 12km 
southwest of Nicosia in the Mesaourian Plain. 
                                                          
a
 It subsequently came to light that one of these individuals could, in fact, trace their ancestry to the 
Troodos region. 
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Figure 5.2-4 Two additional Cypriot families 
In both families the CHFR5 duplication cosegregated with microscopic haematuria and/or renal failure (shaded 
black). Asterisks represent individuals who gave a history of synpharyngitic macroscopic haematuria. No DNA was 
available from some individuals who reported renal disease (shaded grey). 
 
Having recognized this as a potential new endemic disease, I identified further affected 
individuals, all of whom were of Cypriot descent and resident in London. The first of these 
people was a 54 year old man undergoing haemodialysis at the West London Renal and 
Transplant Centre (denoted 115301). He had first noticed synpharyngitic macroscopic 
haematuria more than 30 years ago, with recurrent episodes approximately once every 1-2 
years. He had been referred to the nephrology service at St Mary’s Hospital in 1993 and 
underwent a renal biopsy in 1998. Although initially reported as mesangiocapillary 
glomerulonephritis type I, review of this biopsy demonstrated that the clinicopathological 
diagnosis was C3GN: there was immunostaining for C3 but not C1q or immunoglobulins. 
Electron microscopic examination demonstrated mesangial, elongated subendothelial and very 
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occasional subepithelial basement membrane dense deposits. He developed end stage renal 
disease in 2003 and received a cadaveric transplant in 2009 after 6 years of haemodialysis. 
His brother (designated 115302) was aged 59 and had been noted to have microscopic 
haematuria 10 years previously, with normal appearances on cystoscopy and ultrasound 
imaging of the renal tract. He did not recall any episodes of macroscopic haematuria. The blood 
pressure and physical examination were normal and there was no detectable proteinuria. 
Serum creatinine was 79 μmol/l and complement C3 and other blood tests were within the 
normal ranges, with the exception of a serum cholesterol level of 7.5 mmol/l. The CFHR5 
duplication was identified in both these individuals (Figure 5.2-5) and Western blotting 
identified the mutant and wild type CFHR5 proteins in their circulation. While their mother 
(who was found not to harbour the mutation) had been born in Cyprus to Armenian parents, 
their father was from Moutoullas, which is a village in the Troodos Mountains which is almost 
contiguous with Kalopanagiotis (Figure 5.2-3). He had died at the age of 77 from a ruptured 
aortic aneurysm but had been noted to have chronic kidney disease prior to his death.  
 
Figure 5.2-5 Diagnostic PCR reaction in 2 brothers  
Demonstrating the presence of the CFHR5 mutation in 2 brothers (115301 and 115302). Both resided in London 
and although reported paternal ancestry from the Troodos region, were unrelated to the families 1-4. C1 and C2: 
unrelated controls. 
 
100bp     C1 115301      C2 115302 
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Next, I identified an additional patient (designated 116301) who was undergoing regular 
haemodialysis at the Royal Free Hospital in London. He had noticed synpharyngitic macroscopic 
haematuria while a teenager and had undergone a renal biopsy at the ages of 17 and 27. These 
showed mesangiocapillary glomerulonephritis (with only slight mesangial hypercellularity) and 
positive immunostaining for C3 in the capillary walls and absent immunostaining for 
immunoglobulins or C1q. Electron microscopy demonstrated subendothelial electron dense 
material within the glomerular basement membrane and in mesangial regions. There were 
areas of reduplication of the basement membrane and mesangial cell interposition. The second 
biopsy demonstrated increased mesangial sclerosis and interstitial fibrosis when compared 
with the first one. He also reported abdominal pain associated with altered bowel habit. 
Scintigraphy indicated increased uptake of gallium-67 in the colon and colonoscopy revealed 
multiple superficial, discrete, white ulcers but no polyps. Biopsy specimens demonstrated 
increased inflammatory cells and a single focus of cryptitis. There was no evidence of 
granuloma, infection or dysplasia and no firm diagnosis was reached. His renal function 
subsequently deteriorated, with a creatinine of 140 μmol/l at the age of 32. There was an 
abrupt decline in his renal function at the age of 34 and he was treated with oral prednisolone 
and mycophenolate mofetil for several weeks. There was no apparent clinical effect on his 
renal impairment and steroids and immunosuppression were withdrawn. He started regular 
haemodialysis at the age of 35. Genetic testing demonstrated the presence of the CFHR5 
duplication and heterozygosity was confirmed on Western blotting. There was no family history 
of renal disease although his father had died young from intracranial malignancy. Both parents 
were from Nicosia and could not trace ancestry to the Troodos Mountains. Clinical and 
laboratory data from the first 24 people with the mutation identified are shown in Table 5.2-1. 
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Table 5.2-1 Clinical and biopsy features in 24 individuals with CFHR5 nephropathy 
CKD, Chronic kidney disease.  
“Obligate affected” refers to individuals with confirmed affected off-spring and other relatives. 
*p=0.0007, comparing males with females using Fisher’s exact test 
 
5.2.3.1 Clinical features in 103 affected individuals 
Multiple further individuals with the disease were then identified by screening families and 
individuals with microscopic haematuria and or renal impairment and C3GN. Together with Dr 
Pierides and colleagues, we assembled details of 103 individuals with the mutation, all either 
living in Cyprus or of recent Cypriot descent living in London. Ancestry was not confined to the 
Troodos region in this cohort (see Figure 5.2-6). Of these 103 people with the mutation, 93 had 
evidence of haematuria on urinalysis, in 57 of these people this was the only abnormality. 36 
individuals exhibited haematuria and proteinuria of whom 32 (89%) had renal impairment 
(including 19 people with end stage renal disease, ESRD). Renal biopsies had been performed in 
18 individuals (including 2 females with haematuria alone) from 10 different kindreds and in all 
cases showed features consistent with C3GN. In an individual from one large family, the biopsy 
also showed thinning of the glomerular basement membranes.  
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Figure 5.2-6 Geography of CFHR5 nephropathy 
Satellite image of Cyprus showing locations of reported ancestry of the first 17 families with CFHR5 
nephropathy to be identified. Although showing evidence of geographic clustering around the Troodos and 
Mesaourian (Nicosia) region, it is not clear to what extent this represents the effect of ascertainment. 
 
The sexual dimorphism with respect to proteinuria and renal impairment observed in the 2 
initial families (see Chapter 3) was also apparent in this cohort: in affected individuals aged 
between 31 and 50 years, 41% males but only 9% females exhibited proteinuria and renal 
impairment. This rose to 69% of men and 14% women aged 51-70 and 80% men and 20% 
women aged >70 years. In total, 26 out of 54 males and 6 out of 49 females had renal 
impairment, with 15 men and only 4 women having reached ESRD. This apparent difference in 
susceptibility between males and females is statistically significant (p=0.0001 comparing males 
with females using Fisher’s exact test) and I concluded the sexual dimorphism represents a real 
biological effect, although the biology underlying this is not obvious. 
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5.2.3.2 Minimum prevalence of the CFHR5 nephropathy in Cypriots 
The total population of Cyprus is 800,000 and the Cypriot population of London is 
estimated to be approximately 80,000. Based on the cases already identified, the minimum 
possible prevalence of the mutation among the Cypriot community is 1:8500. It seems likely 
that the true prevalence will be somewhat higher than this since additional affected individuals 
are likely to exist. 
5.2.3.3 Geographical distribution of CFHR5 nephropathy 
The identification of multiple ostensibly unrelated individuals and families with the disease 
demonstrated that the disease is endemic in Cyprus and confirmed the existence of a 
substantial at-risk population there and in London. Having identified the disease only in people 
of Cypriot descent, a key question was what the age and distribution of the mutation might be. 
A secondary question was whether the mutation occurred within Cyprus (possibly in the 
Troodos region) or whether it was imported into Cyprus from elsewhere. This was potentially 
important because screening for the disease in other Eastern Mediterranean populations could 
be undertaken if a wide geographical distribution was anticipated. 
I proceeded using two approaches: the first was to define, as precisely as possible, the 
common haplotype shared by the different individuals and families with the disease. This 
would allow firstly a refined estimation of the minimum age of the mutation and secondly 
might provide more information about the geographical distribution of affected individuals 
within Cyprus. The second approach was to identify the frequency of the disease-linked 
haplotype in the Cypriot population. Identification of a haplotype flanking the mutation which 
is rare in the general Cypriot population would suggest an origin outside Cyprus with migration 
into the island of an affected individual or cohort. Conversely, if the mutation existed within a 
haplotype that is common among the Cypriot population this would imply that the mutation 
occurred within Cyprus, or within a population ancestral to a large proportion of Cypriots. 
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Clearly, the mutation could also have occurred by chance on a rare haplotype within Cyprus, 
but the prior probability of this would be correspondingly low. 
I therefore genotyped 300,000 SNPs across the genome (using the Illumina 
HumanCytoSNP-12 panela) in 3 individuals from each of the first 4 families to be identified; 
individuals 115301 and 115302 (family 5) and one individual from each of the next 12 families 
family for whom adequate DNA was available. Families 1 and 2 are described in detail in 
Chapter 3 and they, along with family 5 and 4 further families, reported ancestry in the Troodos 
region. Families 3 and 4 reported ancestry from the Mesaourian plain (near Nicosia) along with 
6 other families and the remaining 2 families reported ancestry in Chloraka (near Paphos) and 
Larnaca and Famagusta (see Figure 5.2-6).  
Where single individuals were genotyped from families it is not possible to determine the 
gametic phase. However, since the purpose of this experiment was to determine the maximum 
possible shared haplotype, identifying homozygosity for different alleles of a given SNP 
between 2 individuals (termed ‘conflicting homozygosity’) is incompatible with inheritance of a 
shared haplotype at that locus by those individuals. I therefore defined the shared haplotype as 
the region for which no conflicting homozygosity occurred between the families in question 
(see Appendix A: Conflicting Homozygosity analysis). 
Comparison of genotypes in this region in affected individuals from 17 families firstly 
defined the haplotype flanking the mutation and secondly demonstrated that the minimum 
possible common haplotype (i.e. the genotypes across which no conflicting homozygosity 
occurred) comprised 127 SNPs across 1.07 cM. The recombinations defining the boundaries of 
this common haplotype occurred in the ancestry of family 10 (Kalopanagiotis 2) and family 14 
(Lakatamia 1). In the absence of shared ancestry at this locus, the likelihood of observing no 
                                                          
a
 It was more cost-effective to run a commercially available chip to genotype 300,000 SNPs across 
the whole genome in each person than it would have been to perform targeted genotyping for 100 or so 
SNPs across the region of interest. 
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conflicting homozygosity (in just these 2 families) across this distance would be (1-0.059)127 =  4 
x 10-4. Observing no conflicting homozygosity across this region in all 17 families tested is 
clearly vanishingly unlikely in the absence of shared ancestry. This interval therefore defines 
the maximum possible size of the haplotype shared by all the families tested. 
The haplotypes are represented graphically in Figure 5.2-7. This analysis also allowed 
inference of common sub-ancestry of some of the families, since they shared private 
haplotypes (implying shared ancestral recombination events) in which there is no conflicting 
homozygosity. Geographic clustering of families sharing common recombination events was 
observed, with ‘private’ haplotypes segregating in 3 families from the Troodos region and 
multiple families from Mesaouria. 
 
Figure 5.2-7 Common CFHR5 nephropathy haplotype 
A shared haplotype (green) was present in all families harbouring CFHR5 mutation studied. In addition, private 
flanking shared haplotypes (orange, yellow, purple and blue bars) existed between subsets of the families, consistent 
with their reported geographic ancestry. 
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The size of the shared haplotype allowed refinement of the estimate of the number of 
generations since the MRCA of the most distantly related families to 93 generations (Figure 
5.2-8, 95% confidence interval 29 to 334 generations), representing a most likely minimum age 
of the mutation of approximately 2500 years (95% confidence interval 725 to 8350 years).  
 
 
Figure 5.2-8 Estimated time since the most recent common ancestor of 17 families 
The likelihood estimate was maximised at 93 generations (~2500 years) 
 
5.2.3.4 Cypriot population structure 
In order to understand better the population structure in Cyprus, and in particular to 
estimate whether the Troodos mountains region was genetically isolated from Mesaouria, I 
obtained samples of DNA which had been collected by Dr Andrie Panayiotou and Prof Andrew 
Nicolaides as part of a programme to investigate genetic factors contributing to cardiovascular 
risk. The collection consisted of 778 DNA samples: 427 from the village of Pedhoulas, in the 
Troodos mountains (within 5km of Moutoullas) and 247 from Nisou on the Measourian plain 
(Figure 5.2-6). 
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I first tested for the CFHR5 duplication in all 778 samples and did not identify it in any of 
these individuals (Figure 5.2-9). Next, haplotype-tagging SNPs spanning a 330 kbp region which 
included CFH and the CFHR1-5 genes were genotyped in this collection, and also in affected 
individuals from the 4 families. Haplotype tagging SNPs were selected using the Hapmap CEU 
database (North American Caucasians of Northern and Western European ancestry) genotypes 
using HAPLOVIEW (Barrett, Fry et al. 2005) and genotyping was performed by Kbioscience Ltd 
(Essex, UK) using KASPar, a competitive allele-specific PCR with 3'-5' exonuclease-deleted DNA 
polymerase and a fluorescence resonance energy transfer quenching reporter oligonucleotide. 
The resulting genotypes were assembled into haplotypes using HAPLOVIEW. As would be 
anticipated in identical-by-descent inheritance of the mutation, the same haplotype was 
present in all affected families tested. This haplotype was common in Cyprus, occurring with a 
frequency of 0.128 (compared with 0.075 for the CEU population, see Figure 5.2-10). This 
haplotype was not more common in individuals from Pedhoulas (Troodos) compared with 
Nisou (Mesaouria) (p=0.6, Cochran-Armitage trend test). 
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Figure 5.2-9 Diagnostic PCR in 778 additional Cypriot individuals 
CFHR5 duplication was not demonstrated in any of these individuals. Positive controls were included with each 
plate and are marked by white asterisks. 
 
This demonstrated that the mutation occurred on a haplotype which was common in the 
Cypriot population, consistent with the mutation having occurred within Cyprus. This result 
indicates that the CFHR5 mutation is not simply tagging a rare haplotype which was imported 
into Cyprus and could hypothetically contain a ‘second mutation’ responsible for the disease. 
The similarity of frequency of the disease-linked haplotype in Pedhoulas compared with Nisou 
does not provide evidence that the Troodos region is a genetic isolate which is distinct from the 
Mesaourian plain, consistent with a model in which bidirectional gene flow between the 
Troodos region and the rest of Cyprus has allowed spread of the mutation across the island.  
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Figure 5.2-10 Haplotype blocks across the CFH/CFHR cluster 
Common Haplotype blocks in the Cypriot and Caucasian populations across the CFH/CFHR gene cluster are 
shown. Individuals with the mutation all harboured the haplotype marked with a red box (which therefore lies on 
the green extended haplotype shown in Figure 5.2-7). This haplotype is more common in Cypriots than in the US 
Caucasian population (CEU). 
 
5.2.4 Summary 
CFHR5 nephropathy is a highly penetrant and common cause of renal disease in Cypriots 
(both in Cyprus and abroad) and detection of the CFHR512123-9 mutation is a robust clinical test. 
The disease is not confined to the Troodos region of the island and is likely to have existed for 
at least 2500 years. There is, as yet, no evidence to support the hypothesis that the mutation is 
prevalent in other populations, although a logical next step would be to test individuals with 
inherited C3GN or microscopic haematuria and renal disease in other Eastern Mediterranean 
countries. All the Cypriot individuals with C3GN tested so far have been shown to harbour the 
CFHR512123-9 mutation and there exists no evidence in favour of the existence of a putative 
‘second mutation’ in a gene other than CFHR5 but within the common haplotype which is 
responsible for the disease. This is issue will most likely only be resolved by identification of 
additional mutations in CFHR5 which cause a similar phenotype.  
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5.3 Discussion 
The findings presented in this and the previous chapters prove the existence of an 
autosomal dominantly inherited renal disease, characterised by C3 deposition in the 
glomerulus, which is endemic in Cyprus. The disease cosegregates with a heterozygous internal 
duplication of CFHR5 which is likely to cause dysregulation of complement at the glomerular 
surface, providing a mechanism which may explain the pathophysiology. These findings raise 
three important questions:  
1) Why has CFHR5 nephropathy only now been recognised? 
2) Why is CFHR5 nephropathy so common in Cyprus?  
3) Why is CFHR5 nephropathy unrecognised in the rest of the world? 
5.3.1 Why has CFHR5 nephropathy not been recognised before? 
A crucial question is why, if it is such an important and common disease in Cyprus, has 
CFHR5 nephropathy only now been recognised? This is an important question to consider, not 
least because understanding the answer may allow determination of whether the disease is 
likely to be found in other populations. The answer is probably a combination of the following 
factors: 
Firstly, provision of expert nephrology in Cyprus is a recent development, with a dedicated 
service offering reliable renal biopsy examination only being available in the last 25 years or so. 
Family history in many pedigrees reveals the existence of men in previous generations who 
died young (sometimes of kidney failure) who were never seen by a nephrologist. 
Retrospective review has revealed that several affected individuals (both in Cyprus and London) 
were diagnosed with IgA nephropathy on clinical grounds and never underwent renal biopsy. 
Furthermore, in at least one case where presentation was with classical microscopic and 
synpharyngitic macroscopic haematuria, the absence of mesangial immunostaining for IgA on 
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examination of the kidney biopsy was judged to be more likely a consequence of imperfect 
sample processing than owing to the presence of a disease entity not described in the 
published literature (Dr A Pierides, personal communication). 
Secondly, renal impairment in CFHR5 nephropathy is rare in females, children and young 
adults. Most of the morbidity and mortality is borne by males over the age of 50, a high 
proportion of whom are hypertensive. This has led to under-appreciation of the familial nature 
of the condition. In addition, many clinicians (in both the UK and Cyprus) regard this population 
with ‘diagnostic nihilism:’  the widely-held (and not entirely unreasonable) view that chronic 
kidney disease in middle age (in the absence of nephrotic syndrome or features of systemic 
diseases such as vasculitis) is unlikely to be amenable to therapy other than blood pressure 
control, and therefore the value of obtaining a pathological diagnosis does not justify the risk 
associated with invasive investigations such as a kidney biopsy. In addition, many of the 
affected individuals only presented to a nephrologist at a time when they had advanced renal 
disease and small kidneys – a scenario in which renal biopsy carries an especially high risk and 
has a low diagnostic yield. 
Thirdly, initial presentation of CFHR5 nephropathy is usually with isolated microscopic 
haematuria which, under current guidelines, is not investigated further (Cohen and Brown 
2003; Halpin 2008). The lack of (or very slow) disease progression in many affected individuals 
has led to the under-appreciation of the number of affected people and the autosomal 
dominant nature of inheritance. In addition, the recent description of familial microscopic 
haematuria with progression to focal segmental glomerulosclerosis associated with thin 
glomerular basement membranes and mutations in COL4A3 and COL4A4 (also endemic in 
Cyprus) had led nephrologists on the island to believe that some of the families which turned 
out to have CFHR5 nephropathy (and manifested autosomal dominant microscopic haematuria 
and renal failure) were actually harbouring mutations in collagen-related genes. This illustrates 
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the importance of open-minded investigation of individuals and families using histological and 
molecular techniques. 
Finally, the morphological categorisation of renal biopsy pathology is not always conducive 
to appreciation of the pathophysiology of the underlying disease. Almost all the patients with 
CFHR5 nephropathy who were biopsied were initially ‘diagnosed’ with primary 
mesangiocapillary glomerulonephritis type 1 (MCGN type 1) on the basis of the light 
microscopic findings. MCGN has a number of recognised causes (Table 5.3-1) and the 
remaining cases are regarded as ‘primary MCGN type 1’ (Jeanette 2008) which is said to carry a 
poor prognosis and is not amenable to treatment. Furthermore, IgA nephropathy and SLE both 
frequently produce the morphological appearances of MCGN type 1 on light microscopic 
examination, but the other clinicopathological features usually allow the clinician and 
pathologist to make the correct diagnosis: a biopsy report of ‘MCGN type 1’ in this context 
(while not being incorrect) is usually highly misleading. There is now growing evidence to 
suggest that ‘primary MCGN type 1’ is not a useful diagnostic entity at all, and cases could more 
usefully be regarded as ‘MCGN type 1 of unknown cause.’ The corollary is that ‘MCGN type 1’ is 
analogous to ‘purpuric rash’ in that it is a distinct clinical feature which has finite (if diverse) 
aetiologies, each defined and diagnosed by the presence or absence of other clinical and 
pathological features. In CFHR5 nephropathy, recent advances in the understanding of the 
biology of complement regulation, coupled with the appreciation of C3GN as a distinct subset 
of MCGN type 1 (usually caused by genetic or acquired defects in complement alternative 
pathway regulation), allowed recognition of the pathophysiological unity of the disease 
affecting families 1 and family 2, and hence identification of the mutation. 
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Table 5.3-1 Causes of mesangiocapillary glomerulonephritis 
MCGN, or alternatively membranoproliferative glomerulonephritis, after (Jeanette 2008). 
 
5.3.2 Why is CFHR5 nephropathy so common in Cyprus? 
In an isolated population, mutations can become established (i.e. their frequency increase) 
in a population as a consequence of one of two effects. Either they can confer some phenotypic 
characteristic which results in increased ability to transmit the allele to the next generation (i.e. 
positive selection) or else the frequency can change as a consequence of genetic drift. 
Conventionally, positive selection in human Mendelian diseases is regarded as associated with 
autosomal recessive disorders, in which the survival advantage occurs in the heterozygous 
state (such as in sickle cell trait). 
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Genetic (or allelic) drift refers to changes in allele frequency caused by random fluctuations 
in transmission rate from one generation to the next. Owing to the factorial nature of the 
binomial probability distribution, these changes are much more pronounced in small 
populations compared with large onesa and since the expected allele transmission frequency 
depends on the frequency of the allele only in the preceding generation (i.e. it obeys the 
Markov property – see Chapter 1), over time rare alleles are more likely to be either lost or 
amplified in small populations compared with larger ones, in which their frequency is less likely 
to change. Since Cyprus is an island and therefore has been a relatively isolated population for 
much of its history, both genetic drift and selection could theoretically be responsible for the 
observed prevalence. 
Many of the common disease-associated genetic variants are believed to confer a survival 
advantage on those who harbour them, at least in some environmental contexts. In particular, 
there is now good observational evidence that α-thalassaemia alleles, in both the heterozygous 
and homozygous states, and sickle cell trait confer protection against severe falciparum malaria 
in children (Williams, Mwangi et al. 2005; Williams, Wambua et al. 2005). In addition, a host of 
other abnormalities of haemoglobin and red cell structure have been documented in regions in 
which malaria is endemic and many have been reported to confer protection from the disease 
(reviewed in (Williams 2006)). 
Malaria was endemic in Cyprus until its vector (the Anopheles mosquito) was eradicated in 
1946 (Constantinou 1998), an achievement for which the island’s then governor, Lord Winster, 
won a cask of wine (Hansard 1960). However, the genetic legacy of the disease remains evident 
by the high prevalence of haemoglobin variants on the island (for example the β-globin gene 
variants Hb Limassol (β8(A5)Lys→Asn) and Hb Nicosia (β17(A14)Lys→Gln) as well as at least 10 
                                                          
a
 Analogous to the large disparity in the probability of throwing 7 or more heads in 10 coin tosses 
(p=0.172) compared with throwing 70 or more heads in 100 coin tosses (p<0.0001) despite the same 
percentage deviation from the expected number. 
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other variants which are present with a combined frequency of 0.4% of Cypriots. However, 
although some of these variants have only been described in Cypriots, haplotype analysis has 
indicated that others were imported into Cyprus, probably in historical times: the commonest 
variant is the HbS allele which is predominantly found along the Northern coastal region of the 
island and is linked to the so-called ‘Benin’ haplotype. It is likely that the allele was transmitted 
from Benin along the trans-Saharan trade routes to North Africa and thence to the Eastern 
Mediterranean region where it has been identified in several populations, including Greeks, 
Syrians and Turks (Kyrri, Felekis et al. 2009). The historical record indicates that, between the 
5th and 10th centuries AD, Northern Cyprus was frequently raided by pirates based in North 
Africa. At that time the island was under Byzantine rule and was guarded by a cosmopolitan 
army from all over the far-flung Byzantine Empire which included black Africans. It is therefore 
easy to postulate the introduction of genetic variants during this period but what is less clear is 
the extent to which these alleles have become established and maintained within Cyprus as a 
consequence of positive selection as opposed to genetic drift in a relatively isolated population.  
5.3.2.1 Innate immunity and susceptibility to disease in childhood 
While CFHR5 nephropathy is associated with significant morbidity in late adulthood, 
symptomatic renal disease has only been observed in individuals beyond reproductive age, 
implying that any negative effect on reproductive ability would be relatively minor. In 
considering how the CFHR5 mutation might offer a selective advantage, one possibility is that 
could increase the likelihood of surviving childhood, during which period the major threat to 
life (especially in the pre-antibiotic era) arises from infectious diseases. The first months of life 
are recognised to pose a particularly high risk of death from infection and this is thought to 
result from immaturity of a range of innate and adaptive immune mechanisms, including bone 
marrow exhaustion, failure of neutrophil chemotaxis and microbial killing and relative 
complement deficiency (Wilson 1986). In addition, young children exposed to an invading 
microorganism for the first time will not have developed specific immunity to it and will be 
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dependent either on passive immunity (i.e. from maternal immunoglobulins) or innate 
defences.  
Variation in a range of genes coding for components of the immune system exert their 
greatest effect in the young. It is well recognised that diseases such as common variant 
immunodeficiency and severe combined immunodeficiency (which are consequences of 
mutations causing severe defects of adaptive immune function) most commonly present with 
infectious diseases in infancy. In addition genetic variation in the innate immune system can 
also modify infection risk in children, with examples being mutations in Mannose Binding 
Lectin, which are over-represented in children hospitalised for infection compared with 
controls (Summerfield, Sumiya et al. 1997; Cedzynski, Szemraj et al. 2004); Complement Factor 
I deficiency, which is associated with increased susceptibility to infection (Amadei, Baracho et 
al. 2001); and Toll-like Receptor and Tumour-Necrosis Factor-α polymorphisms, which are 
associated with altered susceptibility to childhood Helicobacter pylori infection (Wilschanski, 
Schlesinger et al. 2007; Moura, Almeida et al. 2008). 
Although most of the identified variants are associated with increased susceptibility to 
infection, recently, it has been shown that rare variants of the genes TRIM5α and CCR5 are 
associated with decreased susceptibility to HIV (Reiche, Ehara Watanabe et al. 2008; Nakajima, 
Nakayama et al. 2009). Clearly, it is difficult to argue that HIV has exerted selection pressure on 
the populations in which these variants have been described, since the duration of the HIV 
pandemic has been so short – it appears more likely that the protective variants exist as 
(previously) neutral polymorphisms in the population. However, it may be that, in the absence 
of effective therapy, positive selection for these variants would occur in the future. 
Alternatively these variants may have been under positive selection in an ancestral population 
in which a similar retroviral pathogen was endemic. 
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In addition to variation in components the immune system (and as discussed above), 
disease-causing variants of haemoglobin and red cell structure and function have been shown 
to confer protection against malaria. Advances in pharmacology, public health and sanitation in 
most developed countries (including Cyprus) have decreased the burden of disease caused by 
infectious organisms and have shifted the balance from the beneficial and towards the 
detrimental effects of these genetic variants. Clearly, in an environment where malaria is either 
absent or effectively treated pharmacologically, there is little or no reproductive benefit 
conferred by thalassaemia or sickle cell traits: in clinical practice in London, for instance, the 
disease burden of sickle cell disease far exceeds that of malaria. 
Together these findings demonstrate that mutations (even those responsible for disease) 
can confer protection against infectious diseases in some circumstances. This provides at least 
a biological precedent for the hypothesis that CFHR5 nephropathy, while detrimental in adults 
in modern societies, may confer an advantage to children exposed to infectious diseases which 
was significant in the pre-modern era. Support for this hypothesis (in the modern era with low 
childhood mortality from infectious disease) could be obtained by an in vitro demonstration of 
increased microbial killing of serum harbouring CFHR512123-9 compared with wild type CHFR5.  
5.3.3 CFHR5 nephropathy in the rest of the world 
Clearly, the fact that CFHR5 nephropathy is not a recognised disease entity in other 
communities could have two explanations: either it only exists in the Cypriot population or else 
it exists in other populations but is not recognised as a disease entity there owing to lack of 
appropriate investigation (see above). The results presented earlier in this chapter have failed 
to identify direct genetic evidence that the CFHR512123-9 mutation was imported into Cyprus 
from a separate parent population (since the haplotype on which the mutation exists is 
common in the Cypriot population), and it remains unclear whether or not the disease existed 
prior to the arrival of the ancestors of the majority of the current inhabitants of the island. If it 
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did, then it would be reasonable to hypothesize that other populations in the Eastern 
Mediterranean region would be at risk of harbouring the disease. The prevalence of the allele 
in such a ‘cousin’ population would depend on considerations of genetic drift, selection (see 
above) and admixture with neighbouring or migrating populations on the continental mainland. 
5.3.3.1 Cypriot origins 
In order to determine whether a population outside Cyprus is likely to harbour individuals 
with the mutation it is necessary to understand the genetic heritage of modern Cypriots. Owing 
to ethnic conflict in the late 20th century, the question of Cypriot origins has significant political 
implications and is an area fraught with claim and counter-claim. Cultural considerations have 
led to the popular perception that ‘Greek Cypriots’ are closely related to people from Greece, 
and ‘Turkish Cypriots’ are closely related to people from Turkey. While this may be true on 
linguistic, cultural and religious grounds, consideration of archaeological, historical and genetic 
evidence suggests that Greeks, Turks and Cypriots are each descended from very different 
ancestral populations. 
Archaeological record in Cyprus 
The archaeological record indicates that the first evidence for human habitation in Cyprus 
dates to the early Neolithic period (approximately 10,000 to 6000 BC). These inhabitants are 
thought to have introduced animals, such as dogs, sheep, goats, deer and foxes which together 
probably led to the extinction of native pygmy hippopotamus and dwarf elephant. No ceramic 
artefacts have been identified in the remains left by these early inhabitants and the type of 
circular architectural ruins they produced is similar to the pre-pottery Neolithic B culture which 
is thought to have its origins in Northeastern Anatolia or the Levant (the Mediterranean coast 
of Asia). No remains at all have been found dating from 6000 BC until around 4500 BC, 
consistent with extinction of this original community and coinciding with the ‘8.2 kiloyear 
event’ which was a cooling in the climate lasting approximately 4 centuries from 6200 BC. 
Chapter 5: CFHR5 nephropathy: clinical spectrum, prevalence and distribution 
245 
 
Whether the inhabitants actually died out during this period or simply ceased producing 
buildings or burial sites is not known. 
The architectural record resumes with the Neolithic II (or ceramic Neolithic) period (4500 to 
3800 BC) which was destroyed following an earthquake and was followed by the Chalcolithic 
period which lasted from 3800 to 2300 BC and was characterised by more variation in the 
architectural remains left behind and the first signs of metalwork. Remains from this period are 
mostly copper, but traces of tin imply contact with Anatolia (what is now Asiatic Turkey) during 
this period. 
The Bronze Age began in Cyprus in around 2400 BC and the distinctive Philia Culture 
architectural remains attests to import of this technology from Anatolia. Regions of Cyprus, in 
particular the foothills of the Troodos mountains, are rich in copper and evidence of copper 
export from Cyprus and significant international trade dates from this time through to the late 
Bronze Age (Knapp, Kassianidou et al. 2001). The late Bronze Age also saw the appearance of 
Cypriot pottery as far afield as Palestine and Crete, and the first architectural features 
characteristic of those found on the Greek mainland (namely Cyclopean walls) appeared in 
Cyprus. While this is compatible with Greek settlement, other archaeological remains 
demonstrate that links with other regions (including Egypt) were present in this period. 
Intriguingly, one of the earliest ever representations of the human kidney was a bronze model 
dated to the 13th century BC which was found with an inscription in the Cyprominoic script at 
Kition in Cyprus (see Figure 5.3-1). Whether this represents an early appreciation of the 
importance of kidney disease in Cyprus remains to be determined. 
Chapter 5: CFHR5 nephropathy: clinical spectrum, prevalence and distribution 
246 
 
 
Figure 5.3-1 One of the earliest known human representations of the kidney 
This bronze sculpture was found in Kition, in Cyprus and is thought to date from the 13
th
 Century BC, after 
(Marketos, Eftychiadis et al. 1993). 
 
History of Cyprus 
Cypriot mythology links the early Iron Age with the foundation of numerous towns by 
Greek heroes following the Trojan war (examples being Salamis which is traditionally believed 
to have been founded by Teucer, brother of Aias and cousin of Hector; and Paphos which was 
purportedly founded by Agapenor, King of the Arcadians). Physical evidence of Greek influence 
in Cyprus comes from Greek inscriptions (albeit written in the Cypriot syllabic script) found on a 
tomb dating from the 11th century BC. Further evidence of Greek cultural influence (for 
instance cremation of the dead) is seen in the following centuries, alongside the appearance of 
Phoenician colonisation. 
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The historical record shows that Cyprus was under Assyrian rule in the 8th Century BC. It 
was then independent for approximately 100 years but came under the political control of the 
Egyptians and then the Persians in the 6th Century BC. Alexander the Great gained control of 
the island which then passed to the Ptolemaic kingdom and remained firmly within the Hellenic 
world (situated as it is near the important trade route between Alexandria and Athens) for 
most of the period until Roman rule started on the island in 58 BC.  
Following the division of the Roman Empire in 285 AD, Cyprus lay within the Eastern Roman 
Empire and was ruled from Byzantium until it was invaded by the Arabs in 688. For the ensuing 
3 centuries the island was governed jointly by the Arabs and the Byzantines until it was 
reconquered by the Byzantines who controlled Cyprus until the 12th Century when it fell under 
Crusader control, initially being ruled by Richard the Lionheart of England and subsequently by 
the Knights Templar and then the Franks who established an independent Kingdom of Cyprus 
(under Guy of Lusignan) with the Latin language and Church. The Maronites arrived in Cyprus 
during this period and a few communities persist in the North of the island. The Lusignan 
dynasty ended when the last member sold the island to the Venetians in 1489.  
Cyprus came under Ottoman rule in 1571 and a significant proportion of the population 
died or fled, both as a result of bloody uprisings and also the plague which ravaged the country 
between then and 1700. Cyprus was occupied by the British in 1878 owing to its strategic 
position near the Suez canal and was annexed in 1914. The island achieved independence from 
Britain in 1960 and was partitioned in 1974 into the Republic of Cyprus (Southern Cyprus) and 
Turkish administered Northern Cyprus, which declared itself the Turkish Republic of Northern 
Cyprus in 1983 and is recognised as such only by Turkey. 
Phylogeography of Cyprus 
While providing significant insight into the flow of language, religion and culture into and 
out of Cyprus, the archaeological and historical records are less good at revealing the bulk 
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movements of people: political and cultural influence in one country from another only rarely 
results in replacement of the people living there – more commonly the inhabitants simply 
adopt (and subsequently adapt) the language and culture of the ruling nation. To address the 
question of the genetic origins of modern Cypriots, the genetic record is a potentially important 
source of information. While much work remains to be done in this area, it is clear that 
mitochondrial DNA differs significantly between modern inhabitants of Cyprus and Northern 
Greece (Irwin, Saunier et al. 2008) and principal component analysis of 500,000 autosomal 
genetic markers in Europeans from multiple countries indicates that, in general, genetic 
similarity is very tightly correlated with geographical proximity in European populations and 
that Cyprus is ‘distant’ from both Greece and Turkey (Figure 5.3-2, after (Novembre, Johnson et 
al. 2008)). Specific analysis of mitochondrial DNA variants in modern Cypriots, Cretans and 
people from the Levant has indicated the presence of variants in Cyprus found in the 
neighbouring regions (while certain variants which are common in the Levant are absent in 
people from Crete) (GENEMILL 2003). Importantly, Eastern Eurasian variants were completely 
absent in Cyprus although they are found in populations speaking Altaic languages (i.e. an arc 
between Turkey and Northeast Asia/Japan). This suggests that immigration into Cyprus 
occurred prior to the spread of East Eurasian populations westward.  
Together, these findings suggest that the genetically closest relatives of modern Cypriots 
are likely to reside in the Levant and the ancestral population was likely to have lived there 
several thousands of years ago – probably in Neolithic times. In view of the estimate for the 
minimum age of the mutation, it remains unclear whether CFHR512123-9 arose within Cyprus in 
prehistoric times or was imported into the island by the ancestral population from the Levant. 
It does, however, appear less likely that the mutation was imported by any of the waves of 
settlement or occupation of the island which occurred in historical times. It is also likely that 
affected individuals from Northern Cyprus will be identified if enough individuals from this 
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population are tested, since the mutation is likely to antedate the linguistic and cultural division 
of the island. 
 
Figure 5.3-2 Genes mirror geography in Europe 
Principal component analysis of autosomal genetic variants among different European populations. There is a 
clear correlation with geographical location and Cyprus is an outlier, being significantly different from both Greece 
and Turkey. After (Novembre, Johnson et al. 2008). 
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6.1 Conflicting Homozygosity analysis – theory  
Since current SNP genotyping technology yields diploid genotypes rather than phased bi-
allelic data, the most likely haplotypes have to be estimated computationally from these data, 
and different algorithms have been employed to do this (for instance the maximum likelihood 
estimation approach used by GENEHUNTER (Kruglyak, Daly et al. 1996)). However, whatever 
the algorithm used, the problem of assigning haplotypes has been termed NP-hard (non-
deterministic polynomial-time hard) because verification of the ‘correct’ solution is 
computationally as hard as generating that solutiona (Gusfield 2001). In this context, increasing 
the density of SNPs genotyped increases the computational demands and in any case still relies 
on whether sufficient informative individuals from the family have been genotyped. In practice, 
linkage studies are performed on subsets of genotyped SNPs (for instance the program PLINK 
removes SNPs which are in LD with each other – reducing 300,000 SNP genotypes to 
approximately 10,000 SNPs which are then analysed). Running parametric linkage analyses on 
untrimmed dense SNP marker datasets is impractical, even with modern supercomputers. In 
addition, the very large number of possible inheritance vectors, each with a correspondingly 
minuscule likelihood estimate, potentially provokes computational malfunction as a result of 
rounding errors owing to the need for very small floating point numbers. 
The conflicting homozygosity (CH) approach, rather than estimating the haplotypes and 
then asking whether they are co-transmitted with the trait, simply asks the question: “Is the 
genotype data at each SNP among a set of affected individuals compatible with identical-by-
descent (IBD) inheritance?” If one or more individual in the set is homozygous for the minor 
allele and one or more individual is homozygous for the major allele of a SNP this excludes IBD 
inheritance of a haplotype which spans that SNP. Clearly, if genotypes from a small number of 
                                                          
a
 An example of an NP-hard problem is the travelling salesman problem: “Which is the shortest route 
which passes through all specified points exactly once?” This contrasts with the NP-complete problem: 
“Is there a route passing through all points exactly once of length less than 10 miles?” which is easy to 
verify for any proposed solution. 
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individuals are compared, most SNPs considered in isolation will be non-informative since, even 
if there is no IBD inheritance most individuals will be homozygous for the major allele or 
heterozygous. However, if a dense enough SNP array is used, such that an IBD haplotype 
contains a large number of SNPs, the chance of none of them demonstrating CH purely by 
chance (i.e. in the absence of IBD inheritance of one or two alleles from a common ancestor) 
begins to fall. In this situation, identifying large (i.e. >1 cM) regions of the genome for which 
there is no CH in multiple individuals implies co-inheritance of the same haplotype from a 
single common ancestor. 
The Illumina HumanCytoSNP-12 panel consists of 300,000 SNPs across the human genome, 
which consists of approximately 3,000,000,000 base pairs spanning approximately 3,000 cM. 
The average spacing of SNPs is therefore 100 SNPs per cM. Although in an outbred population 
the likelihood of each allele of a given SNP may be dependent on the allele of neighbouring 
SNPs on the same chromosome (i.e. nearby SNPs may be in linkage disequilibrium), the 
probability of homozygosity is independent of this (since the allele of any SNP on the 
maternally inherited chromosome is independent of the allele of the paternally inherited SNP). 
Therefore, the probability of conflicting homozygosity of a given SNP in two individuals (in the 
absence of shared ancestry at the locus in question) is dependent only on the allele frequency 
of the SNP.  
Consider a SNP with alleles A and B occurring at frequencies of p and (1-p). In order for 
conflicting homozygosity to occur at this locus in individuals X and Y would require genotypes 
of either AA in person X AND BB in person Y OR BB in person X AND AA in person Y. This 
probability of conflicting homozygosity occurring in any 2 individuals, P(CH), is therefore given 
by: 
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And the chance of observing no CH in n independent consecutive SNPs is given by: 
                  
 
 
Since the average minor allele frequency in the Illumina HumanCytoSNP-12 panel is 0.22 
(Illumina 2010) the probability of observing conflicting homozygosity for a given SNP in 2 
individuals (who do not share ancestry at this locus) is 2 x 0.222 x (1-0.22)2 = 0.059, 
corresponding to an expected value (from the binomial theorem) of 16.98 SNPs for each 
episode of CH, assuming independent inheritance of neighbouring SNPs. 
While the likelihood of observing homozygosity (and hence CH) in a given SNP is only 
dependent on the allele frequency of that SNP, neighbouring SNPs along a chromosome are not 
actually independently inherited – rather, in the general (unrelated) population the alleles 
occur in haplotype blocks (or LD blocks). Of considerable importance is the size of these blocks 
which, in Northern Europeans typically extend 60 kbp, with substantial variation across the 
genome (Reich, Cargill et al. 2001). Given the size of the human genome, it can be estimated 
that a 300,000 SNP panel is likely to produce, on average, 6 SNPs per 60 kbp block.  
The extended haplotypes which are inherited identical-by-descent from a recent common 
ancestor are several orders of magnitude larger than these LD blocks, starting at an average of 
50 cM (approximately 50,000 kbp) in size and (on average) halving with each generation.  
For a single SNP, homozygosity can arise either because of inheritance of 2 copies of the 
same haplotype block (haplotype homozygosity), or alternatively because of inheritance of 2 
different haplotypes which both happen to have the same allele at the SNP in question. Clearly, 
in the former case, the neighbouring SNPs within the block will also be homozygous, whereas in 
the latter case the probability of homozygosity of neighbouring SNPs is independent. As the 
haplotype diversity increases, the likelihood of haplotype homozygosity decreases (since 
haplotype frequency must be equal to or less than allele frequency at each SNP). In any group 
Appendix A: Conflicting Homozygosity Analysis 
 
254 
 
of individuals, co-inheritance of the same haplotype block (as a function of the frequency of 
that haplotype block in the population, rather than because of a recent common ancestor) will 
result in a run of no CH the length of that block. This defines the lower limit of sensitivity of this 
approach, since completely unrelated people will therefore share runs of no CH as a 
consequence of shared haplotype blocks, as well as by chance. However, since the size of these 
blocks (in numbers of SNPs genotyped) is small compared with the expected number of SNPs 
between episodes of CH in non-IBD regions (~17 comparing 2 individuals), detection of 
haplotype blocks will not be possible with this density of SNP panel. Equally, the contribution 
that LD blocks make to the likelihood of observing run lengths will be small for runs spanning 
regions of the genome of significantly greater than the average block sizes (i.e. for runs >20 
SNPs). 
In the absence of inheritance from a common ancestor, the likelihood of observing n 
consecutive SNPs for which there is no conflicting homozygosity in 2 individuals genotyped with 
the Illumina HumanCytoSNP-12 panel is (1-P(CH))n = (1-0.059)n. It follows that, for any 2 
individuals, observing a run of 50 consecutive SNPs (spanning, on average, 500 kbp) from the 
Illumina HumanCytoSNP-12 panel without encountering conflicting homozygosity is ~20 times 
more likely to occur as a consequence of shared inheritance of a haplotype at that locus (in 
which case identical-by-descent inheritance of one haplotype renders conflicting homozygosity 
impossible) than it is to occur by chance.  
Clearly, when additional individuals are compared at the same locus, the absence of 
conflicting homozygosity across a region becomes even less likely to occur by chance, reducing 
according to a binomial distribution. For each SNP, the likelihood of observing no CH in N 
people who do not share ancestry at a given locus is P(no CH in N people) = (1-P(CH))N  
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Therefore, L(no CH) the likelihood of observing no episodes of conflicting homozygosity 
across n SNPs in N people (in the absence of shared inheritance at the locus in question) is  
given by: 
                   
 
 
 
 
                      
  
 
6.1.1 Effect of genotyping errors 
Mendelian error checking (using PEDCHECK) demonstrated that the genotyping error rate 
was very low (<0.1% genotypes). Genotyping error could result in failure to detect 
homozygosity when it was actually present potentially leading to failure to detect conflicting 
homozygosity. However, multiple consecutive errors of this type would be needed to produce a 
significant increase in the observed run length of SNPs for which there is no conflicting 
homozygosity. This is illustrated in Figure 6.1-1, in which the number of consecutive SNPs for 
which there is no CH is plotted against position along the chromosome. In the areas where 
there is no IBD inheritance (and hence CH occurs according to the distribution outlined above) 
the run length varies (randomly) between 0 and ~20 SNPs. Where there is IBD inheritance (and 
hence CH is impossible) the run length increases. 
The other potentially important consequence of genotyping error (or non-Mendelian 
inheritance) would be the introduction of conflicting homozygosity in areas which are actually 
inherited IBD by two or more individuals. However, unless there was clustering of multiple 
types of this error, it would result in a single episode of CH (as a consequence of error) flanked 
by regions in which there is no CH (as a consequence of IBD inheritance) – leading to a double 
peak on a graph such as the one shown in Figure 6.1-1.  
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Figure 6.1-1 Conflicting Homozygosity analysis yields clear IBD signal 
The run length (i.e. number of consecutive SNPs) for which there is no conflicting homozygosity (CH) in 17 
ostensibly unrelated Cypriot families is plotted against position across an 80cM region of chromosome 1. All families 
are known to share a mutation 
6.2 Conflicting Homozygosity analysis – empirical 
validation 
This analysis was performed for the 6123 SNPs located in the 80cM spanning CFHR5 in 17 
index cases, all harbouring the CFHR512123-9 mutation, each from a different family. This 
produced an average spacing of 0.0129 cM between each SNP across this region (or 78 SNPs 
per cM) and the result of CH analysis is represented graphically in Figure 6.2-1 in which the 
cumulative number of occurrences of conflicting homozygosity, N(CH), in each of 16 individuals 
compared with  the 17th individual who harboured the ancestral haplotype across CFHR5 (i.e. 
the longest run of no conflicting homozygosity with any other family) is plotted against distance 
from the mutation in number of SNPs. This graph demonstrates that there is an area of no 
conflicting homozygosity flanking the mutation in all the families (i.e. consistent with IBD 
inheritance) and in each family this zone of N(CH) = 0 is flanked by genomic regions where 
N(CH) increases linearly with distance. A linear regression line plotted through the points for 
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which N(CH) > 0 (i.e. where there is no identical by descent inheritance) has a slope 
ΔN(CH)/(number of SNPS) which is the reciprocal of the number of SNPs per episode of 
conflicting homozygosity. For all 16 families tested, the mean of the regression coefficients was 
0.056475, corresponding to an average of 17.7 SNPs per episode of conflicting homozygosity. 
The mean minor allele frequency for all the SNPs in all the individuals included in this analysis 
(in these 17 individuals) was 0.211439. It is notable that: 
 
                           
 
 
        
          
Which is the expected number of SNPs per episode of CH across this region of the genome 
and is in good agreement with the observed distribution of CH. This implies that, as predicted 
above, the effect of haplotype blocks in individuals from this population is small enough not to 
cause a significant increase in average non-CH run length. 
The empirical data therefore supports the hypothesis that occurrences of conflicting 
homozygosity (in areas with no recent IBD inheritance) obey this binomial probability 
distribution and hence that the absence of conflicting homozygosity over large enough 
distances is evidence of identical by descent inheritance. This result also implies that the effect 
of the population LD structure is small, as predicted by the small size of LD blocks (compared 
with the size of a recent IBD haplotype). 
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Figure 6.2-1 Likelihood of CH is constant in non-IBD regions 
Cumulative number of episodes of Conflicting Homozygosity (CH) across an 80 cM region of chromosome 1 
spanning CFHR5. 17 ostensibly unrelated Cypriot families known to share a mutation in CFHR5 were compared. A 
common haplotype in which no CH occurs spans the locus in all families. Outside the shared haplotype (identical by 
descent, IBD, region), dy/dx is constant and approximately equal in all families indicating a similar, fixed probability 
of observing CH in any SNP in regions not inherited identically by descent.  
 
The frequency of run length of consecutive non-CH SNPs occurring in 17 families across the 
whole genome was measured and the result for run lengths >40 SNPs) is shown in Figure 6.2-2. 
The box indicates the single run of 115 consecutive SNPs which occurred in the one region of 
the genome known to be shared IBD by all 17 families (i.e. the locus containing CFHR5). There 
were 2 runs of ~90 SNPs in regions not known to be inherited IBD by all the families (i.e. likely 
to be observed by chance) and an exponentially rising number of loci with smaller run lengths 
of non-CH SNPs. Even if the a priori low probability of observing a run of this length is ignored, 
simply considering that the human genome spans in excess of 3000 cM the likelihood of 
observing no CH across only the 1 cM region spanning the mutation purely by chance can is less 
than 1:3000. To see a run length of this size occurring only at the locus inherited IBD by all the 
individuals is therefore extremely unlikely to have occurred except as a consequence of IBD 
inheritance. Repeating the analysis with the inclusion of a single unaffected relative in the 
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analysis completely removed the signal from the CFHR5 locus. This experiment therefore 
demonstrated that CH can be used to exclude IBD inheritance at a locus in ostensibly unrelated 
families, and its absence is evidence for IBD inheritance. 
A logical next step would be to use this type of analysis within a family in order to identify 
any regions of the genome inherited IBD by affected members of a kindred. 
 
Figure 6.2-2 IBD signal is rare across the genome 
In 300,000 SNPs genotyped in a single member of 17 unrelated Cypriot families the only run length >100 SNPs in 
the entire genome (red box) occurred in the region known to be inherited IBD in all the families since it spanned the 
shared CFHR5 mutation. 
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7.1 Ethical Approval 
All research involving human participants was performed with informed consent and was 
approved by the Hammersmith and Queen Charlotte’s and Chelsea Research Ethics Committee 
(06/Q0406/151) according to the principles of the Declaration of Helsinki. The information 
sheet and consent forms used are found in Appendix C. 
7.2 DNA Extraction 
Genomic DNA was extracted from either EDTA-preserved whole blood (QiaAMP, Qiagen, 
Germany) or saliva (Oragene, DNA Genotek, Ontario, Canada) according to the manufacturer’s 
instructions. 
7.3 Single Nucleotide Polymorphism (SNP) Genotyping 
SNP genotyping for linkage studies was performed at the Genome Centre, Queen Mary 
University London using the Illumina Linkage IV 6008 SNP panel according to the 
manufacturer’s instructions. Additional SNP genotyping was performed at the Genome Centre, 
University College London, using the Illumina Cyto-SNP12 300,000 SNP panel according to the 
manufacturer’s instructions. 
7.4 Linkage analysis 
Analyses was performed on a Hewlett-Packard desktop PC with a 2.66 GHz Intel Core Duo 
CPU and 2.0 GB RAM running either Microsoft DOS or Microsoft Windows – either XP 
Professional (32-bit) or Vista (64-bit). Tab-delimited text files containing SNP genotypes in 
AB/00 format were generated using JUJUEDIT (Jujusoft, USA) and EXCEL2007 (Microsoft, USA). 
Pedigree files were written using NOTEPAD++ (Sourceforge). The data were first interrogated 
for missing data (using EXCEL) and Mendelian errors (using PEDCHECK). An individual in whom 
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>100 Mendelian errors were detected was re-genotyped from a fresh DNA sample. Repeat 
analysis indicated <10 Mendelian errors involving this person. SNPs with Mendelian errors were 
omitted from further analyses. Data were analysed in duplicate firstly using PEDCHECK and 
MERLIN under DOS and secondly using PEDCHECK, GENEHUNTER and MERLIN running behind 
the EasyLINKAGE graphical user interface under Windows. Parametric linkage analysis was 
performed using a dominant model (penetrance vectors: wt/wt: 0; wt/mt: 1; mt/mt 1) and a 
codominant allele frequency algorithm. Non-informative subjects (unaffected/unknown 
individuals with genotyped parents and no affected descendants) were discarded from 
kindreds with >15 meioses. 
Analyses were performed using sets of 100 markers and repeated using sets of 71 markers 
(to prevent loss of accurate haplotype generation at section boundaries). 
7.5 Haplotype analyses  
Haplotypes within each family were estimated using GENEHUNTER and used as input files 
for HAPLOPAINTER. The output of HAPLOPAINTER was used to compare directly predicted 
haplotypes at linked loci in affected members of all families. Haplotype analysis for estimation 
of identical by descent inheritance in unrelated individuals was performed on genotype data 
from 300,000 SNPs typed across the genome using the Illumina CytoSNP-12 panel. The average 
distance between each SNP is approximately 0.01 cM (i.e. there are approximately 100 SNPs 
per cM). SNP alleles were assigned numbers 1 and 2 (with allele A = 1 and allele B = 2) with 
possible genotypes therefore being 11, 12 or 22. At each SNP, numerical genotype for each 
individual was compared with the all other individuals using EXCEL. Numerical genotypes 
differing by exactly 11 indicated conflicting homozygosity and excluded identical by descent 
inheritance of a haplotype across this locus (see Appendix A).  
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7.6 PCR and primers 
Unless otherwise stated, all PCR reactions using genomic DNA were performed with 1 unit 
Platinum Taq (Invitrogen, UK) according to the manufacturer’s instructions with 50-200 ng 
template DNA; 200 μM dNTPs; 2.5 mM MgSO4; and 400 nM primers. Sequencing primers were 
designed using PRIMER3 (http://primer3.sourceforge.net/) and blasted against the genome to 
ensure a single predicted product. For specific amplification of regions of high genomic 
complexity such as the Complement Factor H/CFH-Related gene cluster, the whole genomic 
region was loaded into SEQUENCE SEARCHER (Viral Bioinformatics) and a fuzzy search allowing 
5 mismatches performed using each primer sequence. Primers where rejected if there was 
more than one match to the genomic region using this search strategy unless the 3’-nucleotide 
was one of the mismatches. Primers used for amplification of the exons and bordering intronic 
regions of the candidate genes sequenced are shown in Table 7.6-2.  
Amplification was performed with the following program: 
Step Temperature Time 
1 95°C 2 min 
2 95°C 30 s 
3 58°C 30 s 
4 68°C 30 s 
 Table 7.6-1 PCR program for sequencing reactions 
Steps 2 - 4 were repeated 34 times 
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Gene Exon Forward (5’ → 3’) Reverse (5’ → 3’) 
STK11 1 GGAAGTCGGAACACAAGGAA GGGAGGAGAGAAGGAAGGAA 
HIF2A 9 TGCATCTAGGGGAGCAGAAT GCCAGGGAGGCCTGTTATAG 
HIF2A 12 TTGAGCAGCACTGTGAAACA ACATGGCTTGAGGTGATTCC 
HIF2A 16 CAGACACCACTGAAGGAGCA TGGGTTCCCCATAGGATACA 
CFHR5 1 CAGTCCCATTTCTGATTGTTCCA CCCCTTCAAATTATCCTCAGC 
CFHR5 2 GGCATTTAAGCTGAATGAAAAA TCCGGCACATCCTTCTCTAT 
CFHR5 3 TGATGTCAGTTTTCAAAGTTTTCC ATAATTAGCAAAACTGAGAGAGTGGT 
CFHR5 4 CACATTAAATTTGTTTCTGCAATGA TCACCTTCTTGTTTCATCACTTCT 
CFHR5 5 CCATTTAAGCATTATTTATGGTTTC TGCAAAGTAATAGTAACTGTCCTGTTT 
CFHR5 6 AAATATTTTCAGAGTAAGCACTCATTT ACAATCCCAATCAAAATGATAAA 
CFHR5 7 TGCAGATATTTTATTGACATAATTGTT TCTTGTAAAGAAGCAACAAGATCAAC 
CFHR5 8 CCATTTTCCTGAAACACTACCC TTGGGGTACAGTGCAACAGA 
CFHR5 9 AATTATTTGAATTTCCAGACACCTT GGGTTATTCTATGAAATTAGTCCAAAA 
CFHR5 10 AGCCCATACACAGTGCTAAGAA TGAGTTAAACAACACCTGAAAGAA 
HIF2-ARMS  Inner ACTGGCACCCTATATCCCCATGGCCA CAGATGGGGCTTAGCTGGAAGTCTTCACC 
HIF2-ARMS  Outer AGTGCTTGAGATGAATGGCTCTGCAGGA TTGCTCTCCAGCTGCTGCTGAAACTTGT 
CFHR1 1 GCACAACCCTCCATGAACTT GCATACACACAAAAACCGATAAA 
CFHR1 2 TTCTTGAAGACAATGCAGGAGA GGACTACATCTCCCATC 
CFHR1 3 TGCAGTTGTACTTTTTCTTTGC CCACTTGGACACAATTGGAA 
CFHR1 4 TGATTTGCTACTCAAAATGAACACT CCTGCTATACTCCCCCAAAA 
CFHR1 5 TGCTGTGTTTGTATTTGCCTTA TTTTTCCAGCCACGTGAATA 
CFHR1 6 TTGAAAACCTGAAAGTCTATGAAGAT TCTTGCCACAAACATTTTATGAAC 
    Table 7.6-2 PCR primers for amplification of genomic DNA 
 
Amplification Refractory Mutagenesis System (ARMS) PCR primers (Table 7.6-2) were 
designed according to the method described previously (Ye, Dhillon et al. 2001). 400 nM inner 
primers were used but outer primers were present at a concentration of 40 nM. Amplification 
was performed using the following touchdown PCR program Table 7.6-3: 
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Step Temperature Time 
1 95°C 2 min 
2 95°C 1 min 
3 72 - 55°C 30 s 
4 72°C 30 s 
5 95°C 1 min 
6 55°C 30 s 
7 72°C 30 s 
 Table 7.6-3  PCR program for ARMS-PCR 
Steps 2 – 4 were repeated 12 times with decreasing annealing temperature; 5 – 7 were then repeated 25 times 
 
Specific amplification of the CFHR5 internal duplication used primers 
TGGAAGCCTGTGGTATAAATGA-3’ and 5’-TCCGGCACATCCTTCTCTAT -3’ amplified with the 
following program Table 7.6-4: 
Step Temperature Time 
1 95°C 2 min 
2 95°C 30 s 
3 58°C 7 min 
4 68°C 30 s 
 Table 7.6-4 PCR program for amplification of duplication 
Steps 2 - 4 were repeated 34 times 
 
 The 3 primer diagnostic PCR which specifically amplified the mutant CFHR5 allele was 
performed with the primers 5’-GATTCCATTTGTCAAATATTG-3’, 5’-
TCTTCTCCAAAACTATCTAATGTCAA-3’ and 5’-TTTGAATGCTGTTTTAGCTCG-3’ and amplified with 
the following program Table 7.6-5: 
Step Temperature Time 
1 95°C 2 min 
2 95°C 30 s 
3 58°C 30 s 
4 68°C 30 s 
 Table 7.6-5 PCR program for 3-primer diagnostic PCR 
Steps 2 - 4 were repeated 34 times 
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7.7 MLPA probes 
Probes used in multiplex ligation dependent probe amplification (MLPA) assay are shown in 
Table 7.7-1: 
Product size Gene Exon/Intron Probe sequence 
256 KCNT2 Exon 3 TTACCATTCA-TTTCCTTGTG 
399 KCNT2 Exon 1 GTTTCGAGAT-TTGCTGCTAG 
202 CFH Exon 1 TGCTACACAA-ATAGCCCATA 
142 CFH Exon 2 GGTCTGACCA-AACATATCCA 
179 CFH Exon 3 TCCTTTTGGT-ACTTTTACCC 
419 CFH Exon 4 ATTACCGTGA-ATGTGACACA 
337 CFH Exon 6 AAAGAGGAGA-TGCTGTATGC 
238 CFH Exon 9 AATCAAAATC-ATGGAAGAAA 
292 CFH Intron 10 TAGGTAGTCA-TATTTGGAAC 
373 CFH Intron 12 TGGACACATT-ATGATTGAGT 
310 CFH Exon 13 AGTTGGACCT-AATTCCGTTC 
218 CFH Intron 15 AGCTGAGTGA-CATGAGGTAG 
382 CFH Exon 18 GGAACCATTA-ATTCATCCAG 
122 CFH Exon 23 TCAATACATA-AATGCACCAA 
164 CFHR3 Intron 1 AGGTAAGTTA-AAAGAGATCT 
274 CFHR3 Intron 1 CATTTTCTTG-TGGAATTACA 
391 CFHR3 Intron 3 CGGACGACAG-TCTCAGACTT 
364 CFHR3 Intron 4 GGGTTATATG-AATTCCTACA 
148 CFHR3 Intron 5 TTCCCCAACA-TCACAGCAGA 
168 CFHR3 Exon 6 TCCCTTCCCG-ACACACTGCT 
282 CFHR1 Intron 1 GGATAATTCA-ATTGAAATGG 
346 CFHR1 Intron 3 AGAGTTTCAG-GTCCATGTGT 
413 CFHR1 Intron 5 AATCTGTGAT-TATTTTGTTA 
191 CFHR1 Exon 6 CCTGTTCTCA-AATAAAGCTT 
454 CFHR1 Exon 6 TTTTCCAAGT-TTTAATATGG 
406 CFHR2 Intron 1 AACTATGTCT-TGGAGTTTCG 
265 CFHR2 Intron 2 AGATCATAAA-CACTTGATAA 
226 CFHR2 Intron 3 AATACCTGTG-TGTGGTTTAT 
184 CFHR2 Exon 4 ATGCTCCAGG-TTCATCAGTT 
328 CFHR5 Exon 1 TGGGTATCCA-CTGTTGGGGG 
427 CFHR5 Exon 2 TGAAGAAGAT-TATAACCCTT 
232 CFHR5 Exon 3 CTTCAGGACT-AATACATCTG 
 
Table 7.7-1 Probes used in MLPA assay 
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7.8 Southern Blotting 
7.8.1.1 Buffers 
1. 20xSSC:  175.3 g sodium chloride and 88.2 g sodium citrate were dissolved in deionised 
water and made up to 1 L, pH 7.0 (with NaOH) 
2. Denaturing buffer: 43.8 g sodium chloride added to 50 mL of 5 M sodium hydroxide 
diluted to 500 mL deionised water 
3. Neutralisation buffer: 43.8 g sodium chloride added to 30.25 g Tris chloride dissolved in 
a total volume of 500 mL deionised water. HCl added to correct pH to 7.0 
4. Wash buffer: 10 mL 20xSSC with 1g sodium dodecyl sulphate (Sigma) made up to 1 L 
with deionised water 
7.8.1.2 Blot 
10 μg genomic DNA was digested with the desired restriction enzyme in the appropriate 
buffer overnight. It was then subjected to electrophoresis at 80 V for 3 hours through an 0.8% 
agarose gel, photographed and exposed to ultraviolet radiation for 90 seconds. The gel was 
trimmed, a notch cut in the top left hand corner and left to soak in denaturing buffer for 30 
minutes with gentle agitation. The gel was then rinsed in water and soaked in agitated 
neutralisation buffer for 30 minutes, changing the buffer after 15 minutes. A ‘bridge’ was 
fashioned using assorted plasticware and the gel placed on 3 Whatman 3M papers soaked in 
20xSSC, with overhanging Whatman 3M paper dipping into a large reservoir of 20xSSC which 
was covered to prevent evaporation. A sheet of Saran wrap with a large rectangular hole very 
slightly smaller than the gel was placed over the gel and on top of the hole (and in contact with 
the gel and Saran wrap) was placed a piece of Hybond-N membrane (GE Healthcare, Little 
Chalfont, UK) which had been trimmed to the same size as the gel and soaked in deionised 
water for 5 minutes. On top of this was placed 3 Whatman 3M papers (trimmed to the same 
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size as the membrane) and then a 10 cm tower of paper towels under a glass plate and 0.5 kg 
mass. This contraption was left overnight to allow the DNA to transfer to the membrane. 
The next morning, the set up was dismantled and notch cut in the top left hand corner of 
the membrane which was photographed (alongside the gel) to confirm transfer of DNA. The 
membrane was then rinsed with 2xSSC and allowed to air dry for < 1h on Whatman 3M paper. 
The membrane and Whatman 3M paper were then baked at 80°C for 1-2h to dryness and 
exposed to UV light for 3 minutes to denature the DNA.  
7.8.1.3 Probe 
DNA from a control individual was used as a template for PCR amplification of the desired 
probe sequence. The amplicon was run on a 2% agarose gel and gel purified. The purified 
amplicon was quantified and diluted to 25 ng in 45 μL in TE buffer (Sigma), denatured by 
heating to 95°C for 5 minutes before snap cooling on ice. It was then labelled with 32P-dCTP 
(purchased from GE Healthcare) with random primers using the Rediprime II kit (GE Healthcare) 
according to the manufacturer’s instructions. Unincorporated radioactive oligonucleotides 
were removed using NucAway spin columns (Applied Biosystems, Warrington, UK) according to 
the manufacturer’s instructions. 
7.8.1.4 Hybridization 
The membrane was prehybridized in PerfectHyb buffer (Sigma) for 30 minutes at 60°C. 220 
μL of purified, radiolabelled probe was added to 15 mL PerfectHyb buffer and the membrane 
incubated under this in a cylindrical chamber within a rotating hybridization oven at 68°C for 3 
hours. The membrane was then washed in wash buffer at 60°C for 10 minutes. This was 
repeated a total of 3 times until radioactivity not readily detectable over the membrane. The 
membrane was then placed in an intensifying cartridge between acetate sheets and next to 
Kodak MXB autoradiography film (GRI, UK) and stored at -80°C for 3-5 days.  
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7.9 Plasmid generation and amplification 
7.9.1 Antibiotic Stock (100 mg/mL) 
1000x ampicillin and kanamycin stock solutions were prepared by dissolving 1 g of 
antibiotic powder in 10 mL of dH2O.  500 μL aliquots of the stock solution were then prepared 
and stored at -20oC. 
7.9.2 Luria-Bertani (LB) broth (Millers modification) 
15.5 g of LB powder (Millers modification) was dissolved in 1 L of deionised H2O and 
autoclaved.  Antibiotics were added after sterilisation to produce selection media. 
7.9.3 LB-agar plates 
LB agar was prepared by placing 8.75 g of LB agar powder and 250 mL of deionised H2O in a 
glass bottle.  The mixture was then autoclaved to sterilise it and the LB agar was incubated in a 
water bath at 55oC before adding antibiotic at a final concentration of 100 μg/mL.  
Approximately 10 mL of LB agar was poured into each plastic bacterial culture dish and then 
allowed to set at room temperature, before being sealed with parafilm and stored at 4oC.  
7.9.4 Transformation of E. coli  
Chemically competent Escherichia coli (DH5α) cells were prepared by Tapan Bhattacharyya 
(Imperial College, London) and stored in aliquots at -80oC.  Immediately prior to transformation 
DH5α were thawed on iced and 50 μL cells were transferred into a pre-chilled 15 mL 
polypropylene Falcon tube (Beckton Dickinson, Erembodegem, Belgium) for each 
transformation (and one control tube into which no plasmid DNA was to be added).  1-10 ng of 
plasmid DNA was added to the competent cells which were incubated on ice for 30 minutes.  
Next, the tubes were placed in a water bath at 42oC for 45 seconds to heat-shock the cells.  The 
tubes were then placed immediately on ice for 2 minutes.  500 μL of LB broth (without 
antibiotics) at 42oC was added to each tube and the tubes were placed into a bacterial shaker 
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(Wolf laboratories, UK) for 1 hr at 37oC and 250 rpm.  100 μL of the LB mixture was 
subsequently spread onto an LB-Agar plate with antibiotic selection and incubated at 37oC 
overnight.  Plates were inspected for colonies the following morning to identify whether 
transformation had occurred, and this was confirmed by checking that the plate inoculated 
with the control transformation (i.e. with no plasmid DNA) showed no colonies. 
Single colonies were picked using a sterile pipette tip which was added to 3 mL of LB 
containing antibiotic (selection media) in 20 mL universal tubes (Bibby, UK).  Cultures were 
grown overnight in a bacterial shaker (Wolf laboratories, UK) at 37oC, 150 rpm.  DNA was then 
extracted using a QIAprep spin miniprep kit (Qiagen) according to the manufacturer’s 
instructions.  Briefly bacterial cells are pelleted, resuspended in buffer and lysed using alkaline 
lysis.  The mixture was then neutralised and placed on a column containing a silica membrane 
to recover the DNA in high salt conditions.  DNA was washed and eluted from the column to 
yield pure plasmid DNA which was verified either by restriction digestion or resequencing 
(Wolfson Institute of Biomedical Research, University College London).  
7.9.5 Maxiprep of plasmid DNA 
Following verification of the plasmid by restriction digestion or sequencing, a larger amount 
of DNA was prepared using a Qiaquick plasmid maxi prep kit (Qiagen).  Colonies were picked 
from an LB-agar plate and cultured for 8 hrs in 2 mL of selection media.  250 μL of these 
cultures was used to seed a 250 mL culture of LB supplemented with antibiotic.  The larger 
culture was then incubated overnight in a bacterial shaker (Wolf laboratories, UK) at 37oC, 150 
rpm. Cells were pelleted and DNA extracted according to the manufacturer’s instructions.  This 
kit follows the same key steps described above.   
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7.9.6 Restriction digestion 
DNA digestions with restriction enzymes were performed according to the manufacturer’s 
instructions in the appropriate buffer (New England Biolabs, UK). The digested DNA was then 
analysed by agarose gel electrophoresis to confirm complete digestion. 
7.9.7 DNA agarose gel electrophoresis 
5x stock Tris Borate EDTA (TBE) buffer was made by mixing 54 g 
Tris(hydroxymethyl)aminomethane hydrochloride (Sigma, Poole, UK) with 27.5 g Boric acid 
(Sigma) and 100 mL 0.1M EDTA (Sigma) and the mixture made up to 1 L with dH2O. 
Agarose gels were prepared by diluting agarose powder in 1xTBE buffer to the desired 
concentration (0.8% w/v to separate fragments >1kbp, 1-2% for fragments between 200bp and 
1kbp and 3% to separate products of similar size, such as those resulting from ARMS-PCR).  The 
mixture was heated until boiling in a microwave oven and ethidium bromide was added to the 
molten agarose immediately prior to casting to yield a final concentration of 0.5 μg/mL.  
Samples were mixed with 6x loading dye (New England Biolabs) and loaded on the agarose gel 
alongside the appropriate DNA size ladders (100 bp ladder, 1 kb ladder; New England Biolabs).  
A typical electrophoresis run was performed under 1xTBE at a constant 100 V.  DNA bands 
were visualised and photographed under ultraviolet light (Syngene, Cambridge).   
7.9.8 Alkaline phosphatase treatment 
1 unit of Calf intestinal alkaline phosphatase (Invitrogen, UK) was added to 50 μL restriction 
digestion and incubated at 37oC for 5 minutes. The alkaline phosphatase was inactivated by 
heating to 65oC for 15 minutes. 
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7.9.9 Gel purification 
DNA bands of the desired size were resected from agarose gel following electrophoresis 
using a scalpel under ultraviolet light. The DNA was extracted using a QIAquick gel extraction kit 
(QIAGEN, Germany) according to the manufacturer’s instructions. 
7.9.10  Ligation 
Ligation was performed using T4 DNA ligase (Promega) using gel-purified linearised, 
phosphatased vector and gel-purified digested insert which were quantified using a Nanodrop 
ND-1000 spectrophotometer (Thermo Scientific, Waltham, MA, USA). Molecular equivalents 
(MEs) were calculated by dividing the measured concentration (in ng/μL) by the size of the DNA 
molecule (in nucleotides) and the desired ratios made up in the reaction mix according to the 
manufacturer’s instructions. The mixture was incubated at 16oC for 16 hours. 
7.9.11  Generation of mutant HIF2α alleles 
pcDNA3.1 constructs containing the human HIF2α coding sequence with and without a C-
terminal MYC epitope tag were kindly supplied by P Maxwell (UCL) and these were used for 
functional studies.  
7.9.11.1  Mutagenesis 
Variants encoding HIF2αGly537→Arg and Gly537→Trp were generated using Quikchange 
(Stratagene, La Jolla CA) according to the manufacturer’s instructions. Briefly, 33-mer primers 
were designed incorporating the desired (i.e. mutant) nucleotide at position 16-18 (Table 
7.9-1).  
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Gene Name Sequence (5’ → 3’) 
HIF2A 537 Arg F CCTATATCCCCATGGACAGGGAAGACTTCCAGC 
HIF2A 537 Arg R GCTGGAAGTCTTCCCTGTCCATGGGGATATAGG 
HIF2A 537 Trp F CCTATATCCCCATGGACTGGGAAGACTTCCAGC 
HIF2A 537 Trp R GCTGGAAGTCTTCCCAGTCCATGGGGATATAGG 
   CFHR5 C5ex2-3 F ACTCCTCCCATATGCAGCTTCACTAGAACACTTTGTG 
CFHR5 C5ex2-3 R GGCTGAGCATCTACATTGGCTTCTAAAATTGGAACATGAC 
   Table 7.9-1 Primers used for the generation of mutant constructs 
Single nucleotide substitutions are shown in red 
 
 
10 ng of pcDNA3.1HIF2α plasmid DNA was used as a template for a PCR reaction which 
used PfuUltra HF DNA polymerase and the following program Table 7.9-2: 
Step Temperature Time 
1 95°C 30 s 
2 95°C 30 s 
3 55°C 1 min 
4 68°C 1 min/kb plasmid length 
   Table 7.9-2 PCR program for Quikchange mutagenesis 
Steps 2 - 4 were repeated 16 times 
 
The reaction mixture was then digested with DpnI at 37°C for 1 hour to destroy the 
(methylated) template DNA. The nicked (mutant) amplicon plasmids were then used to 
transform chemically competent cells. 
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7.10 Cell culture 
All tissue culture reagents described were supplied by Gibco (Invitrogen, UK) unless 
otherwise stated.   
HepG2 hepatocellular carcinoma cells were a kind gift from Bhathiya Wijeyekoon (Oxford 
University). The basal media used was RPMI 1640 supplemented with 10% foetal calf serum 
(FCS), 2 mM L-Glutamine, 50 IU/mL penicillin and 50 μg/mL streptomycin.  Stock cell cultures 
were maintained in 100 mm tissue culture dishes (TPP, UK) in a GalaxyR CO2 incubator (Wolf 
Laboratories, UK) with a humidified atmosphere of 5% CO2 at 37
oC.  To passage cells, 
monolayers were washed with RPMI 1640 with no supplements and then dissociated with 
trypsin-EDTA solution.  Complete medium was added and cells were transferred to a 50 mL 
Falcon tube.  Cells were then spun at 1000 rpm for 5 minutes in a centrifuge (Hettich 
Zentrifugen, Tuttlingen) to pellet the cells.  After spinning the supernatant was removed and 
the pellet resuspended into an appropriate volume of complete medium before re-plating into 
fresh tissue culture dishes.   
7.10.1 Preparation of frozen cell stocks 
Cells from a confluent 100 mm tissue culture dish were trypsinised as described above.  
After pelleting, cells were resuspended in 3 mL of FCS.  3 mL of 2x freezing medium (20% 
dimethyl sulphoxide (DMSO), 80% FCS) was then added to the cells in a dropwise manner.  2 
mL aliquots of cells were prepared in cryovials.  The cryovials were placed in a -80oC freezer 
overnight before being transferred to liquid nitrogen for long-term storage.  Cells were 
defrosted by hand warming until the cryovial contained a slurry. This was emptied into a 50 mL 
Falcon tube containing complete medium. The cells were then pelleted and resuspended in 1 
mL complete medium before adding them to tissue culture plates. 
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7.10.2 Transfection of cultured cells for HRE-reporter assay 
HepG2 cells in 6-well plates were co-transfected using Lipofectamine 2000 (Invitrogen, 
Paisley UK) according to the manufacturer’s instructions. All experiments were performed in 
triplicate on at least 2 separate occasions. In brief, 5.5 μL Lipofectamine 2000 was added to 
244.5 μL Optimem and incubated for 5 minutes. This was then added to a mixture containing: 
the desired amount of the expression plasmid; 2 µg of pGL3PGK6TKpLUC reporter construct 
(which incorporates a multimerised Hypoxia Response Element (HRE) linked to thymidine 
kinase-driven Firefly Luciferase gene(Vaux, Wood et al. 2001)); 150 ng pRL-SV40 containing 
Renilla Luciferase (Promega, Southampton UK) made up to a volume of 250 μL with Optimem. 
After 20 minutes, this 500 μL mixture was added to cell monolayers in 6-well plates under 2.5 
mL of RPMI supplemented with 10% FCS and 2 mM L-Glutamine but no antibiotics.  
Hypoxic incubation was performed using a GalaxyR tissue culture incubator (Wolf 
Laboratories, UK). CO2 was fixed at 5% and hypoxia was maintained with supplemental N2.  
48 hours after transfection, cells were lysed and luminescence measured using Stop and 
Glo (Promega) according to the manufacturer’s instructions. Luminescence was measured using 
a TD-20/20 Luminometer (Turner Designs, Sunnyvale CA).  
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Figure 1. Frequencies of BCR-ABL in B-precursor ALL according to age groups. Fifteen (0.6%) patients showed both types of transcripts (M-bcr and m-bcr) and were not 
included in this diagram.  
 
investigated for BCR-ABL transcripts with 2 different polymerase chain 
reaction (PCR) methods as previously described in detail.1,2 Forty-six 
(1.8%) cases showed an ambiguous result and were not considered for 
further analysis. Of the remaining 2498 cases, 904 (36.2%) were 
BCR-ABL (599 24% minor breakpoint region [m-bcr] and 282 
11.3% major breakpoint region [M-bcr], 15 0.6% both, M-bcr and 
m-bcr, and 8 atypical transcripts), and 1594 were BCR-ABL . 
Atypical transcripts were not systematically detected before 20001 and  
 
positive ALL may arise from different sets of hematopoietic progenitor 
cells,3 but this does not explain the age dependency. A number of genetic 
markers in ALL show a marked age dependency (reviewed in Arm- 
strong and Look4), eg, TEL-AML1, TLX1, and TLX3, MLL aberrations 
(especially in infant ALL). Our data provide additional information on 
the biology of BCR-ABL-positive ALL and substantiate evidence of 
age-dependent variation in the genetic background of ALL.  
 
Thomas Burmeister, Stefan Schwartz, Claus R. Bartram,  
thus had to be excluded from further analysis. We grouped patients into  
age cohorts at 10-year intervals according to their age at diagnosis, each 
comprising between 277 and 481 patients and found a remarkable 
increase of BCR-ABL frequency in adolescents and young adults (Figure 
1). It increased from 12.7% in adolescents (15-24 years) to 30.6% and 
43.7% in patients aged 25 to 34 and 35 to 44 years, respectively. In  
Nicola Gokbuget, Dieter Hoelzer, and Eckhard Thiel ¨ 
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increment and ranged between 42% and 44%. The increase of BCR-  
ABL frequency was paralleled by a relative increase of M-bcr tran- 
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cases in adolescents (15-24 years). Their relative frequency increased to  
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To the editor:  
 
 
Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an  
activating HIF2 mutation  
 
Erythropoietin production is regulated by the transcription factor 
hypoxia-inducible factor (HIF). Erythrocytosis with raised erythro- 
poietin levels due to dysregulated HIF activity is recognized as a 
consequence of a hypomorphic HIF E3 ubiquitin ligase (VHL)  
allele (Chuvash polycythemia), inactivating mutations of the HIF  
hydroxylase PHD2 and, very recently, activating mutations of 
HIF2 .1-3 We report that erythrocytosis in a large kindred  
originally reported in 19794 is due to an activating HIF2  
mutation. Two affected individuals developed severe pulmonary  
 
hypertension, a hitherto unrecognized consequence of mutations 
in the pathway.  
This study was approved by the Hammersmith and Queen 
Charlotte's and Chelsea Hospitals local research ethics committee. 
Informed consent was obtained in accordance with the Declaration 
of Helsinki. At presentation, affected family members (Figure 1A) 
exhibited erythrocytosis (hemoglobin up to 228 g/L) with elevated 
total red cell volume and reduced plasma volume (Figure 1B). 
Other hematological parameters, serum biochemistry, arterial  
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Figure 1. Data and findings for selected family members. (A) Family tree. (B) Hematological parameters in selected family members. I-2 was diagnosed with "heart failure" at age 62; 
echocardiography was not available. *Not contemporaneous measurements. - indicates data not available. (C) Genome-wide linkage to autosomal dominant erythrocytosis. 
(D) Parametric LOD score at region circled in red in panel C. (E) Sequencing trace of showing G/A heterozygosity at base 2097, predicting a change from glycine to arginine at residue 537, 6 
codons from critical hydroxyl acceptor proline (underlined). (F) HRE-Fireﬂy:Renilla luciferase activity following cotransfection of a plasmid containing the coding sequence of HIF2 with or 
without mutations shown. Results shown are means plus or minus SD of 3 independent experiments, each performed in triplicate.  
 
oxygenation, and oxygen-hemoglobin dissociation were normal. 
Serum erythropoietin was elevated, rising to more than 2000 
milli-IU/mL. II-1 and II-3 both had documented pulmo- nary 
arterial (PA) hypertension in their sixth decade without any 
evidence of thromboembolism. A genome-wide single nucleo- 
tide polymorphism screen was compatible with linkage to HIF2 
(Logarithm or odds ratio [LOD] 1.81, Figure 1C,D) and  
resequencing disclosed heterozygosity for a G 3 A substitution  
at position 2097 (Figure 1E), predicting a glycine-to-arginine  
change at residue 537 of the protein (HIF2 Arg537), present in all 
affected and no unaffected individuals. Expression of HIF2 
Arg537 in HepG2 (a hepatoma cell line) cells revealed increased 
activation of a hypoxia response element-luciferase reporter 
construct compared with wild-type (Figure 1F). HIF2 Arg537 
was more active than HIF2 Trp537, consistent with a more severe 
phenotype in this family.  
These findings confirm that an activating HIF2 mutation  
dysregulates erythropoietin production in humans. That HIF2  
plays a central role in regulating erythropoietin is supported by 
several observations. First, in hepatoma and neuroblastoma cell 
lines, erythropoietin mRNA was suppressed by siRNA-mediated 
silencing of HIF2 , but not HIF1 .5 Second, in VhlR/R mice 
homozygous for a mutation equivalent to that underlying 
Chuvash polycythemia in humans, there was erythrocytosis in 
normoxia associated with stabilization of HIF2 , but not HIF1 .6 
Third, reduced oxygen delivery to the kidney in rats activates 
HIF2 , but not HIF1 in the fibroblasts which produce  
erythropoietin.7  
 
This report provides the first evidence that genetic HIF activa- 
tion could cause severe pulmonary hypertension in later life. This is 
plausible; although clinically important pulmonary hypertension is 
not evident in Chuvash polycythemia, there is a detectable increase 
in resting PA pressure and an exaggerated hypoxic pulmonary 
vasoconstriction response.8,9 There is also experimental support for 
a critical role of HIF2 in the pulmonary vasculature since hif2 / 
mice are protected from right ventricular hypertrophy in  
hypoxia.10  
These findings have several implications. First, there should be a 
high index of suspicion for pulmonary hypertension in other 
kindreds with activation of the HIF pathway. Second, inhibitors of 
PHD enzymes, which are in late stage clinical trials for treatment of 
anemia, may cause pulmonary hypertension. Third, it raises the 
possibility that polymorphic variation in HIF2 contributes to the 
marked differential susceptibility to erythrocytosis, reduced plasma 
volume, and pulmonary hypertension in humans at high altitude.  
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